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Neutrophil extracellular traps in thrombosis and inflammation 
 
 
Abstract 
 
 
Neutrophil extracellular traps (NETs), chromatin released by activated 
neutrophils, were first described for their antimicrobial properties.  NETs have a 
backbone of DNA and histones lined with microbicidal proteins such as 
neutrophil elastase. NET release has pathological consequences, particularly 
within blood vessels where NETs can trap red blood cells and platelets, thus 
contributing to thrombosis (Chapter 1-Overview). NET formation (NETosis) is an 
active and coordinated biological process involving many enzymatic components.  
One enzyme in particular, peptidylarginine deiminase 4 (PAD4), citrullinates 
histones and is required for chromatin decondensation during NETosis. 
Neutrophils from PAD4-deficient mice are unable to form NETs. We obtained 
these mice from our collaborator Dr. Yanming Wang, and thus were able to 
compare PAD4-/- mice to wild-type (WT) mice in mouse models where NETs are 
formed.  These studies have allowed for investigation of the biological relevance 
of PAD4 and NETs in vivo in thrombotic and/or inflammatory disease.  
This dissertation focuses on mouse models of deep vein thrombosis and 
of sepsis.  In venous stenosis, thrombosis is initiated by restricting blood flow in 
the inferior vena cava (IVC).  Here, PAD4-/- mice were greatly protected from 
thrombus formation (Chapter 2).  Leukocyte rolling and platelet plug formation in 
response to vessel injury were unaffected, indicating that endothelial and platelet 
activation occurred normally in these mice. The mice did not exhibit any defects 
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in hemostasis, and could be induced to produce deep vein thrombi by infusion of 
WT neutrophils that formed NETs as a part of the thrombus scaffold. Because 
there is potential to develop anti-NET therapies in thrombosis, I investigated if 
NET-deficiency would render mice immunocompromised (Chapter 3).  PAD4-/- 
mice had similar mortality in the cecal ligation puncture model, and they were 
protected from shock in an LPS sepsis model where NETs are released in the 
absence of live bacteria. Therapies aimed at NET prevention or destruction 
would likely be beneficial without compromising host immunity. Thus, in summary, 
studying PAD4-deficient mice has revealed the impact of NETs in 
thrombotic/inflammatory disease and identified PAD4 as an attractive therapeutic 
target. 
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Section 1.1: Thesis Overview and Attributions 
Overview 
The original publication observing neutrophil extracellular traps (NETs) 
came out in Science just over 10 years ago, and described a novel antibacterial 
function of neutrophils1.  NETs were defined as extracellular DNA strands also 
staining positive for histones and neutrophil elastase, with an ability to physically 
trap and kill both Gram-positive and Gram-negative bacteria1.   These structures 
were studied extensively in response to many different pathogens, and were later 
also found to interact with fungi and viruses2,3. The process of NET formation 
after initial stimulation involves the decondensation of chromatin, dissolution of 
the nuclear membrane, and expulsion of chromatin into the extracellular 
environment4. NETosis is an active, specific cell biological process rather than a 
passive form of cell death5 and much remains to be studied about the molecular 
mechanisms by which NETs occur, as well as the consequences of their release. 
 Neutrophil hyperactivation has detrimental effects on healthy bystander 
tissue and thus neutrophils are implicated in many inflammatory disease 
pathologies6,7.  As one can imagine, the release of highly charged histones, 
serine proteases, and myeloperoxidase concentrated on DNA fibers into the 
extracellular space can contribute to such pathologies.  Indeed, aberrant NET 
production has been implicated in preeclampsia8, autoimmune disease9, 
cancer10-12, cardiovascular disease13,14, thrombosis15,16, sepsis17, and others18-21.  
Our lab observed that NETs can bind platelets and red blood cells (RBCs) in 
whole blood and therefore contribute to thrombosis16.  Since venous thrombi are 
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RBC rich, the lab looked for and found NETs in a baboon model of deep vein 
thrombosis16.  We found similar evidence of NETs being formed in the mouse 
inferior vena cava (IVC) stenosis model of DVT (15, Appendix A-3), and found 
that DNase, which can degrade NETs, prevented thrombus formation.  We have 
since then also identified NETs during in maturing human thrombi in patients 
suffering from venous thromboembolism (22, Appendix A-4).   
 In the same month that our lab’s paper defining the role of NETs in 
thrombosis was published16, a key study came out in the Journal of Experimental 
Medicine describing the essential role of the enzyme peptidylarginine deiminase 
4 (PAD4) during NET formation23. PAD4 acts by deiminating arginine residues to 
citrulline.  This PAD enzyme is unique as it contains a nuclear localization signal 
and therefore can enter the nucleus and modify histones.  The citrullination of 
histone tails leads to the decondensation of chromatin that occurs extensively in 
NETosis.  Dr. Yanming Wang’s group at Pennsylvannia State University 
generated mice deficient in PAD4, and showed that these mice not only had 
strongly reduced chromatin decondensation, but also that they were completely 
unable to release NETs23.  They were able to elegantly show that NETs could 
help contain a bacterial infection by using a mutant form of Group A 
streptococcus which did not secrete a nuclease that would degrade NETs, thus 
showing a potential role for NETs in vivo.    This thus represented the first tool 
which could be used to specifically study the role of NETs in vivo.   
 Our lab obtained PAD4-/- mice from Dr. Wang and began studying them in 
mouse models in which we had evidence of NETs being formed.  This genetic 
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approach therefore allowed us to study the importance of NETs in various 
disease pathologies. With Melanie Demers in the lab, we developed a 
microscopy-based approach to quantify NET formation in vitro by isolating 
peripheral blood neutrophils, stimulating them, and then staining for the histone 
modification produced by PAD4, citrullinated histone H3 (H3Cit)10,24.  This 
method was applied to identify cells that were beginning to undergo NETosis by 
isolating neutrophils from healthy or tumor-bearing mice, performing cytospins, 
and immunostaining for H3Cit.  I developed an unbiased thresholding method to 
quantify cells with hypercitrullinated histones using ImageJ, which we now also 
use routinely to quantify baseline NET-primed cells in whole blood.   We 
optimized this technique further as an immunohistological method of identifying 
NETs in various tissues, staining for neutrophil membrane markers, H3Cit and 
DNA in association.  This was used to identify NETs in transfusion-related acute 
lung injury18, in deep vein thrombi from mice (15, Appendix A-3, Chapter 2) and 
humans (22, Appendix A-4, Chapter 1), as well as in myocardial 
ischemia/reperfusion injury14, cancer (10, Appendix A-5, and unpublished results), 
and skin wounds (Appendix A-6, and unpublished results), sepsis (Chapter 3).  I 
have also developed a method to detect the presence of NETs in plasma by 
performing Western blots for H3Cit (10,11, Chapter 3).  These methods were 
helpful in identifying NETs in mouse models of various inflammatory diseases.  
We next turned to the PAD4-deficient mice to study the impact of a lack of NET 
release in these disease models.  
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 There is a growing body of literature that highlights the importance of 
NETs in pathological thrombosis.  In Chapter 1, I provide an overview of what is 
known about the cell biology of NET production, and how NETs represent an 
important player in thrombosis.  Previous studies using DNase to degrade 
extracellular DNA showed a highly protective effect of DNase 1 in DVT in 
mice15,25.  Chapter 2 shows the phenotype of the PAD4-/- mice in thrombosis 
models, which nearly completely phenocopies DNase pre-treatment. I therefore 
proposed that PAD4 is an ideal target for inhibiting NET formation in disease 
settings, but was wary that such an approach could render subjects more prone 
to infection.  I therefore studied the PAD4-deficient mice in mouse models of 
sepsis, where the balance between bacterial killing and tissue damage is critical.  
In Chapter 3, I will describe that NETs are not crucial for host defense in sepsis 
and may in fact even be detrimental by contributing to endotoxemic shock.  This 
dissertation ends with a discussion section in Chapter 4 providing future 
directions.   
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Section 1.2.1: Thrombosis: tangled up in NETs 
Overview 
NETs can entrap platelets and red blood cells, thus contributing to 
thrombosis.  It is now clear that venous thrombi, in addition to known 
proteinaceous factors such as fibrin, also contain DNA-NETs as an integral 
component of the thrombus scaffold.  This has now been studied in animal 
models15,16 and identified to be relevant in human disease13,22.  
After a thorough literature search, Denisa Wagner and I outlined several 
sections of interest that have either contributed to the lab’s 2010 discovery that 
NETs are important in thrombosis, or resulted from it.  There are many aspects of 
NET formation itself and in the context of thrombosis that remain unknown.  We 
summarize crucial unresolved questions for the field moving forward, and 
propose how what we’ve learned could be applied to future therapeutic 
approaches to either prevent or treat deep vein thrombosis.   
 
Attributions 
This was an invited review submitted to Blood in October 2013 and published in 
December 2013.  Denisa Wagner and I reviewed the literature and wrote the 
manuscript.  Figures were reproduced from previously published work from key 
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I took the micrographs and assembled Figure 1.4.  Figure 1.5 was kindly 
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generated by graphic designer Kristin Johnson from a sketch drawn by Denisa 
Wagner.   We thank Siu Ling Wong, Melanie Demers, and Lesley Cowan for 
careful reading and editing of the manuscript while it was under preparation.  We 
also thank Dr. Paul Kubes and Dr. Charles Esmon for granting us permission to 
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Abstract  
The contributions by blood cells to pathological venous thrombosis were only 
recently appreciated.  Both platelets and neutrophils are now recognized as 
crucial for thrombus initiation and progression.  Here we review the most recent 
findings regarding the role of neutrophil extracellular traps (NETs) in thrombosis. 
We describe the biological process of NET formation (NETosis) and how the 
extracellular release of DNA and protein components of NETs, such as histones 
and serine proteases, contributes to coagulation and platelet aggregation.  
Animal models have unveiled conditions in which NETs form and their relation to 
thrombogenesis.  Genetically engineered mice enable further elucidation of the 
pathways contributing to NETosis at the molecular level. Peptidylarginine 
deiminase 4 (PAD4), an enzyme that mediates chromatin decondensation, was 
identified to regulate both NETosis and pathological thrombosis. A growing body 
of evidence reveals that NETs form in human thrombosis as well and that NET 
biomarkers in plasma reflect disease activity. The cell biology of NETosis is still 
being actively characterized and may provide novel insights for the design of 
specific inhibitory therapeutics.  After a review of the relevant literature, we 
propose new ways to approach thrombolysis and suggest potential prophylactic 
and therapeutic agents for thrombosis.  
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Neutrophils are an often underappreciated cell with crucial functions in 
immunity and injury repair.  Because neutrophils are packed with microbicidal 
proteins and, when activated, generate high concentrations of reactive oxygen 
species, their ability to kill pathogens comes at a high cost to surrounding tissue.  
Indeed, when it comes to neutrophils, you certainly can have too much of a good 
thing.  This became even more evident upon the discovery of neutrophil 
extracellular traps (NETs) by Volker Brinkmann, Arturo Zychlinsky, and 
colleagues.1 NETs have been investigated in the context of host defense and 
also the pathogenesis of several non-infectious diseases.  Here we will focus on 
the role of NETs in thrombosis. 
 
Introduction to NETs 
Pathogens can induce neutrophils to release chromatin lined with granular 
components (such as myeloperoxidase, neutrophil elastase, and Cathepsin G)1,26, 
creating fibrous nets with antimicrobial properties, capable of killing both Gram-
positive and Gram-negative bacteria.1 NETs also have the ability to trap and kill 
fungi2, are released in viral infections27, and can sequester viruses.3 Interestingly, 
this ability of the host to release extracellular traps in order to protect itself from 
pathogens is evolutionarily conserved in plants, with root border cells secreting 
extracellular DNA as part of a defense mechanism against bacterial and fungal 
infection.28   
The cell biological mechanisms that allow for NET release are still being 
characterized. NETosis has been distinguished from apoptosis and necrosis as a 
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new cell death process.5 In the Fuchs et al. study, the importance of reactive 
oxygen species (ROS) via NADPH oxidase was revealed.5 Because ROS are 
rapidly cell permeable, addition of exogenous sources of ROS can rescue 
deficiencies in NADPH oxidase.5 In the presence of some neutrophil stimuli, ROS 
may not be needed to form NETs.29-31 Crucial steps in NETosis were evaluated 
morphologically in early in vitro studies.4,5 First, the nucleus loses its 
characteristic lobular shape and swells. It is now known that the nuclear swelling 
is due to chromatin decondensation driven by peptidylarginine deiminase 4 
(PAD4).32 PAD4 is a protein citrullinating enzyme that enters the nucleus to 
modify histones.32,33  Upon the hypercitrullination of specific arginine residues on 
histones H3, and H4, there is a loss of positive charge from the transformed 
arginine residues, and the linker histone H1 and heterochromatin protein 1β 
dissociate from the nucleosome structure.33,34 Overexpression of PAD4 results in 
chromatin decondensation and the release of NET-like structures in cells in vitro 
that don’t normally undergo this form of cell death.34 Thus, activation of PAD4 is 
likely the primary driving force in NETosis. Neutrophils from PAD4-/- mice 
generated by Yanming Wang’s group23 are completely unable to form NETs 
(Figure 1.1A).  Therefore, PAD4-/- mice provide an excellent framework in which 
to study the role of NETs in vivo.23,24   
It was proposed that some neutrophil granular enzymes such as 
neutrophil elastase translocate to the nucleus and help in chromatin 
decondensation by cleavage of histones.35 Genetic evidence determining to what  
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Figure 1.1.  NETosis is a regulated process.   A. Representative image of a 
wild-type (WT) or PAD4-/- neutrophil stimulated with calcium ionophore.  WT 
neutrophils undergo histone hypercitrullination (H3Cit, green) and throw NETs, 
while PAD4-/- neutrophils fail to citrullinate histones, decondense chromatin, or 
release NETs. Reproduced from Martinod et al. PNAS 201324.  Scale bars, 10 
µm. B. In response to Staphylococcus aureus skin infection, neutrophils can 
secrete their nuclear contents (right panel) while retaining the ability to crawl and 
phagocytose, thus “multitasking.” Reproduced from Yipp et al. Nat Med 2012 with 
permission36. 
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what extent individual granular proteins contribute to NETosis remains to be 
established.  The serine protease inhibitor Serpin B1 may also regulate NET 
formation, and it also translocates into the nucleus.37 The timing of PAD4 
activation relative to the above mentioned enzymes’ nuclear translocation and its 
own potential nuclear import still needs to be characterized.  Finally, the 
chromatin network is released into the extracellular milieu.1,4,5 What happens to 
the plasma membrane, cytoskeleton, and other organelles during NETosis is not 
known.   
There is likely more than one mechanism of NET release.  The process 
described above takes a fair amount of time (2-4 hours) before NETs are 
released.5  Recently, a second mechanism was observed first in vitro and then in 
vivo using intravital microscopy. Here, the neutrophils rapidly expel NETs (within 
minutes) in response to live Staphylococcus aureus.36,38 The neutrophil ejects 
either a portion or all of its decondensed nuclear contents (Figure 1.1B) without 
releasing the cytoplasmic contents or lysing the plasma membrane36. The 
denucleated neutrophil still retains the ability to crawl and phagocytose bacteria 
trapped by its own NETs in a highly efficient process called “vital NETosis.”36,39 
Large biologically active anuclear fragments of neutrophils were already 
observed in the 1980s.40 The mechanism by which nuclear contents are secreted 
in either process is yet unknown, as are the triggers that induce one form of 
NETosis over another.   
While the beneficial effects of NETs in fighting pathogens were being 
reported1,2,41, the pathological nature of NETs rapidly began to emerge.  NET 
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formation was observed in diseases without an obvious microbial trigger such as 
preeclampsia8, small vessel vasculitis42, and systemic lupus erythematosus and 
its associated nephritis.43 Defective serum DNases help to drive lupus 
pathogenesis, resulting in antibody production against self-DNA.43  Antibodies 
formed against NET components may promote the pathology of certain 
autoimmune diseases such as rheumatoid arthritis.9 In addition, presence of 
antibodies to neutrophils may induce the formation of NETs such as in 
transfusion-related acute lung injury.18  
There could be a benefit of intravascular NET formation in septic 
conditions where containing an overwhelming bacteremia is likely protective for 
the host.41,44 The large quantities of anti-microbial toxic products released with 
NETs, in particular histones, the main protein component of NETs26, can 
contribute to lethality in sepsis.17 It appears that there is only a fine line between 
the beneficial and harmful effects of NETs for the infected host.   
NETs not only entrap pathogens, they can also bind platelets and red 
blood cells.16 Since red blood cell-rich red thrombi are formed in deep veins, it 
proved fruitful to first look for NETs in deep vein thrombosis (DVT).16 Indeed, the 
thrombus experimentally formed in a healthy baboon was full of extracellular 
DNA (Figure 1.2A). Infection is a risk factor for DVT45, perhaps through the 
generation of NETs.  The link between NETosis and coagulation was made 
because of the presence of neutrophil elastase (NE) on NETs.  NE inactivates 
tissue factor pathway inhibitor (TFPI) through cleavage, thus resulting in 
increased procoagulant activity.46  Procoagulant activity leads to platelet  
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Figure 1.2. NETs are part of deep vein thrombi and histones produce 
toxicity in vivo.  A.  A deep vein thrombus was formed in an otherwise healthy 
baboon by balloon catheterization.  The thrombus was excised and analyzed for 
the presence of extracellular DNA (green) and von Willebrand factor (red), which 
were found to codistribute. Scale bar, 100 µm. Reproduced from Fuchs et al. 
PNAS 201016.  B. Intravenous histone infusion was detrimental to both 
endothelium and epithelium, as shown by vacuolization (stars) of these cells in 
and around the lung capillaries (right).  Av, alveolae.  Cav, caveolae. Ep-I, type I 
epithelial cell.  EC, endothelial cell. Scale bars, 500 nm. Reproduced from Xu et 
al. Nat Med 2009 with permission17.  
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activation and activated platelets can enhance NET formation25,41,46, but platelet 
depletion does not necessarily prevent NETosis.18 
 
Nucleic acids, histones and NET enzymes: effects on coagulation 
 
Before the link to NETs was established, nucleic acids and nuclear 
components were studied individually for their ability to induce coagulation.  
Nucleic acids activate coagulation47,48, with RNA binding both Factor XII and XI in 
the intrinsic pathway.  RNA is present in fibrin-rich arterial thrombi,47 but its origin 
is not known and whether RNA is released with NETs is still an open question. 
Also, histones increase thrombin generation49 in a platelet-dependent manner.50  
Histones activate platelets16, and platelet activation, in turn, promotes 
coagulation.51 Histone infusion leads to formation of platelet-rich microthrombi in 
a sepsis-like model17, while also contributing to thrombocytopenia.52  As noted 
earlier, infused histones are toxic and lead to endothelial and epithelial cell 
vacuolization (Figure 1.2B)17 and cell death53, and this toxicity is mediated by toll-
like receptors 2 and 4.54  In vivo, histones likely circulate as part of 
nucleosomes.17,55 Intact nucleosomes/NETs promote coagulation and increase  
fibrin deposition.16,46 In vitro, the addition of DNA and histones in combination 
results in greater fibrin clot stability than the individual components.56 
NETs deposition in a flow chamber perfused with blood promotes fibrin 
deposition and NETs bind plasma proteins important for platelet adhesion and 
thrombus propagation such as fibronectin and von Willebrand factor (VWF).16  In  
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this flow model, RBCs bind to NETs but not collagen.16  Within thrombi formed in 
vivo, NETs colocalize with VWF.16  At times it appears as if VWF connects NETs 
to the vessel wall (Figure 1.2A).  Interaction of NETs with fibrin was also 
observed after intraperitoneal administration of alum adjuvant resulting in the 
formation of nodules containing both extracellular DNA and fibrin31, perhaps 
trying to encapsulate the foreign substance.  Fibrin and NETs likely work together 
toward immune defense in a process now defined as “immunothrombosis.”57  
NET fibers contain various other factors that can render them 
procoagulant.  As mentioned earlier, serine proteases inhibit TFPI58, and in 
addition, tissue factor has been shown to be deposited on NETs.25,59,60  The 
source of tissue factor could be from blood25 or from the vessel wall.61 Factor XII 
is present and active on NETs.25,46 The negatively charged DNA in NETs may 
provide a scaffold for Factor XII activation which is aided by platelets, but the 
exact mechanism has not been determined.25  
 
 
NETs in thrombosis: Animal models 
 
Insights from animal models about the presence and role of NETs in 
thrombosis are extensive.62-64  The first analysis of baboons with thrombi from 
balloon catheter-induced DVT revealed the presence of NETs not only within the 
thrombus (Figure 1.2A) but also their biomarkers in the plasma16, with their 
appearance paralleling that of the fibrin degradation product D-dimer.65  The 
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mouse models of DVT have allowed for more detailed investigation of the time 
course of NET formation and the testing of potential therapies.15,25 Mouse models 
have also shown a possible role of NETs in arterial thrombosis.46   
Arterial thrombosis 
NETs have been studied in arterial vessel injury induced by ferric chloride 
application. In this model, the lack of serine proteases in neutrophil 
elastase/Cathepsin G-deficient mice lessens coagulation via reduced TFPI 
cleavage.46  Infusion of the anti-H2A-H2B-DNA antibody66 that neutralizes 
histones leads to prolonged time to occlusion as well as lower thrombus stability 
in the carotid arteries of WT mice, while no effect of antibody infusion is observed 
in the neutrophil elastase/Cathepsin G-deficient mice.46 Thus, externalized 
nucleosomes contribute to thrombogenesis by exposing serine proteases to TFPI.   
NETs are also present in the carotid lumen in ApoE-deficient mice on high-fat 
diet, proximal to atherosclerotic lesions67, supporting the clinical observation that 
NETs are implicated in coronary atherosclerosis.13     
Deep vein thrombosis 
Platelets and neutrophils are indispensible in the mouse inferior vena cava 
(IVC) stenosis model of DVT, as well as VWF that might help recruit both of 
these cell types.25,68 The release of VWF from Weibel-Palade bodies from 
endothelial cells is likely driven by hypoxia69. Ischemic stroke also elevates 
plasma nucleosome levels, and systemic hypoxia produced by placing animals in 
a hypoxic chamber results in release of histone-DNA complexes into 
circulation.19 After a day in the hypoxic chamber, mice become highly susceptible 
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to IVC thrombus formation.70 Interestingly, hypoxia induces HIF-1α, which is 
implicated in NETosis.71 Through their histones, NETs may further enhance 
endothelial activation as histone infusion in combination with IVC stenosis greatly 
accelerated thrombus formation.15 Histone infusion leads to VWF release15 and 
signs of microthrombosis in mice.17  Weibel-Palade body secretion also 
upregulates endothelial P-selectin, an adhesion receptor for leukocytes.51 
Neutrophils are among the first leukocytes to be recruited to the activated 
endothelium at the onset of thrombosis and comprise a great majority of the 
thrombus leukocytes during the early stages of thrombosis.25,72   
Both the baboon and mouse models show NETs in close association with 
VWF within thrombi.15,16 In vitro binding of VWF to NETs is also observed.16 The 
interaction of the A1 domain of VWF with histones was originally described73 long 
before NETs were discovered and these recent studies help to provide relevance 
to a phenomenon that was at the time found to have “no conceivable 
physiological role.”73  Similarly, fibronectin, a molecule important in 
thrombosis74,75 contains four DNA-binding domains that also interact with 
heparin76, and indeed fibronectin binds to NETs.16  
 While the presence of NETs within deep vein thrombi is undeniable, their 
importance in DVT pathophysiology is still being actively investigated. Treatment 
with DNase 1, known to degrade NETs1, diminishes the frequency of thrombus 
formation15,25, indicating that the presence of NETs in DVT is functionally 
important and that DNase could be therapeutically useful.  At earlier time points 
after IVC stenosis, only a few NETs are present within the forming mouse 
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thrombus as seen by intravital microscopy, while at later time points NETs are 
widespread (Figure 1.3A).25 This was confirmed using citrullinated histone H3 as 
a marker for NETs24, revealing an extensive meshwork of NETs throughout the 
48-hour-old thrombus (Figure 1.3B).  The use of PAD4-/- mice, that cannot 
undergo the histone modification required for chromatin decondensation in 
NETosis, demonstrated that NETs are indeed a crucial component of the 
thrombus scaffold, as the lack of NETs results in fewer thrombi early after IVC 
stenosis (6 h), with almost no thrombi present after 48 h.24  In PAD4-/- mice, 
platelets and leukocytes do accumulate along activated endothelium, and 
neutrophils are present within the rare thrombi that form24, showing that NETosis 
is the critical function of neutrophils in thrombosis.  CXCL7 released from 
platelets in thrombi may generate the chemotactic gradient that directs 
leukocytes within thrombi77, and platelets also promote NETosis25 through a 
mechanism that is not completely elucidated.25,41,46   
Venous injury 
 There may be a difference between arterial and venous responses to 
injury with respect to NETs. In contrast to the arterial injury model, in venous 
ferric chloride injury there is no delay in time to occlusive thrombus formation in 
PAD4-/- mice where NETosis is inhibited.24  Alternatively, the importance of NETs 
may depend on vessel size.  Arterial injury was examined in the carotid artery25, 
which takes longer to occlude than injury of small veins24 and thus NETs have 
the time to be produced.  In large arteries, NETs may be necessary in addition to  
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Figure 1.3.  NETs form in mouse models of thrombosis and cancer. 
A. Intravital microscopy of developing thrombi shows the release of NETs 
early (3h) and more prominently in occlusive thrombi (48h).  Arrows indicate 
NETs.  Sytox Green, DNA.  Scale bars, 50 µm.  Reproduced from von Bruhl et al. 
JEM 201225.  B.  Composite image of a thrombus formed in a WT mouse 48h 
after IVC stenosis.  Mosaic generated using MosaicJ plug-in for ImageJ 
software78. Citrullinated histone H3 (H3Cit) staining (green) shows evidence of a 
NET meshwork throughout the red portion of the thrombus. Scale bar, 100 µm. C.  
Mice bearing a mammary carcinoma develop spontaneous thrombi in the lung 
(right) after 28 days, a time point when NETs are spontaneously generated in 
these mice.  This does not occur in tumor-free mice (left).  VWF, green.  
Fibrinogen, red.  DNA, blue.  Scale bar, 50 µm. Reproduced from Demers et al. 
PNAS 2012.10,42 
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fibrin to stabilize the thrombus against arterial shear.  Importantly, the PAD4-/- 
mice retain normal tail bleeding time.  Therefore, NETs may not play a critical 
role in platelet plug formation in response to a small injury.  They could, however, 
provide long-term stability of thrombi in large wounds but this is yet to be 
investigated. Targeting PAD4 may be beneficial in pathological venous 
thrombosis because it will not cause spontaneous hemorrhaging or have drastic 
consequences on physiological hemostasis.   
Cancer-associated thrombosis 
 A high percentage of cancer patients both with and without chemotherapy 
experience lethal thrombotic complications.79  Cell-free DNA increases transiently 
during the course of chemotherapy in patients and in a mouse model.80 Adding 
cell-free DNA isolated from in vitro chemotherapy-treated blood to recalcified 
plasma increases thrombin generation due to contact pathway activation.80  Mice 
bearing solid tumors develop an accompanied neutrophilia during tumor 
progression.  In mammary carcinoma and Lewis lung carcinoma, this is 
associated with increasing plasma DNA levels.10 Of note, when cancer patients 
develop neutrophilia, this is usually a sign of poor prognosis.81  Isolated 
neutrophils from tumor-bearing mice are primed to undergo NETosis.10 It is 
thought that tumors secrete cytokines, such as G-CSF, that systemically prime 
the neutrophils.10,11 The elevated DNA and propensity of neutrophils to throw 
NETs provides a new explanation for cancer-associated thrombosis, as mice with 
high levels of NET biomarkers, such as plasma H3Cit, show spontaneous 
thrombosis (Figure 1.3C).10   
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NETs in human thrombosis 
 
While NETs were initially described as occurring within tissues1,8,82, 
subsequent work has shown they can form within vasculature.16,41,46  This may 
increase the ability to measure certain biomarkers of NETs in plasma.  Indeed, 
DNA83 and nucleosomes84 are elevated in septic patients, and cell-free DNA 
levels were a better predictor of progression to sepsis after traumatic injury than 
IL-6 or CRP, markers of inflammation.85 MPO-DNA complexes are elevated 
specifically during active disease in patients with small-vessel vasculitis42, when 
their thrombotic risk is the highest.86 Also, a case study in a patient with ANCA-
positive microscopic polyangiitis showed NETs within a venous thrombus.87  
Thrombotic risk is elevated in other chronic diseases in which NETs form, 
including cancer, colitis, and rheumatoid arthritis.  
The interplay of inflammation and thrombosis is well established.  In 
coronary artery disease, MPO-DNA complexes are elevated in the more severe 
cases, positively associated with elevated thrombin levels, and robustly predict 
adverse cardiac events.13  DNA, nucleosome, and MPO levels correlate with 
disease state in patients with thrombotic microangiopathies (TMAs), including 
thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome, and 
malignant tumor-induced TMA.20  In TTP characterized by low ADAMTS13 (A 
disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13), 
NETs biomarkers are elevated during acute TTP compared to the same patients 
in remission (Figure 1.4C)20, making it a possibility that the disease could be  
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Figure 1.4. Evidence of NETs in human pathological thrombosis. A.  
Composite image of a human pulmonary embolism specimen obtained surgically 
and stained by immunohistochemistry for platelets (blue) and leukocytes (brown) 
showing that areas of the thrombus are rich in both cell types. Scale bar, 100 µm.  
Mosaic generated using MosaicJ plug-in for ImageJ78. Immunohistochemical 
analysis by Alexander Savchenko. B.  Representative image of diffuse 
extracellular DNA staining (green) present in a surgically-harvested pulmonary 
embolism patient specimen.  Green, DNA.  Scale bar, 20 µm. Anonymous 
specimens in A and B kindly provided by Richard Mitchell. C.  Cell-free DNA, a 
plasma biomarker of NETs, is elevated in patients with thrombotic 
microangiopathies (left): thrombotic thrombocytopenic purpura (TTP), hemolytic 
uremic syndrome (HUS), malignancies (tumor) and non-specified cases (NOS). 
Patients suffering from acute TTP present significantly elevated plasma DNA 
compared to when in remission (right).  This research was originally published in 
Blood. Fuchs TA et al. Circulating DNA and myeloperoxidase indicate disease 
activity in patients with thrombotic microangiopathies. Blood. 2012;120:1157-
1164. © American Society of Hematology.  
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precipitated by an infection or other stimulus that induces NETosis.  Circulating 
NET levels can be used to predict which patients will develop TMAs after bone 
marrow transplant.88  Blood products may also contain NETs if not leukodepleted 
prior to transfusion.21  These infused NETs could be toxic after transfusion and 
may possibly contribute to thrombotic events in hospitalized patients.   
Risk factors for DVT include trauma, surgery, infection, immobilization and 
hypoxia45,89,90, several of which are associated with NET formation. Deep vein 
thrombi and pulmonary emboli have regions of platelet and leukocyte 
accumulation (Figure 1.4A) and unpublished observations from our laboratory 
show that these are also rich in extracellular DNA (Figure 1.4B). Establishing 
suitable biomarkers for DVT diagnosis is of interest, because for now ultrasound 
remains the best diagnostic method but is not always reliable.91 Circulating 
nucleosomes and markers of neutrophil activation (elastase-α1-antitrypsin, MPO) 
are significantly increased in persons with DVT, compared to patients with 
symptoms but lack of confirmed DVT diagnosis.92,93 Plasma DNA positively 
correlates with VWF and negatively correlates with levels of ADAMTS1393, 
supporting a relationship between NETs and VWF in DVT.  In fact, the ratio of 
ADAMTS13:VWF is the lowest in DVT patients.93  
Extracellular histone/DNA complexes have also been identified in arterial 
thrombi following thrombectomy56,94 obtained from abdominal aortic aneurism 
patients.94 The codistribution of fibrin and NETs is apparent in arterial thrombi.56  
Combination therapies digesting fibrin and DNA may be needed for efficient 
thrombolysis16 (Figure 1.5) as will be discussed below.   
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New possibilities to prevent thrombosis and improve thrombolysis 
 
Thrombus development involves an ongoing process of maturation.95 
Animal models of DVT have established a time course of initial neutrophil and 
platelet recruitment followed by monocyte infiltration and eventual thrombus 
resolution.25,68,96,97 There are several potential new targets for either the 
prevention of thrombosis or enhancement of thrombolysis (Figure 1.5).  Platelets 
and platelet adhesion to VWF are essential to thrombus generation25,68, and two 
recent clinical trials showed that aspirin, long regarded as an antiplatelet therapy, 
prevents venous thromboembolism recurrence.98,99  Interestingly, aspirin can 
also inhibit NETosis in vitro.100  Preventing Weibel-Palade body release, for 
example with agents that increase nitric oxide generation101 or otherwise interfere 
with endothelial VWF/P-selectin secretion102, or targeting platelet-VWF 
interactions would both prevent platelets and neutrophils from tethering onto the 
vessel wall, and their possible recruitment of other platelets and neutrophils upon 
activation. The A1 domain of VWF binds to glycoprotein 1β on platelets, 
promoting their adhesion.  In vivo, inhibition of this interaction targeting the VWF 
A1 domain by antibodies or aptamers (reviewed in103,104) greatly reduces 
thrombus formation in arteries and veins.68,104 Inhibiting VWF would prevent 
PSGL-1-mediated leukocyte rolling and also firm adhesion via β2 integrins such 
as Mac1.105 ADAMTS13, a protease that specifically cleaves VWF106, can be 
administered in vivo to reduce thrombosis107 and to aid in thrombolysis of thrombi 
in venules.108 Recombinant ADAMTS13 (rADAMTS13) can prevent  
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Figure 1.5.  Emerging targets for thrombus prevention and thrombolysis. 
Here we summarize advances in the field of thrombosis with respect to neutrophil 
recruitment and NETosis and pinpoint targets that should be investigated as 
potential therapeutics (black).  Existing treatments are in gray.  We propose 
PAD4 inhibition as a way to prevent NET release.  For thrombi that have already 
formed, neutralizing the toxic components of NETs is key. Thrombolytic 
strategies should involve the targeting of both DNA (blue) and the protein 
elements (red and green) of the thrombus scaffold. 
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microthrombosis such as in ischemia reperfusion injury occurring in myocardial 
infarction or stroke.109,110 rADAMTS13 could also be used in DVT prophylaxis by 
reducing initial platelet accumulation and neutrophil recruitment, as well as in 
aiding thrombolysis in combination with fibrinolytic or NET-degrading therapies.  
Some improvement after combining ADAMTS13 and DNase 1 was observed in a 
murine myocardial ischemia/reperfusion model.14 It is of interest to note that 
polymorphisms in both ADAMTS13 and DNase 1 linked to reduced activity are 
associated with myocardial infarction in humans.111,112  
Targeting P-selectin, the other important component of Weibel-Palade 
bodies and α-granules, is triply beneficial, as it reduces neutrophil recruitment, 
the activating interaction between neutrophils and platelets, and the generation of 
TF-containing microparticles.51 P-selectin inhibition is protective in DVT animal 
models25,65,72,113, significantly reducing neutrophil recruitment to the vessel 
wall25,72, NET generation25, and reducing the procoagulant activity of P-
selectin.113,114 The ideal antithrombotic agent will prevent pathological thrombosis 
with minimal impact on hemostasis.  In this respect, neutrophils are such a target.  
Neutrophil depletion was reported to reduce thrombus size in mouse DVT25 and 
this is likely due to their ability to make NETs through the action of PAD4.24  
PAD4 inhibitors would prevent NETs from being formed, while DNases could be 
used to degrade NETs that are already present (Figure 1.5).  A variety of 
nucleases could be tested for thrombolysis, perhaps even ones of bacterial origin 
as streptokinase effectively digests fibrin.   
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Central to the feasibility of NETs degradation is their structure: they are 
strands of highly decondensed chromatin exposed to the extracellular 
environment and thus accessible to DNases.1,26 Certain pathogens produce 
nucleases that allow them to evade capture and killing by NETs.82,115,116  Such 
nucleases may be good candidates to improve thrombolysis.  Administration of 
DNase I has a protective effect in vivo in murine models of ischemic stroke19, 
myocardial infarction14 and deep vein thrombosis.15,25  Combination therapies 
including DNase with ADAMTS13 and/or tissue plasminogen activator (tPA) 
could allow for more complete penetration of thrombolytic agents within large 
thrombi.  Current therapies are centered on anticoagulation and fibrinolysis117 
that, with the exception of heparin (see below), are unlikely to dismantle or 
degrade the NET component of the venous thrombus scaffold.  Indeed, clots 
produced with NETosing neutrophils could only be degraded with a combination 
of tPA and DNase I.16 Similarly, addition of histones and DNA to fibrin clots in 
vitro makes them more resistant to fibrinolysis.56  
Interestingly, the widely used anticoagulant heparin dismantles NETs16 
and prevents histone-platelet interactions52, thus likely decreasing NET-driven 
thrombosis.  DNase I activity on chromatin is enhanced in vitro by the presence 
of serine proteases, and this can be mimicked by heparin as it dislodges histones 
from chromatin and allows for greater accessibility for the enzyme.118  Combining 
DNase 1 with heparin could further reduce the risk of future thrombotic events.     
Neutralizing the toxic components of NETs provides another possible 
strategy to prevent endothelial injury and thrombosis.  Activated protein C 
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degrades histones and prevents histone-associated lethality.17 In mice, infusion 
of histones precipitates DVT15 and exacerbates ischemic stroke.19  Inhibiting the 
serine proteases on NETs could allow for TFPI activity and decreased TF-
promoted coagulation.46  TF is found on NETs25, and it is likely that TF-containing 
microparticles are recruited to NETs or NET-associated platelets.   Reducing 
these procoagulant factors would mitigate the damaging effects of NETs until 
their eventual clearance.   
It is likely that macrophages infiltrating the thrombus can act as an 
endogenous clearance mechanism of NETs during thrombus resolution.  
Macrophages are able to phagocytose NETs and degrade them with their high 
lysosomal DNase II contents.119 In vitro, DNase I preliminary digestion aids the 
clearance of NETs by macrophages.119 Addition of exogenous DNase 1 could 
enhance the accessibility of macrophages to NETs and the removal of 
fragmented NETs. Monocytes/macrophages also provide plasminogen 
activator120 thus helping fibrinolysis.  Any potential anti-thrombotic should not 
negatively impact macrophage function as this could potentially impede thrombus 
resolution and result in pathologies from excess NETs products.  
 
 
Questions for the future  
 
From the observations described above, it is clear that inhibiting NETosis 
would be beneficial to prevent toxic side effects of NETs in inflammation and 
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reduce occurrence of pathological thrombosis.  However, the importance of 
NETs in preventing infection cannot be neglected and needs more thorough 
evaluation. NETs alone44 or together with fibrin46 may wall off local infections and 
prevent dissemination57 which could be promoted by DNase/fibrinolysis. Since 
PAD4-deficient neutrophils are competent in phagocytosis, ROS generation and 
recruitment to inflammatory sites23 (K.M. and D.D.W. unpublished data 2013), it 
is possible that only an overwhelming infection would be problematic when 
NETosis is inhibited. Although PAD4-/- mice were more susceptible to a mutant 
Group A streptococcal infection (unable to secrete a nuclease), PAD4-/- mice did 
not fare worse in necrotizing fasciitis induced by the DNase-secreting Group A 
Streptococcus.23  Also, PAD4-/- mice were similar to WT in influenza infection.121  
We thus do not anticipate major problems in treating an uninfected host. 
Antibiotics could be administered together with the NETosis inhibitors when 
needed.  
Assuming NET inhibition is safe, it will be important to examine at which 
step NETosis is best arrested.  The original stimulus and the signaling 
mechanisms leading to chromatin release during thrombosis need to be 
uncovered. Hypoxia and its activation of the transcription factor HIF1α were 
implicated in NETosis71 and ROS generation could also be important. Whether 
DVT is modified in mice deficient in HIF1α and mutants that overproduce or 
underproduce ROS should be evaluated.  Interaction of platelets with neutrophils 
promotes NETosis, and there may be an enhancing effect by the forming clot 
itself. Fibronectin, present in clots, was shown to have such an effect.30 We noted 
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that NETs were mostly present in the RBC-rich (red) portion of the clot.15 RBCs 
may not only be recruited by NETs, but may also enhance their production. 
Whether inhibition of any of these interactions would reduce NETosis remains to 
be seen. 
Little is known about the signaling inside the cell that leads to chromatin 
release. Raf/MEK/ERK122, Rac2123, and NADPH oxidase5 can participate.  Which 
of these are implicated in pathological thrombosis such as DVT should be 
determined and tested with available inhibitors.  What are the signals that direct 
neutrophils to either release only nuclear components or the entire cell contents? 
Which of these NETosis mechanisms is more common in thrombosis? Are the 
neutrophils within thrombi that have formed NETs dead or do they retain 
function? Does partial chromatin release36 occur during thrombosis, serving to 
enhance neutrophil adhesion to other cells within thrombi? Most importantly, 
learning more about PAD4, a key therapeutic target candidate, its intracellular 
substrates other than histones, and how it is activated or translocated to the 
nucleus may help to design inhibitors with high specificity.   
It will be instructive to determine the implications of NET formation on 
thrombotic disease progression and as a biomarker of disease activity. What is 
the exact role of NETs in thrombosis? Do they contribute to thrombus stability 
like fibrin74? Are they implicated in post-thrombotic syndrome? NETs may play a 
role in vessel wall injury and recruitment of new cell types into the thrombus, 
including endothelial cells for thrombus vascularization. During thrombosis, NETs 
fragments appear in circulation.15,16 These may be useful biomarkers of active 
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thrombotic disease16,92,93 and should be studied carefully as they may reveal 
more about the process of NETs generation and degradation.  Furthermore, it will 
be critical to know how long these NETs fragments retain pro-coagulant activity 
and how this depends on their size or composition. We know that NETs 
generation in diseases such as cancer has a systemic effect on the host10 and 
the pro-coagulant activity generated by NETs could promote cancer growth as is 
the case with thrombin.124 
It will be important to learn how NETs and their fragments are naturally 
cleared.  Animal studies indicate that it would be therapeutically beneficial to 
clear NETs from the circulation and away from vessel walls. Is VWF implicated in 
anchoring NETs to the vessel wall, and would ADAMTS13 free the NETs? VWF 
and DNA plasma levels seem to correlate in human thrombosis.93 Except for 
macrophages, with their intracellular DNase II119, and dendritic cells125-127, no 
other cell type has been implicated in NET clearance.  The role of platelets and 
RBCs that bind NETs should be evaluated. DNase I is elevated after ischemia128 
and also early in sepsis129: is this to reduce the risk of thrombosis? DNase I-/- 
mice should be studied to further examine the enzyme’s role in NET clearance119 
and as a natural thrombolytic.  
In conclusion, we have learned a lot about NETs activity in thrombotic 
disease since the first observation in 2010 of their presence in a deep vein 
thrombus. There is certainly plenty more to investigate. Now is the time to test 
the effect of NET inhibition in DVT prophylaxis and of combination therapies in 
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thrombolysis, therapies that not only cleave the proteinaceous components of 
thrombi, but also attack the nucleic acid backbone. 
We just saw it from a different point of view 
Tangled up in blue130   
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Section 2.1: Overview and Attributions 
Overview 
As discussed in the previous chapter, NETs are found in various thrombotic 
settings, including deep vein thrombi which are platelet, leukocyte, and red blood 
cell-rich.  The lab routinely studies genetically modified animals in the IVC 
stenosis model of DVT.  This model activates the endothelium directly distal to 
the ligation to release the contents of Weibel-Palade bodies in the absence of 
endothelial cell injury.  Thrombi that form are morphologically similar to those 
found in human venous thromboembolism patients, and therefore this model is 
highly relevant.  In the Brill et al. study1 (Appendix A-3), it was shown that 
infusion of DNase prior to IVC ligation rendered mice highly protected from 
forming thrombi.  Also, neutrophil depletion was shown to greatly decrease the 
size of thrombi that form in WT mice2.  We aimed to study the PAD4-/- mice 
because of their complete inability to form NETs, and therefore subjected them to 
the IVC stenosis model.  We were surprised by how strong the phenotype was, 
and therefore we investigated to see if the mice had any inherent defects in 
endothelial, leukocyte, or platelet activation.  In all respects other than NETosis 
and thrombus initiation, the mice responded normally.  Also, mice were able to 
form platelet plugs in response to vessel injury, and therefore NETs are not 
highly contributing to basic hemostasis.   
 
Supplemental figures are provided in Appendix A-1.  
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For this chapter, I performed all deep vein thrombosis surgeries and analyses 
related to the inferior vena cava (IVC) stenosis model, and was responsible for 
breeding PAD4-/- animals to establish and maintain a colony fully backcrossed to 
the C57Bl/6J background.  Melanie Demers taught me how to properly isolate 
platelets for platelet aggregation studies. She also taught me how to prepare 
animals for intravital microscopy, used for the ferric chloride mesenteric venule 
injury and to measure leukocyte rolling after infusion of activated platelets.  We 
performed all intravital microscopy experiments together and I analyzed the 
results independently. I learned from Tobias Fuchs how to harvest IVCs after 
stenosis to visualize leukocyte/platelet aggregates along the vessel wall.  He 
quantified the number of leukocytes adherent in WT vs PAD4-/- animals.  Siu Ling 
Wong performed hematoxylin and eosin staining of thrombus sections and 
showed me how to identify extracellular DNA patterns using this technique which 
she had previously developed to look at NETs in skin wounds.  Maureen Gallant 
isolated bone marrow neutrophils for infusion into mice with DVT surgery and 
helped to prepare cryosections of thrombi for immunostaining. Yanming Wang at 
Pennsylvania State University kindly provided the PAD4-/- mice his lab generated 
for us to establish our colony, and provided helpful advice.  His graduate student, 
Jing Hu, performed 2 generations of the backcross prior to their arrival in our lab.  
Denisa Wagner supervised the study, designed experiments, and we wrote the 
paper together. 
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Abstract: 
Deep vein thrombosis and pulmonary embolism are a major health problem 
associated with high mortality. Recently, DNA-based neutrophil extracellular 
traps (NETs) resulting from the release of decondensed chromatin were found to 
be part of the thrombus scaffold and to promote coagulation. However, the 
significance of nuclear decondensation and NET generation in thrombosis is 
largely unknown.  To address this, we adopted a stenosis model of deep vein 
thrombosis and analyzed venous thrombi in peptidylarginine deiminase 4 (PAD4) 
-deficient mice that cannot citrullinate histones, a process required for chromatin 
decondensation and NET formation.  Intriguingly, less than 10% of PAD4-/- mice 
produced a thrombus 48 hours after inferior vena cava stenosis whereas 90% of 
wild-type mice did.  Neutrophils were abundantly present in thrombi formed in 
both groups, while extracellular citrullinated histones were seen only in thrombi 
from wild-type mice.  Bone marrow chimera experiments indicated that PAD4 in 
hematopoietic cells was the source of the prothrombotic effect in deep vein 
thrombosis.  Thrombosis could be rescued by infusion of wild-type neutrophils 
suggesting that neutrophil PAD4 was important and sufficient. Endothelial 
activation and platelet aggregation were normal in PAD4-/- mice, as was 
hemostatic potential determined by bleeding time and platelet plug formation 
after venous injury. Our results show that PAD4-mediated chromatin 
decondensation in the neutrophil is crucial for pathological venous thrombosis 
and unveil neutrophil activation and PAD4 as potential drug targets for deep vein 
thrombosis. 
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Introduction 
 
Venous thromboembolism is associated with high mortality, with 
approximately 300,000 deaths resulting from an estimated 900,000 cases in the 
US annually3.  Neutrophil extracellular traps (NETs) are produced by a novel cell 
death pathway shown to be important in innate immunity against microbes4-7. 
Recently, NETs were also shown to be involved in thrombosis by binding 
erythrocytes and platelets8, and in promoting coagulation by degrading tissue 
factor pathway inhibitor9. Coagulation, platelets, neutrophils and NETs have all 
been implicated in thrombus generation in mouse models of deep vein 
thrombosis (DVT)1,2,10. Also, certain cancers associated with neutrophilia result in 
an increased propensity of circulating neutrophils to form NETs and spontaneous 
thrombosis 11.  NETs are comprised of decondensed chromatin fibers lined with 
antimicrobial proteins such as neutrophil elastase and myeloperoxidase4. A 
proteomic analysis identified histones as the major protein component of NETs12. 
Histones are highly cytotoxic to the surrounding environment into which NETs 
are released13,14, and can enhance thrombin generation15. Histone infusion leads 
to rapid Weibel-Palade body (WPB) secretion from endothelial cells, promoting 
platelet and leukocyte adhesion and leading to accelerated thrombus generation1. 
Pretreatment with DNase 1, which can degrade NETs, reduces thrombus 
incidence in wild-type (WT) mice1,2. Neutrophils play an important role, as 
neutrophil depletion greatly reduces thrombus weight in this model2.  Whether 
NETs are involved in the pathogenesis of DVT or whether they are merely a 
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consequence of leukocyte recruitment to the thrombus is unknown. Similarly, the 
role of NETs in normal platelet plug formation in response to injury, where their 
presence was also observed9, remains to be addressed.  
While the cellular changes occurring in the neutrophil during NETosis 
have been well described, the molecular players and processes leading to NET 
formation are incompletely defined.  A critical step in NET formation is the 
decondensation of chromatin that occurs in the nucleus.  Peptidylarginine 
deiminase 4 (PAD4) is a nuclear enzyme that converts specific arginine residues 
to citrulline on histone tails.  Upon PAD4 activation, histones can become 
hypercitrullinated at histone H3Arg-8 and -17 or histone H4Arg3 residues, 
resulting in the extensive chromatin decondensation that leads to nuclear 
delobulation and swelling during NETosis16,17. PAD4-deficient mice are incapable 
of decondensing chromatin or forming NETs18, while overexpression of PAD4 is 
sufficient to drive chromatin decondensation to form NET-like structures in cells 
that normally do not form NETs19. Since NETs are present in pathological 
thrombi and their dissolution by DNase 1 reduced the frequency of DVT, it was 
important to address the role of histone modification by PAD4 in the process of 
NET formation and its involvement in thrombosis.  
 
Results 
PAD4-/- neutrophils fail to produce NETs in response to LPS or ionomycin 
PAD4 is a calcium-dependent enzyme with a nuclear localization signal 
that distinguishes it from other PAD family members20,21. The enzyme is 
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activated by Ca2+ 17, therefore the calcium ionophore ionomycin was used to 
induce histone hypercitrullination in isolated peripheral blood murine neutrophils 
(Fig. 2.1A). This led to NET formation in WT and PAD4+/- neutrophils, whereas 
PAD4-/- neutrophils did not citrullinate histone H3 or form NETs (Fig. 2.1A, 2.1B). 
Lipopolysaccharide (LPS) from Klebsiella pneumoniae was also unable to induce 
histone citrullination or NETs in PAD4-/- neutrophils, whereas it is a potent 
inducer of NETosis in WT neutrophils (Fig. 2.1A, 2.1B).  Moreover, 
immunostaining showed H3Cit-positive NETs being released from WT 
neutrophils, while in PAD4-/- neutrophils H3Cit staining was absent (Fig. 2.1C). 
Although PAD4-/- nuclei lost their lobulated shape characteristic of neutrophils, 
they did not swell, indicating that nuclear decondensation is not occurring in 
PAD4-/- mice and confirming that other PAD enzymes do not compensate for 
PAD4 deficiency in vitro. Ionomycin-induced NETosis has been shown to be 
independent of reactive oxygen species22 and here we show that it is dependent 
on PAD4. Thus, PAD4-/- neutrophils have shown a complete inability to produce 
NETs18 (Fig. 2.1B).   
 
PAD4-/- mice are protected in the venous stenosis model of DVT 
Biomarkers of NETs are abundant in baboon8 and mouse DVT1. We 
performed the venous stenosis model of DVT in mice10. Briefly, the inferior vena 
cava (IVC) is ligated to induce a 90% restriction in blood flow. This results in the 
formation of a thrombus that is macroscopically similar to human deep vein 
thrombi.  It contains a platelet-rich white portion (distal to the ligation site) and an  
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Figure 2.1. PAD4 is necessary for NET formation in response to Ca2+ 
ionophore and LPS from Klebsiella pneumoniae.  A, B. Neutrophils 
isolated from WT and PAD4+/- mice became hypercitrullinated at histone H3 
(A) and form NETs (B) in response to stimulation with LPS or ionomycin for 2 
h.  Stimulated PAD4-/- neutrophils were negatively stained by an antibody 
recognizing histone H3 citrullination at residues 2, 8, and 17 and did not form 
NETs.  C. Representative micrographs of ionomycin stimulated cells showing 
an H3Cit-positive NET emerging from a WT neutrophil and a condensed, 
delobulated nucleus in a PAD4-/- neutrophil.  H3Cit staining was absent in 
PAD4-/- neutrophils.  H3Cit, green; Gr1 antigen on plasma membrane, orange; 
DNA, blue.  Representative of n=4, scale bar, 10 µm.  *p<0.05  
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erythrocyte-rich red portion (proximal to the ligation site).  Since PAD4-deficient 
mice do not form NETs in vitro, we hypothesized that NET formation would be 
greatly impaired in these mice during thrombosis and this may affect thrombus 
formation and/or stability. PAD4-/- mice were partially protected from producing 
venous thrombi early after stenosis, with only 28.6% of PAD4-/- mice forming 
thrombi at 6 h compared to 66.7% of WT mice (p=0.04, Fig. 2.2A).  Thrombi that 
formed in PAD4-/- mice were similar in length to WT thrombi (Fig. 2.2B). PAD4-/- 
mice also maintained normal platelet counts compared to control sham-operated 
animals and after stenosis had significantly higher platelet counts than WT mice 
(Fig. 2.2C). In contrast to the diffuse extracellular H3Cit pattern in thrombi 
previously described at 48 h1, immunostaining revealed that the majority of H3Cit 
was nuclear rather than extracellular in the WT thrombi at this early time point 
(Fig. S2.1A), while H3Cit staining was not detected in PAD4-/- thrombi (Fig. S2.1B, 
WT, 28.3 ± 0.75 H3Cit+ cells per mm2; PAD4-/-, no H3Cit+ cells detected. n=4). 
The thrombi presented similar histological morphologies with comparable density 
of leukocytes as seen by hematoxylin and eosin staining (Fig. S2.1C).  To see if 
this early protection could be a result of delayed thrombus formation in PAD4-/- 
mice, we next maintained stenosis for 48 h, when the great majority of WT mice 
form a thrombus10, and found that while 90% of WT stenotic vessels thrombosed, 
fewer than 10% of PAD4-/- mice had a thrombus at this time point (p=0.0002, Fig. 
2.2D, 2.2E). Thrombocytopenia was associated with thrombus formation in WT 
mice, while PAD4-/- mice retained normal platelet levels (Fig. 2.2F). Thus, 
platelets are likely consumed by the thrombus.  It is important to note that at 
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Figure 2.2. PAD4-/- mice are protected from DVT, especially at 48 h after 
stenosis. A,B. PAD4-/- mice were less likely to form thrombi at 6 h than WT mice. 
C. Platelet count is decreased in WT compared to PAD4-/- mice after 6 h in the 
venous stenosis model. D,E. At 48 h, only one small thrombus was present in a 
PAD4-/- mouse, while all but one of the WT mice had thrombi. F. WT and PAD4-/- 
mice have similar platelet counts before stenosis (Baseline). WT mice are 
thrombocytopenic at 48 h, while platelet counts remain stable in PAD4-/- mice. 
G,H. Composite image of a section from an entire thrombus collected at 48 h 
showing diffuse, extracellular H3Cit (green) staining in a WT mouse (G), which is 
completely absent in the sole thrombus from a PAD4-/- mouse (H). Hoechst 
staining of DNA is shown in blue and shows extensive presence of leukocytes in 
both thrombi. Scale bars, 100 µm. I. H&E staining of 48 h thrombi shows less 
dense nuclear staining and diffuse, likely extracellular, DNA (arrows) in WT  
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Figure 2.2 (Continued). thrombi compared to dense nuclei found in the PAD4-/- 
thrombus. Scale bar, 20 µm. J. Thrombi collected from WT mice or the PAD4-/- 
mouse that formed a thrombus 48 h after IVC stenosis showed an abundance of 
neutrophils by Ly6G immunostaining (red). Scale bar, 20 µm. DNA is shown in 
blue. *p<0.05,  **p<0.01, ***p<0.001 
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baseline, WT and PAD4-/- mice had similar platelet counts (Fig. 2.2F).  The 
extracellular H3Cit meshwork seen in WT thrombi at 48 h post ligation was  
again completely absent in the sole PAD4-/- thrombus, indicating that also in vivo, 
only PAD4 modifies histone H3 to produce H3Cit  (Fig. 2.2G, 2.2H).  Hematoxylin 
and eosin staining revealed many swollen neutrophil nuclei in WT thrombi, while 
the PAD4-/- thrombus contained smaller and more dense neutrophil nuclei (Fig. 
2.2I). Neutrophils are abundantly present within WT thrombi at 48 h1, and also in 
the only thrombus in the PAD4-/- mouse (Fig. 2.2J), suggesting that neutrophils 
are recruited to the PAD4-/- thrombus.  NETs were absent in the single small 
PAD4-/- thrombus we obtained and analyzed by immunofluorescence staining.  
Thus, PAD4 deficiency was highly protective in the DVT mouse model at 48h, 
when in WT mice extracellular chromatin is prominently displayed1 (Fig. 2.2G).   
 
Endothelial activation and platelet function are not affected by PAD4 deficiency 
Although PAD4 is highly expressed in neutrophils, it is also present at 
lower levels in many cell types, where citrullination of histones may regulate gene 
expression17,23.  Therefore, it was important to establish in which cell type PAD4 
was responsible for this prominent role in pathological thrombosis.  First, we 
wished to investigate whether endothelial release of adhesion molecules for 
platelets and leukocytes, von Willebrand factor (VWF) and P-selectin, from 
WPBs occurs normally in PAD4-/- mice.  Both VWF and P-selectin were 
determined to be important in the stenosis model of DVT2,10.   We turned to a 
time point (6 h) by which WPBs have been released, resulting in massive platelet 
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and neutrophil adhesion to the endothelium10.  Platelet/leukocyte adhesion and 
aggregate formation on the IVC vessel wall were similarly present in both WT 
and PAD4-/- IVCs 6 h after stenosis (Fig. 2.3A; WT 8.97 ± 0.50, PAD4-/- 13.56 ± 
2.11 leukocytes per 200 µm of vessel wall, p=0.10, n=3). 
Another way to examine the capacity of mice to release WPBs is by 
infusion of activated platelets, which results in systemic WPB release from 
endothelial cells and consequently increases leukocyte rolling in veins24. 
Leukocyte rolling occurred in both WT and PAD4-/- mice to a similar extent over 
baseline 2 h after activated platelet infusion (Fig. 2.3B, 2.2C), an interaction that 
is dependent on endothelial P-selectin and PSGL-1 on leukocytes24. Plasma 
VWF levels were similarly elevated in WT and PAD4-/- mice 2 h after platelet 
infusion (WT 154.6 ± 8.24%, PAD4-/- 140.0 ± 21.8% of control pooled plasma, 
n=4, p=0.56). Taken together, the protection of PAD4-/- mice in DVT is not due to 
a defect in endothelial activation leading to VWF and P-selectin release, nor in 
the initial leukocyte and platelet adhesion to the vessel wall which is essential for 
thrombus initiation in venous stenosis2,10. Since PAD4 could be expressed in 
megakaryocytes and thus affect the properties of platelets, we next evaluated the 
PAD4-/- platelets.  As Fig. 2.2F shows, at baseline the platelet count in PAD4-/- 
mice was normal.  PAD4-/- platelets aggregated normally in response to low and 
high doses of thrombin (Fig. 2.3D, 2.2E).  This shows that, in general, platelet 
activation, granule secretion, and integrin activation are not affected in these 
mice.  We then examined in vivo models in which platelets respond to injury by 
forming a platelet plug: tail bleeding time and the ferric chloride model of  
!! 61 
 
#A# VWF#
CD41#
DNA#
WT% VWF#
CD41#
DNA#
PAD4-/-%
D# E#
G#
 WT!  PAD4-/-!
H#
#
#
#
#
#
#
#
F#
WT!
!
PAD4-/-!
!
CB#
WT
 B
L
PA
D4
-/- 
BL
WT
 2h
PA
D4
-/- 
2h
0
20
40
60
80
100
*
NS
NS
# 
Le
uk
oc
yt
es
 ro
lli
ng
 / 
m
in
Figure 2.3. Normal adhesive interactions among platelets, leukocytes, and 
endothelium in PAD4-/- mice. A. Representative images of platelets, leukocytes, 
and platelet-leukocyte aggregates on endothelium in WT (left) or PAD4-/- (right) 
IVCs collected 6 h after ligation. VWF, red; CD41 (platelets), green; DNA, blue. 
n=3-4. Scale bar, 20 µm. B,C. Activated platelets were infused into WT or PAD4-/- 
mice. B. Leukocyte rolling was assessed in mesenteric venules by counting the 
number of cells crossing a defined line per minute. Baseline leukocyte rolling was 
determined in untreated mice. n=4-6. C. Representative still images from intravital 
microscopy movies showing numerous rolling leukocytes 2 h after activated  
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Figure 2.3 (Continued). platelet infusion in WT or PAD4-/- mice. Scale bar, 100 
µm.  D,E.  Aggregometry of washed platelets stimulated with thrombin at 1 U/ml 
or 0.01 U/ml. D. Maximum aggregation was similar between WT and PAD4-/- 
mice. E. Representative traces showing similar kinetics of aggregation between 
WT and PAD4-/- platelets. Red line, PAD4-/-; black line, WT. n=4-5. F. A 2 mm tail 
segment was transected and bleeding monitored for 15 min. The time to the first 
cessation in bleeding was recorded for each mouse. One mouse from each group 
failed to stop bleeding and these were determined to be statistical outliers using 
Grubb’s test and excluded from means. G,H. Venous thrombosis after injury. 
Mesenteric venules were externalized and injured with application of 10% FeCl3-
soaked filter paper for 5 min. G. Time to vessel occlusion was measured and 
found to be similar in WT and PAD4-/- mice. H. Representative images of 
occlusive thrombi formed in WT (left) or PAD4-/- mice (right).  n=11-12. Scale bar, 
200 µm. 
 
!! 63 
thrombosis.  Tail tip transection results in severing of both veins and artery and 
the rapid cessation of blood flow depends on platelet function and coagulation.  
Time to cessation of bleeding was similar in WT and PAD4-/- mice (Fig. 2.3F), 
indicating that these mice have normal hemostatic potential.  In the venous 
stenosis model, flow restriction leads to WPB secretion potentially due to local 
hypoxia25, resulting in platelet-leukocyte interactions with the endothelium. In the 
ferric chloride model, by contrast, oxidative injury removes the endothelium and 
exposes circulating blood to the subendothelial matrix26.  Platelets bind to the 
subendothelium via GPIb, integrins, and GPVI, then become activated and 
aggregate via integrin receptors27.  We visualized thrombus formation in FeCl3-
injured mesenteric venules using intravital microscopy and found that PAD4-/- 
mice formed occlusive thrombi with similar kinetics (Fig. 2.3G) and thrombus 
morphologies (Fig. 2.3H) as WT mice.  Thus, we have no evidence that PAD4 or 
NETs play a significant role in hemostasis in healthy mice.  For platelet plug 
formation in the injured veins, coagulation is likely driven by vessel wall tissue 
factor and the enhancement of coagulation and thrombosis by NETs may not be 
necessary.  
 
Neutrophil PAD4 is a key player in pathological thrombus formation 
To assess whether the influence of PAD4 was of hematopoietic origin, we 
generated bone marrow (BM) chimeras by infusing WT or PAD4-/- BM cells into 
lethally irradiated WT recipients.  Both groups of mice recovered body mass with 
similar kinetics (Fig. S2.2A).  To test the chimerism, we stimulated leukocytes 
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from whole blood after red blood cell (RBC) lysis with ionomycin and found that 
the PAD4-/- BM chimeras failed to hypercitrullinate arginine residues at histone 
H3 (Fig. S2.2B, S2.2C).  Similar to the thrombus formation frequencies in WT 
and PAD4-/- mice, a majority (6 out of 7) of WT BM chimeras produced thrombi 
after 48 h of stenosis, while only 1 of the 7 PAD4-/- BM chimeras formed a small 
thrombus (Fig. 2.4A, 2.4B).  The H3Cit pattern within thrombi paralleled the 
results seen in WT and PAD4-/- mice, with extracellular H3Cit present in the 
thrombi of WT BM chimeras but H3Cit staining absent in the PAD4-/- BM chimera 
thrombus (Fig. S2.2D, S2.2E).  WT BM chimeras became thrombocytopenic 48 h 
post stenosis, while PAD4-/- BM chimeras maintained normal platelet counts (Fig. 
2.4C).  
 As PAD4 is expressed by other leukocytes besides neutrophils28,29 that 
may enter the thrombus, we investigated whether the infusion of WT neutrophils 
could rescue thrombosis in PAD4-/- mice at 48 h. Infusing 4-5 x 106 isolated WT 
BM neutrophils into PAD4-/- mice restored thrombus generation (Fig. 2.4D, 2.4E). 
Although a significant lowering of platelet count was not achieved by neutrophil 
infusion (Fig. 2.4F), mice that had formed a thrombus in either WT and PAD4-/- 
recipients, did, however, have a significant decrease in platelet count compared 
to baseline levels (Fig. S2.3). Infused neutrophils were of >95% purity as 
assessed by Wright-Giemsa staining (Fig. S2.4C).  The thrombi from neutrophil-
infused PAD4-/- mice contained large numbers of Ly6G+ neutrophils, while F4/80+ 
monocytes/macrophages were rarely seen within all thrombi examined (Fig. 
S2.4A, S2.4B, S2.4D). Thrombi were analyzed by immunofluorescence and  
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Figure 2.4. Venous thrombosis depends on the presence of PAD4 in 
neutrophils.  A-C.  Chimeric mice were generated by infusing WT or PAD4-/- 
BM cells into lethally irradiated WT recipients and later subjected to 48 h IVC 
stenosis.  A. Percent of BM chimeras that produced thrombi.  B. Length of 
thrombi.  C. Platelet counts in BM chimeras 48 h after DVT surgery.  WT→WT 
BM chimeras became thrombocytopenic, while PAD4-/-→WT BM chimeras 
maintained normal platelet counts.  D-H.  WT or PAD4-/- mice received an i.v. 
infusion of 4-5 x 106 WT neutrophils immediately prior to DVT surgery and 2-2.5 
x 106 neutrophils at 24 h. D, E. A majority (80%) of both WT and PAD4-/- mice 
formed thrombi after the infusion of WT neutrophils. F. Similar platelet counts 
were measured 48 h after IVC ligation in WT and PAD4-/- mice infused with WT 
neutrophils.  G, H. Composite images of thrombi collected from mice infused 
with WT neutrophils.  H3Cit-positive nuclei and extracellular staining was 
detected in WT (G) and PAD4-/- (H) thrombi, indicating that the infused WT 
neutrophils integrated into the PAD4-/- thrombus. H3Cit, green; DNA, blue. 
Representative of n=4.  Scale bar, 100 µm. * p<0.05.  
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extracellular H3Cit staining was present within both WT and PAD4-/- recipient 
thrombi after WT neutrophil infusion (Fig. 2.4G, 2.4H), indicating that the WT 
neutrophils were incorporated and produced NETs in the thrombus scaffold in 
PAD4-/- recipient mice. Therefore, PAD4 within neutrophils is important for 
formation of stable thrombi in large veins, as the defect in thrombosis in PAD4-/- 
mice can be rescued by supplementation with WT neutrophils.  
 
Discussion 
For more than 150 years, hypercoagulable state, hypoxia due to flow 
disturbance such as in valves or stasis, and vascular activation were recognized 
as the main players in DVT30.  Only recently has the active contribution of blood 
cells to DVT begun to be appreciated. First, the complex role of inflammatory 
cells was recognized in that they promote thrombosis, for example through 
production of tissue factor, and also contribute to thrombus resolution31.  Second, 
the important role of platelets in DVT has been described in animal models and 
human trials1,32,33. Venous pathological thrombi were thought to be formed by 
fibrin and trapped RBCs and the main treatment in humans is still anti-
coagulation. It is now clear that pathological thrombus formation and stabilization 
are much more complex, with many platelets and leukocytes present, and even 
the RBCs may not be trapped but rather actively recruited to the thrombus by 
NETs8.  Thus, new treatment options are being revealed.   
Here we present a new facet of DVT, the importance of neutrophil post-
translational modification and chromatin decondensation, factors dramatically 
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influencing outcome of stenosis-induced DVT in mice. The enzyme PAD4 allows 
for dissociation of heterochromatin protein 1-β 19, affects linker histone H116, and 
reduces the positive charge of histones by arginine citrullination, thus allowing 
nucleosomes to unravel and chromatin to be expelled from the swollen nuclei. 
Absence of NETosis resulted in the formation of fewer thrombi in PAD4-/- mice 
early after the flow disturbance/hypoxia onset with almost no thrombi by 48 h. 
DVT represents the first non-infectious model in which the PAD4-/- mice are 
affected, and surprisingly to date this is the strongest phenotype described in 
these mice18,34,35.  
We have demonstrated that PAD4 deficiency does not perturb initial 
vessel wall activation and platelet-leukocyte adhesion. Also, platelets from PAD4 
knockout mice are fully functional, and able to produce platelet plugs like WT 
platelets.  The low incidence of DVT in PAD4-/- mice is largely caused by a lack of 
PAD4 in neutrophils as WT neutrophils could rescue the DVT process.  The 
protection in PAD4-/- mice from DVT is due to the failure of neutrophils to form 
NETs as the PAD4-/- neutrophils interact properly with the vessel wall and are 
present in the rare thrombi that form in PAD4-/- veins. Our observation of less 
extracellular H3Cit in WT thrombi at 6 h than at 48 h (Fig S2.1, Fig. 2.2) fits well 
with the report of von Bruhl and colleagues2 showing that neutrophils begin to 
throw NETs by 3 h in this DVT model, but the prominent diffuse staining pattern 
of NETs is present only later, at 48 h. Thus, NETs comprise a crucial part of the 
pathologic thrombus scaffold, and the lack of NETs formation results in fewer 
thrombi early on which appear not to be sustained over time. 
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Our observations help to pinpoint the importance of neutrophils and NETs 
in thromboembolic disease. Inhibitors of neutrophil activation in the thrombus, 
inhibitors of PAD4 activation or inhibitors of NET release would all impact DVT 
outcome.  Therapeutic interventions combining both DNases and proteolytic 
enzymes may improve thrombolysis in patients with DVT.  In addition, specific 
PAD4 inhibitors are not likely to impair hemostasis or neutrophil function in 
thrombus resolution. Thus, a better understanding of the complexity of 
pathological thrombosis, including the process of chromatin decondensation in 
neutrophils, will bring us closer to devising more effective and targeted 
treatments.   
 
Materials and Methods 
Mice  
Experimental procedures in this study were reviewed and approved by the 
Institutional Animal Care and Use Committee of Boston Children’s Hospital 
(Protocol No. 11-03-1919, 11-04-1848, 11-03-1941).  WT mice were purchased 
from Jackson Laboratory.  PAD4-/- mice have been recently backcrossed to 
C57Bl/6J for 7 or more generations.  
 
Neutrophil isolation for in vitro NET assays. 
Peripheral blood was collected via the retroorbital venous plexus and neutrophils 
were isolated from 6-10 week-old male or female WT, PAD4+/-, or PAD4-/- mice 
as previously described 11.  Cells were routinely assessed to be >90% pure by 
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Wright-Giemsa stain.  Neutrophils in RPMI/HEPES were allowed to adhere at 
37°C in 5% CO2 to glass-bottom plates for 20 min prior to stimulation with 10 
µg/ml LPS from Klebsiella pneumoniae (Sigma) or 4 µM ionomycin (Invitrogen).  
After 2 h, cells were fixed in 2% PFA.   
 
Venous stenosis model 
Venous stenosis experiments were performed as previously described10.  Mice 
were anesthetized with 3.5% isoflurane and anesthesia maintained at 2% in 
100% oxygen.  A midline laparotomy was performed and the inferior vena cava 
exposed.  Any side branches between the renal and iliac veins were ligated with 
7/0 polypropylene suture.  A 30 G spacer was placed parallel to the inferior vena 
cava and 7/0 polypropylene suture was used to partially ligate the IVC to ~10% of 
its original diameter. The spacer was removed and the mouse sutured and 
allowed to recover.  After 6 h or 48 h, mice were anesthetized with isoflurane, 
blood was collected via the retroorbital sinus plexus, and the IVCs exposed to 
allow for collection of the inferior vena cava vessel wall or thrombi formed within 
the IVC.  Thrombus length was measured and thrombi were embedded in OCT 
for cryosectioning.  All mice were given buprenorphine (0.1 mg/kg, s.c.) as an 
analgesic immediately prior to surgery and every 8-12 h subsequently.   
 
Immunostaining and fluorescence microscopy 
Fixed cells or tissue sections were washed with PBS and permeabilized (0.1% 
Triton X-100, 0.1% sodium citrate) for 10 min at 4°C.  Samples were blocked with 
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3% BSA for 90 min at 37°C, rinsed, and then incubated overnight at 4°C or for 1 
h at 37 °C in antibody dilution buffer containing 0.3% BSA, 0.1% Tween-20, and 
either rabbit anti-histone H3 (citrulline 2, 8, 17) (0.3 µg/ml, ab5103, abcam), rat 
anti-Gr1 (0.5 µg/ml, clone RB6-8C5, eBioscience), rat anti-Ly6G (0.5 µg/ml, 
clone 1A8, Biolegend, San Diego, CA), or rat anti-F4/80 (1:250, ab16911, 
abcam). After several washes, samples were incubated for 2 h at room 
temperature in antibody dilution buffer containing Alexa Fluor®-conjugated 
secondary antibodies in 0.3% BSA in DPBS: goat anti–rat immunoglobulin (IgG) 
(Alexa555, 2 µg/mL), donkey anti–rabbit IgG (Alexa488, 1.5 µg/mL), or donkey 
anti–sheep IgG (Alexa568, 2 µg/mL, Invitrogen).  DNA was counterstained with 1 
µg/ml Hoechst 33342 and slides coverslipped with Fluoromount gel (Electron 
Microscopy Sciences).  Fluorescent images were acquired using an Axiovert 200 
widefield fluorescence microscope (Zeiss) in conjunction with an Axiocam MRm 
monochromatic CCD camera (Zeiss) and analyzed with Zeiss Axiovision 
software.  All channels were acquired in greyscale and pseudocolored using 
Zeiss Axiovision or ImageJ software (National Institutes of Health, Bethesda, MD, 
USA). Exposure times are identical between WT and PAD4-/- thrombi or 
neutrophils.   Composite images were generated with the MosaicJ plugin36 for 
ImageJ software.  
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Platelet counts 
Whole blood was collected via the retroorbital sinus into EDTA-coated capillary 
tubes.  Twenty-five µl of blood was analyzed by a Hemavet 950FS (Drew 
Scientific) for complete blood counts.   
 
Platelet aggregation 
Murine blood was collected in 10% (v/v) sodium citrate (3.2%) and centrifuged at 
800g for 10 min.  Platelet rich plasma was collected and PGI2 added in Tyrode’s 
buffer.  Platelets were washed and resuspended in Tyrode’s buffer and incubated 
at 37°C. 2.5 x 105 platelets per µl were analyzed using a Chronolog Platelet 
aggregometer. 1 U/ml or 0.01 U/ml of thrombin in the presence of calcium 
chloride were used as agonists for aggregation and samples were analyzed for at 
least 10 min.   
 
Tail bleeding time 
Six to eight-week-old male or female C57Bl/6J or PAD4-/- mice were anesthetized 
using 2.5% tribromoethanol (300 mg/kg) administered intraperitoneally.  A 2-mm 
segment of the tail tip was transected using a single edge razor blade and the tail 
was immediately submersed in 37°C PBS.  Tail bleeding was monitored for 15 
min and the time to stop was recorded when bleeding had stopped for more than 
30 sec. All mice were sacrificed immediately at the end of the observation period. 
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Activated platelet-induced endothelial activation 
Platelets were isolated from C57Bl/6J male or female mice as previously 
described24.  Washed platelets were resuspended in Tyrode’s buffer containing 2 
mM EDTA and 0.2 U/ml thrombin and incubated for 15 min at 37°C before 
addition of 1 U/ml hirudin.  1 x 108 platelets were injected into 4-6-week old 
C57Bl/6J mice via the retroorbital sinus and plasma collected after 2 h for VWF 
analysis.  For leukocyte rolling studies, 1 x 108 platelets were injected into 4-
week-old WT or PAD4-/- males.  After 2 h, rhodamine 6G was injected i.v. in order 
to fluorescently label leukocytes, and mesenteric venules externalized to 
visualize leukocyte rolling.  One venule of between 200 to 300 microns in 
diameter was monitored per mouse. Leukocyte rolling was quantified for 3-5 
independent minutes as the average number of cells rolling past a defined line 
across the vessel per minute.  Baseline was determined in untreated animals.   
 
FeCl3- induced mesenteric venous thrombosis 
Three to four-week-old C57Bl/6J or PAD4-/- male mice were anesthetized using 
2.5% tribromoethanol (300 mg/kg) administered i.p. and the level of anesthesia 
verified by lack of response to footpad squeeze. Rhodamine 6G was given via 
retroorbital injection to fluorescently label platelets and leukocytes.   A midline 
incision was performed and the intestines externalized to reveal mesenteric 
vessels.  A single venule of between 200-300 microns in diameter was visualized 
for each mouse (WT mice, 222.2 ± 20.6 µm; PAD4-/- mice 239.0 ± 44.6 µm). A 1-
mm x 3-mm piece of filter paper was soaked in 10% ferric chloride, gently placed 
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on the vessel for 5 min and then removed.  Occlusion time was noted for each 
mouse.  Vessels were considered occluded when blood flow had stopped for at 
least 10 sec. 
 
Bone marrow chimera preparation and validation 
Four-week-old C57Bl/6J males were lethally irradiated with 1100 rad and 
immediately given an i.v. injection of at least 1 x 107 bone marrow cells from 
either WT or PAD4-/- mice.  Mice were housed in autoclaved cages, monitored 
daily and weighed every other day for one month.  Six weeks post-irradiation, 
100 µl of blood was collected from each mouse, RBCs lysed with ACK lysis 
buffer (Invitrogen), and leukocytes plated and stimulated with 4 µM ionomycin for 
2 h. The total leukocyte population was studied rather than isolated neutrophils in 
order to minimize the volume of blood being drawn from mice prior to DVT 
surgeries.   Immunostaining for H3Cit was performed to verify successful 
chimerism. Following blood collection, mice were allowed to recover for 2 weeks 
prior to DVT surgery.    
 
Neutrophil infusion  
Neutrophil adoptive transfer studies were performed as previously described37.  
BM  neutrophils were isolated from 6-8 week-old C57Bl/6J WT mice using a 
Percoll™ (GE Healthcare Life Sciences) gradient and rapid hypotonic lysis. Bone 
marrow was flushed out of tibias and femurs using a 30 G needle into cold RPMI.  
Cells were pelleted, resuspended in PBS, and layered onto a Percoll gradient 
!! 74 
containing 78%/69%/52% Percoll.  Cells at the 78%/69% interface were collected 
and subjected to hypotonic lysis.  Cells were counted using a hemacytometer 
and resuspended in RPMI. Purity was assessed by Wright-Giemsa staining, 
which was determined to be >95% neutrophils.  4-5 x 106 cells were injected i.v. 
through the retroorbital sinus immediately prior to DVT surgery. A second i.v. 
neutrophil infusion of 2-2.5 x 106 neutrophils was given at 24 h.  Mice were 
sacrificed at 48 h and any resulting thrombi harvested for analysis.   
 
Statistics 
Data are presented as means ± SEM unless otherwise noted and were analyzed 
using a two-sided Student’s t-test or Mann-Whitney U test. Thrombus 
frequencies were analyzed using chi-squared tests of contingency tables.  All 
analyses were performed using GraphPad Prism software (Version 5.0).  Results 
were considered significant at p<0.05.   * p<0.05, ** p<0.01, ***p<0.001 
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Chapter 3 
PAD4-deficiency does not worsen polymicrobial sepsis 
mortality and ameliorates endotoxemic shock 
 
 
 
 
 
This chapter contains one submitted manuscript: 
Martinod K, Fuchs TA, Wong SL, Demers M, Gallant M, Wang Y, Wagner DD.  
PAD4-deficiency does not worsen polymicrobial sepsis mortality and ameliorates 
endotoxemic shock.  Submitted July 10, 2014 to Blood. Major revisions August 9, 
2014. 
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Section 3.1: Overview and Attributions 
Overview 
NETs were shown to trap microbes, but also fuel cardiovascular, thrombotic and 
autoimmune disease.  In Chapter 2 I have shown that PAD4-deficient animals 
are protected from thrombosis, without any obvious hemostatic defects.  
Therefore, inhibiting NET formation could be a useful therapeutic approach for 
preventing pathological deep vein thrombosis and our results show that PAD4 is 
a very attractive target.  However, according to the dogma of the literature, 
inhibition of NETs could come at a cost in the presence of a bacterial infection.  
In the case of severe systemic infection in sepsis, the balance between the 
antimicrobial functions of NETs and the harmful consequences of releasing 
histones and other cytotoxic components of NETs into the extracellular space, 
particularly in the vasculature, remained to be determined.  NETs could be 
providing early protection from bacterial dissemination, but when released in 
excess could eventually lead to hypercoagulability and tissue damage.  It was 
therefore important to study the PAD4-/- mice in a severe infection model where 
NETs have been previously shown to be released and where histones were 
shown to contribute to death in cecal ligation puncture and LPS-induced sepsis1.  
Before pursuing sepsis models, we first investigated whether PAD4-/- neutrophils 
had any defects in functions important for antimicrobial effects, such as 
extravasation to sites of inflammation, generation of reactive oxygen species, 
and the ability to degranulate.  We found that PAD4-/- neutrophils were competent 
in all of these, and therefore the PAD4-/- mouse provides us with a model where 
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NETs are not being released, while neutrophils retain the ability to fight infection 
by other means such as phagocytosis.  When we subjected the PAD4-/- mice to 
severe and mild polymicrobial sepsis, we found that the mice did not develop 
higher bacteremia than wild-type animals, and had similar mortality.  We also 
wanted to compare the PAD4-/- animals in the absence of a live bacterial infection 
to study the effect of NET release on the pathogenesis of endotoxemic shock.  
Here we found that PAD4-/- animals released less nucleosomes into circulation, 
and that this had a protective effect by delaying mortality and diminishing signs of 
shock.  However, there were high amounts of chromatin still detectable in the 
plasma and therefore NETs contribute significantly to mortality but were not the 
sole contributor of toxic histones.  In a world of antibiotics, inhibition of NET 
release may in fact be beneficial, and we hope that our studies will encourage 
the development of specific PAD4 inhibitors.   
 
Supplemental figures are provided in Appendix A-2.  
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Abstract 
 
Neutrophil extracellular traps (NETs), consisting of nuclear DNA with histones 
and microbicidal proteins, are expelled from activated neutrophils during sepsis.  
NETs were shown to trap microbes, but also fuel cardiovascular, thrombotic and 
autoimmune disease.   The role of NETs in sepsis, particularly the balance 
between their antimicrobial and cytotoxic actions, remains unclear.  Neutrophils 
from peptidylarginine deiminase 4-deficient (PAD4-/-) mice, which lack the 
enzyme necessary for chromatin decondensation and NET formation, were 
evaluated. We found that neutrophil functions involved in bacterial killing, other 
than NETosis, remained intact.  We hypothesized therefore that prevention of 
NET formation might not have devastating consequences in sepsis.  To test this 
we subjected the PAD4-/- mice to severe and mild polymicrobial sepsis produced 
by cecal ligation and puncture.  Surprisingly, under septic conditions, PAD4-/- 
mice did not fare worse than wild-type mice and had comparable survival. 
However, PAD4-/- mice were partially protected from lipopolysaccharide-induced 
shock, suggesting that NETs contribute to the toxic inflammatory and 
procoagulant host response to endotoxin. We propose that preventing NET 
formation may have beneficial effects in sepsis, and that PAD4 inhibition in 
inflammatory or thrombotic diseases is not likely to render the host vulnerable to 
bacterial infections.  
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Introduction 
 
Sepsis remains a significant health care problem with approximately 
750,000 cases per year leading to death in 30% of patients in the U.S.2. The 
pathologies of sepsis result not only from the presence of an infection, but also 
from the hyperinflammatory host response3. The vast systemic effects seen in 
sepsis result in diagnostic criteria that are broad in nature4.  Severe sepsis, 
characterized by organ dysfunction, and septic shock, accompanied by 
hypotension, can rapidly progress to an irreversible stage in which survival is not 
possible despite therapeutic intervention3,4.   
Neutrophil extracellular traps (NETs) are the result of a coordinated 
biological process whereby neutrophils release their nuclear DNA accompanied 
by many antimicrobial proteins including histones5-7. The first report identified 
NETs in an infected appendix5. Using animal models of sepsis, the release of 
NETs within the vasculature became evident7-9.  NET biomarkers are elevated in 
septic patients10-12. Microbes trapped within NETs are sometimes killed5,13 and 
thus NETs could represent an important mechanism of host defense, particularly 
in sepsis8,14-16. To date this has not been rigorously tested. NETs have been 
identified in the cecal ligation puncture (CLP) mouse model of polymicrobial 
sepsis17,18 and dissolution of NETs by DNase infusion has been proposed to 
transiently exacerbate sepsis17. 
The release of NETs within the bloodstream has important procoagulant 
and prothrombotic implications14,19.  NETs can bind platelets and red blood 
cells19 and thus participate in the initiation of pathological thrombosis20,21. 
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Peptidylarginine deiminase 4 (PAD4) is essential to chromatin decondensation 
during NETosis by modifying histone charges through citrullination22,23. We have 
seen important anti-thrombotic and cardioprotective effects in the absence of 
NETs24,25 using PAD4-/- mice, which do not decondense chromatin or form 
NETs22. In our colony, these mice do not suffer from opportunistic infections.   
The most abundant proteinaceous components of NETs are histones26, 
which are themselves not only procoagulant1,27-29 but also highly cytotoxic to 
endothelium1,30,31. The hypercoagulable state and organ dysfunction exacerbated 
by histones, some of which may originate from NETs, can quickly lead to host 
mortality1. Therefore, it is important to study sepsis in PAD4-/- mice, which do not 
form NETs, in order to further delineate the balance between antimicrobial host 
defense and the pathological consequences of NET release.  Here we report that, 
unexpectedly, mice that cannot make NETs fared the same or better than wild-
type mice in mouse models of sepsis. 
 
Results 
 
PAD4-/- mice have circulating neutrophil numbers similar to wild-type 
PAD4+/+ mice and their bacterial killing ability by phagocytosis is not impaired22.  
PAD4-/- mice are completely unable to generate NETs, even in response to 
reactive oxygen species (ROS)-dependent stimuli such as PMA22. Exogenous 
H2O2 fails to generate NETs in vitro22, as does calcium increase by ionophores24. 
This highlights the importance of histone citrullination-mediated chromatin 
decondensation during NETosis.  We found that PAD4-/- cells are capable of 
producing ROS, as H2O2 generation occurs in PAD4-/- neutrophils (Figure 3.1A).  
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Figure 3.1.  Neutrophils from PAD4-/- mice are competent in non-NET 
functions. A. Diluted, anticoagulated whole blood was incubated with 1 µM 
ionomycin, 100 nM PMA, or vehicle for 20 min at 37°C in the presence of 
dihydrorhodamine-123.  Rhodamine+ ROS-generating neutrophils are 
quantified for each condition (left panel) and representative plots are shown 
(right two panels).  n=4-13.  B. Diluted whole blood was preincubated with 5 
mM cytochalasin B for 20 min then incubated with 1 µM ionomycin, 100 nM 
PMA, or vehicle for 10 min at 37°C.  Lamp1+ Ly6G+ degranulated cells are 
quantified in the left panel, with representative plots shown in the right panels.  
n=4-13.  C. Leukocyte recruitment was assessed in vivo using thioglycollate-
induced peritonitis.  Infiltrating cells were counted in peritoneal lavage fluid at 
the indicated time points (left panel) and differential counts performed at 4h 
from Wright Giemsa-stained cytospins to assess neutrophil infiltration (center 
panel).  Representative 4h cytospin images are shown in the right panels. 
Scale bar, 10 µm. 
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We also show here that the ability to degranulate is not affected by PAD4-
deficiency (Figure 3.1B).  Leukocyte rolling along activated endothelium occurs 
normally in PAD4-/- mice24. To investigate the ability of neutrophils to extravasate 
in response to an inflammatory stimulus, we quantified leukocyte recruitment to 
the peritoneum in a model of thioglycollate-induced peritonitis and found that 
PAD4-/- mice recruited similar numbers of leukocytes as PAD4+/+ mice over time, 
and that neutrophil recruitment was also not impaired as determined by 
quantification of cells with characteristic neutrophil nuclear morphology (Figure 
3.1C).  Therefore, the use of PAD4-/- animals for sepsis studies appears to 
provide an ideal model in which to examine the role of NETs, because 
neutrophils can be recruited and are otherwise competent in non-NET 
microbicidal functions.   
The CLP mouse model of sepsis involves ligation of the cecum followed 
by perforation, allowing fecal contents to be extruded into the peritoneal cavity 
and resulting in polymicrobial sepsis32. In this model, circulating cell-free DNA is 
elevated in plasma17, and NETs are seen in liver sinusoids18. We performed 
CLP32 in PAD4-deficient animals and compared them to their PAD4+/+ and 
PAD4+/- littermates.  We hypothesized that PAD4-/- mice would be the most 
susceptible in this model due to a reduced ability to kill bacteria via NETosis, 
especially in low-grade CLP where PAD4+/+ mice are able to contain the infection 
well.   
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Figure 3.2. PAD4-/- mice are equally as susceptible to polymicrobial 
sepsis as their PAD4+/+ littermates in the cecal ligation puncture model.   
Mice were subjected to high-grade CLP (panels A-D) or low-grade (panels E-
H) CLP or sham operation (Sham).  A. Survival curves indicating similar 
survival rates of PAD4-/- mice and their PAD4+/- or PAD4+/+ littermates in high-
grade CLP. B. Loss of body temperature was similar in PAD4-/- mice and their 
littermates. C. Bacterial colony forming units (CFU) were quantified from the 
blood of high-grade CLP to measure systemic bacteremia and were not 
significantly different between genotypes. D. High-grade CLP resulted in 
significant increases in circulating plasma DNA in PAD4+/+ or PAD4+/- mice 
compared to PAD4-/- mice E, F. As with high-grade CLP, low-grade CLP 
resulted in similar survival (E) and body temperature changes (F). G. Weight 
loss was comparable in PAD4+/+ vs. PAD4-/- mice, while sham-operated mice 
lost minimal body weight. H. Bacterial load was measured in peritoneal lavage 
fluid, blood, and liver and lung homogenates.  Minimal CFUs were detected in 
control non-operated mice.  Genotypes and treatments were as indicated.  No 
statistical differences between PAD4+/+ and PAD4-/- mice were detected. 
PAD4+/+, black. PAD4+/-, blue. PAD4-/-, red.  
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However, we were surprised to see that all genotypes responded similarly 
to either high-grade or low-grade CLP (Figure 3.2).   Mice exhibited similar 
mortality (Figure 3.2A, 3.2E) and clinical signs of sepsis, including hypothermia 
(Figure 3.2B, 3.2F) and weight loss (Figure 3.2G). As measured in a separate 
group of animals, blood cell counts were not statistically different between 
genotypes (Figure S3.1A, S3.1B, S3.1C). Leukocyte peritoneal recruitment 
occurred to a similar extent (Figure S3.1D, S3.1E), further demonstrating the 
capacity of PAD4-deficient neutrophils to transmigrate.  PAD4-/- mice had lower 
plasma DNA levels (Figure 3.2D, S3.1F), indicating that a significant portion of 
circulating DNA in sepsis originates from NETs.  However, the levels of 
circulating DNA are lower than has been reported in other NET-generating 
models20,33, possibly because NETs may be consumed in microthrombi within 
organs.  The bacterial load was similar in blood of all animals (Figure 3.2C, 3.2H) 
and no difference was seen in bacterial colony forming units (CFUs) in the 
peritoneum, liver, or lung in low-grade sepsis (Figure 3.2H).  Plasma alanine 
aminotransferase (ALT) levels were similarly elevated in both PAD4+/+ and PAD4-
/- animals (Figure S3.1G), suggesting that NETs are not responsible for bacterial 
infection-induced liver injury.  Although NETs form in the CLP model17,18, we 
show that they don’t influence either survival or the overall condition of the mice 
as PAD4-/- mice responded similarly to PAD4+/+ or PAD4+/- mice. The fact that 
PAD4-/- mice do not succumb to low-grade CLP (Figure 3.2E), as we had 
anticipated, shows that they are not severely immunocompromised. 
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DNase I degrades NETs5, and a recent study suggests that DNase 
infusion results in increased susceptibility to death in CLP17.  However, this effect 
was transient and minor, with higher mortality at 24h but similar mortality at 
subsequent time points.  While bacterial loads were elevated in DNase-treated 
mice 6h after CLP, by 24h CFUs were similar between treated and untreated 
mice17.  Histological evidence of increased organ damage was evident by 24h17 
and could be due to liberation of NET fragments by DNase I having a cytotoxic 
effect on distant tissues.  On the other hand, DNase I naturally facilitates 
clearance of NETs by macrophages34, diminishing toxic NET effects.    
There is vast evidence that aberrant NET production has pathological 
consequences in non-infectious conditions, including thrombosis24, autoimmune 
diseases35,36, and ischemia/reperfusion injury25,37.  Histones are an integral part 
of NETs5,26 and are cytotoxic to endothelial and epithelial cells1,31. In vivo, 
histones contribute substantially to mortality in sepsis1 and can induce 
thrombocytopenia38.  In order to study the effect of NETs and endotoxemia in 
mice without a live bacterial infection, we turned to established models of 
lipopolysaccharide-induced shock1,39 to generate large amounts of circulating 
nucleosomes in vivo.  While not an ideal model of human sepsis, LPS infusion 
allowed us to investigate the host response leading to endotoxemic shock, which 
has been extensively studied experimentally1,40. Also, we considered that while 
antibiotics used in patients kills pathogens, toxic products such as LPS may 
remain. In the LPS model, mortality is induced by the innate immune response, 
including cytokine storm and organ damage.   
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Intravenous infusion of lipopolysaccharides (LPS) from Salmonella 
enterica serotype typhimurium in PAD4+/+ mice resulted in reduced platelet and 
leukocyte counts (Figure S3.2A) and release of cell-free nucleosomes and 
lactate dehydrogenase (LDH), a marker of cell lysis, into circulation in mice1 
(Figure S3.2B). Furthermore, Figure S3.2C shows histone release and 
fragmentation over time similarly to that reported by Esmon and colleagues1. 
Although necrotic cells can also release nucleosomes in endotoxemia41, we saw 
that with increasing DNA release over time, citrullinated histone H3, a NET 
biomarker, became detectable in the plasma of PAD4+/+ mice39 (Figure S3.2D), 
indicating that NETs are formed in this model.  
To investigate the role of NETs in this model, we compared PAD4-/- to 
PAD4+/+ mice.  Mortality was significantly (p<0.007) delayed in PAD4-/- mice after 
a highly lethal dose of LPS (25 mg/kg; Figure 3.3A).  Similarly, an intermediate 
dose (10 mg/kg) resulted in 43.5% mortality in PAD4+/+ mice by 24 hours 
compared to 4.3% mortality in PAD4-/- mice (p<0.04; Figure S3.2F).  PAD4-/- mice 
became less hypothermic (Figure 3.3B) and less thrombocytopenic (Figure 3.3C) 
than PAD4+/+ mice. This effect was similar using a non-lethal dose (Figure S3.2G, 
3.3D), along with significantly higher leukocyte and neutrophil numbers in 
circulation (Figure 3.3D).  Plasma DNA levels were significantly lower in PAD4-/- 
mice (Figure 3.3E), indicating again that a portion of the nucleosomes released 
are coming from NETs.  H3Cit was not detected in any PAD4-/- mouse plasma, 
while it was present in PAD4+/+ mice 24 hours after LPS injection (Figure 3.3F).   
By 48h, cell free histone H3 and DNA levels were reduced and H3Cit was no  
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Figure 3.3. PAD4-/- mice release less extracellular DNA and are better 
protected than PAD4+/+ mice in an LPS-induced endotoxemic shock 
model. A. Mice were injected i.v. with a lethal dose of LPS (25 mg/kg) and 
monitored every 2 hours beginning at 12h for moribundity. B,C. Mice injected 
i.v. with a less lethal LPS dose (10 mg/kg) were measured for signs of  
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Figure 3.3 (Continued).  
hypothermia. PAD4-/- mice had a milder temperature drop (B) and had higher 
platelet counts than PAD4+/+ mice (C). D. Using a sublethal dose (2.5 mg/kg) 
which allowed us to follow mice surviving for 24h, similar differences in 
hypothermia and thrombocytopenia were observed.  Total leukocyte and 
neutrophil levels were also higher in PAD4-/- mice.  E,F. Plasma was collected 
at the time of sacrifice and analyzed for NET biomarkers.  E. Twelve hours 
after LPS infusion, DNA levels were lower in PAD4-/- mice.  F. Both histone H3 
and citrullinated histone H3 (H3Cit) were identified in the plasma of PAD4+/+ 
mice at 24h, and were no longer detected at 48h post-injection.  H3Cit was not 
found in PAD4-/- mouse plasma, while histone H3 was detected. 
Representative of n=7 (24h) and n=6 (48h).  G. H3Cit+ neutrophils were found 
in the lungs of PAD4+/+ mice 18h after injection, while no H3Cit+ neutrophils 
were detected in PAD4-/- mice.  Red, Ly6G. Green, H3Cit. Blue, DNA.  Scale 
bar, 20 µm. Representative of n=5.  H. IL-6 levels were similar in PAD4+/+ and 
PAD4-/- mice at 12h, while IL-10 levels were higher in PAD4-/- mice.  PAD4+/+, 
n=13. PAD4-/- n=12.  I,J. Soluble P-selectin levels (I) and thrombin anti-
thrombin complexes (J) in plasma are significantly elevated in PAD4+/+ mice 
compared to PAD4-/- mice, indicating that the presence of NETs activates 
platelets (increases P-selectin shedding) and induces generation of thrombin. 
Results are expressed as fold increase over control, untreated mice.  PAD4+/+, 
black, n=13. PAD4-/-, red, n=11. *p<0.05, **p<0.01 ***p<0.001. 
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longer detectable in plasma (Figure 3.3E, 3.3F).  Neutrophils with 
hypercitrullinated histone H3 are prominent in the lung 18h and 24h after LPS 
infusion in PAD4+/+ mice (Figure 3.3G, S3.2E).  Neutrophils were present in 
PAD4-/- mouse lungs, but they were not H3Cit-positive (Figure 3.3G).  As we and 
others have previously shown, the formation of NETs in the lung is injurious and 
reduces lung function42,43.  
To further investigate the effect of PAD4-deficiency in the endotoxemia 
model, we measured plasma cytokine levels and found similar levels of pro-
inflammatory interleukin-6 (IL-6) in PAD4+/+ and PAD4-/- animals (Figure 3.3H).  
Interestingly, IL-10, an anti-inflammatory cytokine that is critical for reducing the 
progression to irreversible shock44, was significantly higher in PAD4-/- mice 
(Figure 3.3H).  Moreover, using soluble P-selectin (sPsel) as a biomarker of 
platelet and/or endothelial activation, we found that PAD4+/+ mice had 
significantly more sPsel in circulation (Figure 3.3I).  Thrombin anti-thrombin 
complexes were much higher in PAD4+/+ mice compared with PAD4-/- mice 
(Figure 3.3J). The reduced inflammatory and hypercoagulable/prothrombotic 
state in PAD4-/- mice in response to LPS could be explained by the absence of 
NETs45,46.  Thus, PAD4-/- mice exhibit reduced signs of septic shock in an 
endotoxemia model.   
 
Discussion 
Our study supports previously published reports that extracellular histones 
are highly procoagulant, prothrombotic, and injurious when released within the 
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vasculature, resulting in platelet-dependent thrombin generation, 
thrombocytopenia, endothelial cell death, and multi-organ dysfunction1,27-29,38 We 
have previously shown that NETs can be dismantled by heparin19 and that 
heparin inhibits histone-mediated platelet aggregation.19,38 Wildhagen and 
colleagues recently reported that non-anticoagulant heparin reduces histone 
toxicity and thus is protective in sepsis.47 Combined with our current results, it 
appears that this beneficial effect of heparin may be due in part to effects on 
histones released as a component of NETs.   Furthermore, our genetic approach 
of deleting PAD4 function agrees with a new online report showing that use of Cl-
amidine, a pan-PAD (PADs 1-4) inhibitor, in a similar CLP sepsis model is not 
immunosuppressive.48 The pan-PAD inhibitor actually provides a survival 
advantage, not seen with the absence of NETs in our study using the PAD4-/- 
mice. This indicates that in addition to PAD4, other PADs are also involved in the 
negative effects of bacterial sepsis.  This could be due to citrullination of 
additional cellular and plasma proteins.  
During experimental endotoxemia, large quantities of histones are 
released into circulation1 that are in complex with DNA as nucleosomes.49 The 
protective effects of a complete absence of NETs are likely found both at the 
organ level and systemically, resulting in reduced septic shock.  It is important to 
note that there were still prominent levels of nucleosomes in PAD4-/- animals, 
likely coming from necrotic cells.  However, our results indicate that the 
contribution by NETs is substantial enough to impact mortality by increasing the 
inflammatory response.  In the presence of a live pathogen, the balance between 
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the antimicrobial and host-destructive role of NETs is more complex and the 
benefits of reduced toxicity of NETs may be canceled out by increased bacterial 
impact.   
Our study approach differs from previously published work using DNase 
infusion15,17 in that NETs are never released in PAD4-/- mice.  PAD4+/+ mice 
administered DNase likely suffer from the reduced ability to perform other 
antimicrobial functions such as phagocytosis at infection sites once their 
neutrophils have formed NETs. Some cells may undergo “vital NETosis,” and 
retain function as anuclear cytoplasts,7,16 but their existence in polymicrobial 
sepsis remains unknown.  Also, microbes amassed in NETs, upon digestion by 
DNase injection, may become rapidly liberated from the sites of local infection 
and therefore increase their dissemination.16 Anti-NET therapy could be 
combined with antibiotics in settings in which an infection is suspected and direct 
inhibition of NETosis by PAD4 inhibitors might be most beneficial, providing both 
an anti-inflammatory and anti-thrombotic impact.  Anti-histone treatments are 
effective at protecting mice from death only in the presence of antibiotics.1 
However, clinical use of activated protein C (APC), which among other functions 
cleaves histones, is complicated by side effects.50 Ideally, therapeutic 
approaches would prevent NETs from being released in the first place and for 
this PAD4 is an ideal target.  Because NETs are released in ischemia reperfusion 
injury,25 they may be also released during the sequelae of the initial infection.  
Their deposition in organs and pro-thrombotic activity could lead to organ 
failure.1,45,46 
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PAD4-deficient mice have provided evidence of neutrophil antimicrobial 
activity in vivo.22 When using a mutant, DNase-null bacteria, lesion size was 
reduced in WT but not PAD4-/- mice, providing in vivo evidence of the ability of 
NETs to kill bacteria.22 It is, however, important to note that the use of a WT, 
nuclease-secreting microbe did not result in significantly larger skin lesions or 
higher bacterial CFU in PAD4-deficient animals in a model of necrotizing 
fasciitis.22 As NETs are not sufficient to clear a bacterial infection, they may 
indeed cause more harm than good. Moreover, because many bacteria are able 
to evade NETs by secreting nucleases,51-53 the actual physiological impact of the 
antimicrobial function of NETs may be minor, as seen in our study.   
Our results indicate that infections are not exacerbated in the total 
absence of NETs and that excessive NET production contributes to the 
pathology of nucleosome-induced mortality.  This has important implications for 
future development of NET-targeted therapeutics.  We propose that inhibiting 
PAD4 would be highly beneficial and unlikely to result in drastic 
immunosuppressive effects.  Neutrophils would remain able to reach areas of 
infection and have antimicrobial effects other than by NETs, and the cytotoxic 
impact of NETs to the host would be eliminated.  No specific PAD4 inhibitors are 
available and there is reluctance to develop them because of fear of infection.  
We hope that our studies, showing that PAD4 inhibition would not render the host 
severely immunocompromised, will encourage such development. 
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Materials and Methods  
 
Study approvals and animals 
 
All experimental procedures involving animals were reviewed and approved by 
the Institutional Animal Care and Use Committee of Boston Children’s Hospital 
(protocol numbers 11-04-1848, 14-03-2631R).  All mice received food and water 
ad libitum; for in vivo sepsis models, mice were provided Napa Nectar 
enrichment gel (SE Lab Group).  Mice from our PAD4-/- colony, backcrossed for 
9-11 generations to C57Bl/6J background, were continually backcrossed at least 
once per year to C57Bl/6J mice ordered from Jackson labs.  Littermates from 
heterozygous crosses were used in all cecal ligation puncture experiments.  
 
Flow cytometry 
 
Reactive oxygen species formation and degranulation analyses were performed 
using flow cytometry (BD FACSCanto II) and analyzed using FlowJo software 
(TreeStar Inc., Version 8.8.7). Whole blood was collected using heparin-coated 
capillary tubes via the retroorbital plexus and stimulated as previously described 
in the presence of dihydrorhodamine-123 (Invitrogen).54 After stimulation, red 
blood cell lysis, and several washing steps, cells were stained for ROS 
measurements using Alexa 647-conjugated anti-Ly6G antibody (Biolegend), and 
for degranulation measurements using Alexa 647-conjugated anti-Ly6G antibody 
(Biolegend) and FITC-conjugated Lamp1 antibody (BD Pharmingen). Neutrophils 
were gated by forward and side scatter followed by Ly6G gating.  Rhodamine+ 
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neutrophils were quantified for reactive oxygen species production, and Lamp1+ 
neutrophils were quantified for degranulation studies.   
 
Thioglycollate peritonitis 
 
Thioglycollate broth (3% in PBS, Sigma Aldrich) was prepared at least 2 weeks 
prior to use.  One ml was injected intraperitoneally per mouse.  At the indicated 
time points, mice were euthanized and a peritoneal lavage was performed using 
6 ml of PBS.  Total cell counts were performed using a Neubauer hemacytometer 
and a portion of the infiltrate was cytospun for differential cell counting using a 
Statspin Cytofuge II (Beckman Coulter).  Differential counts were performed 
using at least 200 cells stained with Wright-Giemsa histologic stain.   
 
Cecal ligation puncture 
 
Cecal ligation puncture surgery was performed as described 32 using aseptic 
surgical technique. All mice in CLP experiments were obtained by heterozygous 
crosses and therefore were littermates on a C57Bl/6J background. Mice were 
anesthetized using 3.5% isoflurane in 100% oxygen and maintained at 2% 
isoflurane for the duration of the surgery.  A midline laparotomy allowed for 
access to the cecum.  The cecum was ligated with 4-0 silk suture located either 
50% (low-grade) or 75% (high-grade) between the iliocecal junction and the 
distal end of the cecum.  A through-and-through puncture was performed using a 
21G (low-grade) or 18G (high-grade) needle.  A small amount of cecal contents 
were extruded to ensure hole patency before returning the cecum to the 
abdominal cavity.  The peritoneum was closed with 6-0 monofilament absorbable 
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vicryl suture and the skin was closed using a 6-0 nylon suture. Immediately after 
surgery, mice were injected with 0.9% sterile saline (500 µl, s.c.) for fluid 
resuscitation.  Mice received buprenorphine (0.05 mg/kg s.c.) as an analgesic 
immediately prior to surgery and every 8-12 hours subsequently for 72 hours. 
Sham animals underwent the same procedure except for the ligation and 
puncture of the cecum.  Control animals did not undergo surgery and were 
euthanized alongside CLP animals.  All surgeries were done at similar times of 
the day to account for possible circadian rhythm effects on the model.  Mice were 
observed over a 96-hour (low-grade CLP) or 10-day (high-grade CLP) time 
period and assessed for moribundity along with body weight and temperature.  
Temperatures were recorded using a handheld, non-contact infrared 
thermometer (Kintrex).  All mice exhibited clinical sepsis symptoms (lethargy, 
piloerection, reduced interest in food and water, hunched posture).  Any mice 
exhibiting loss of righting reflex when placed in a supine position were identified 
as moribund and immediately euthanized.   
 
LPS endotoxemic shock 
 
LPS from Salmonella enterica spp typhimurium (Sigma Aldrich, Lot number 
109K4087) was injected intravenously via the retroorbital plexus at doses of 
either 25, 10, or 2.5 mg/kg.  Lethal dosing was determined by injecting mice with 
increasing amounts of LPS and observing mortality over a 24 hour period. Mice 
were observed over a 96 hour time period and assessed for morbidity along with 
body weight and temperature. Mice received buprenorphine (0.05 mg/kg s.c.) as 
an analgesic every 12 hours. Temperatures were recorded using a handheld, 
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non-contact infrared thermometer (Kintrex).  All mice exhibited clinical symptoms 
of endotoxemic shock (lethargy, piloerection, reduced interest in food and water, 
hunched posture).  Any mice exhibiting loss of righting reflex when placed in a 
supine position were identified as moribund and immediately euthanized.   
 
Complete blood counts 
 
Blood was collected via the retroorbital plexus into EDTA-coated capillary tubes.  
Blood cell counts were analyzed using a Hemavet 950FS Veterinary Multi-
species Hematology System (Drew Scientific).    
 
Plasma measurements 
 
Blood was collected into sodium citrate anticoagulant (10% v/v). After 
centrifugation of whole blood at 6000 rpm for 5 min, plasma was collected and 
centrifuged at 13200 rpm for 5 min to remove remaining cellular components.  
DNA was measured using the Picogreen Quant-iT dsDNA assay kit (Invitrogen).  
Thrombin anti-thrombin (TAT) complexes (Abcam), soluble P-selectin (R&D 
Systems), IL-6 (R&D Systems), IL-10 (R&D Systems), and alanine 
aminotransferase (Biotron) were measured according to manufacturer’s 
instructions.   
 
Bacterial load 
 
All blood, lavage, and tissue collection and homogenization were performed 
using aseptic technique.  Serial dilutions were plated onto tryptic soy agar pre-
poured petri dishes supplemented with 5% sheep’s blood (Hardy Diagnostics) 
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and incubated overnight at 37°C.  Plates with 20-200 colonies were counted and 
CFUs were normalized per gram of tissue collected.   
 
Circulating histone analysis 
 
Four microliters of plasma were denatured and resolved on Tris-glycine SDS-
Page gels (Lonza) or Bis-tris glycine gels (Invitrogen) under reducing conditions.  
After semi-dry transfer to PVDF membrane, blots were blocked with 3% BSA for 
3 hours at room temperature (RT). After being incubated in primary antibody 
overnight at 4°C (anti-H3Cit, Abcam) or for 1 hour at RT (anti-histone H3, 
Abcam), membranes were washed and incubated in HRP-conjugated secondary 
antibody (goat anti-rabbit IgG HRP-conjugate, Bio-Rad) for 1 hour at RT.  After 
washing, Pierce ECL (enhanced chemiluminescent) substrate (Thermo Scientific) 
was applied to each membrane before exposure onto film.  H3Cit blots were 
exposed for 10 min, while histone H3 blots were exposed for 1 min.   
 
Statistics 
 
Data are presented as mean ± SEM and analyzed using Student’s t-test or 
Mann-Whitney U test unless otherwise noted.  Survival data were analyzed using 
Log-Rank tests of Kaplan-Meier curves.  Data were considered significant when 
P-values were <0.05.     
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Section 4.1: Discussion 
The molecular events leading to NET formation are incompletely defined, 
as are their consequences.  The process of NET formation (NETosis) after initial 
stimulation involves the decondensation of chromatin, dissolution of the nuclear 
membrane, and expulsion of chromatin into the extracellular environment1. This 
initial stimulus still remains incompletely characterized in terms of receptor 
binding and downstream signaling events but there have been key findings in 
recent years that help us to better understand mediators that are regulating the 
process.  Also, a novel form of NET formation was described where a neutrophil 
can release only a portion of its nucleus, termed vital NETosis2,3.  Here 
neutrophils can retain phagocytic function even after releasing their entire 
nuclear contents as NETs3. This intriguing form of NET formation without cell 
death has opened up a whole new avenue of study in disease processes where 
NETs are involved.  Parsing out which factors lead to which type of NETosis in 
non-infectious diseases such as thrombosis is an interesting future direction of 
the work presented in this dissertation.   
 
PAD4 function and regulation 
Here I have focused on one essential aspect of NETosis: chromatin 
decondensation.  This was shown to be mediated by the enzyme peptidylarginine 
deiminase 4 (PAD4), which modifies arginine residues on proteins to citrulline via 
a deimination reaction4.  This was first shown to occur in histones using HL-60 
cells, a human promyelocytic leukemia cell line that can be differentiated to 
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granulocyte-like cells5, and later in primary human neutrophils that had been 
challenged with inflammatory insults such as LPS or TNFα6.  The Neeli et al. 
paper also first identified citrullinated histones as a component of NETs.  Shortly 
thereafter, it was shown that this histone citrullination was responsible for driving 
chromatin decondensation during NETosis7.  The generation of PAD4-deficient 
mice has been a big driving force in the study of NETs in vivo, as these are to 
date the only mice that have a complete lack of NET formation8.   
There is still much to be explored in the cell biology of PAD4 function and 
regulation.  The crystal structure of PAD4 has been published, and from this we 
know that PAD4 is a calcium dependent enzyme that requires calcium binding to 
5 sites in order for the active site to be conformationally available9.  I have seen 
that upon calcium chelation by EDTA, histone citrullination and NET formation 
are completely abrogated in a fashion similar to the neutrophils of PAD4-/- mice. It 
has been shown that both intracellular and extracellular calcium stores are 
needed during NET formation10.  
PAD4 is the only PAD family member to have a nuclear localization 
signal9, and thus is the only PAD able to enter the nucleus and citrullinate 
histones11.  PAD4 activity and therefore NET formation may be regulated by its 
subcellular localization, either outside of the nucleus or intranuclear.  It has been 
reported in other cell types that PAD4 translocates from the cytoplasm into the 
nucleus upon stimulation of the cell12; however, in neutrophils this has not been 
established and PAD4 is presumed to reside in the nucleus13.  Unfortunately, 
PAD4 antibodies that recognize mouse PAD4 are not commercially available so 
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studying PAD4 translocation has not yet been possible in primary mouse 
neutrophils where I would like to investigate what happens to PAD4 during 
various inflammatory insults such as LPS challenge. My preliminary data with 
human neutrophils indicates that PAD4 is located outside of the nucleus in 
healthy blood donors, but that upon stimulation or in certain disease states, 
PAD4 becomes primarily located within the nucleus. Recently it was reported that 
neutrophils from rheumatoid arthritis patients had more nuclear rather than 
cytoplasmic PAD414.  However, more extensive and quantitative analyses remain 
to be done to support the hypothesis that PAD4 is being actively transported into 
the nucleus.   
 
PAD4-/- mice provide an ideal model to study the role of NETs in 
pathological thrombosis 
In this dissertation, I aimed to better understand the importance of NETs in 
pathological conditions involving platelets and leukocytes.  PAD4-/- mice allowed 
for the study of disease models in vivo in the complete absence of NETs and 
thus were a critical tool for this work8. I have now shown that these mice are 
protected from pathological thrombosis (Chapter 2) and partially protected from 
endotoxemic shock (Chapter 3).  Other than their established NET defect8, we 
have not been able to identify any other major phenotype in these mice.  Their 
neutrophils behave normally except for their lack of NET formation: they are able 
to be recruited to sites of inflammation, adhere and migrate towards stimuli, 
produce ROS, degranulate (Chapter 3), and phagocytose and kill bacteria8.  
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Therefore, these mice lack many of the confounding factors present in other 
genetically-deficient mice that may also have a NET defect.  I will discuss three 
other NET-deficient mice below and why ultimately they were not ideal for 
studying NETs in thrombosis.   
 Early studies identified NADPH oxidase (gp91phox) and generation of 
oxygen species as critical players in NET formation, and patients with chronic 
granulomatous disease have a defect in producing NETs that can be rescued 
with addition of exogenous hydrogen peroxide15.   However, studying mice in 
which gp91phox has been genetically deleted posed a problem because their 
phenotype is much more broad than a lack of NET formation. Gp91phox is 
expressed other cell types than leukocytes such as platelets and endothelial16-18, 
meaning that it is could be affecting functions critical for thrombus initiation. For 
example, platelet activation is impaired with this deficiency19,20.  Our lab has 
shown that platelets are essential for the initiation of thrombus formation21. Mice 
lacking Gp1bα, which is needed for platelet binding to von Willebrand factor, fail 
to produce thrombi in the stenosis model22. This highlights the importance of 
maintaining fully competent platelets in order to study NETs in this model. 
Therefore, gp91phox-/- mice would not have been ideal for studying 
neutrophil/NET involvement in thrombosis and I did not perform any DVT 
experiments with these mice.    
Neutrophil elastase (NE) was also thought to be critical for chromatin 
decondensation during NETosis.  This has been proposed to occur via histone 
degradation, and it was shown that NE first translocates from azurophilic 
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granules to the nucleus23, which occurs independently of other granule contents 
such as myeloperoxidase (MPO).  A recently published study proposes that this 
mechanism of nuclear transport is independent of granule membrane fusion23 but 
dependent on reactive oxygen species (ROS) and MPO24.  Our lab has been 
several times asked by reviewers to perform our in vivo NET models in NE-/- mice 
in parallel to PAD4-/- mice to have an additional mouse model where NETs are 
lacking.  However, I found that NE-deficient neutrophils only had a moderate 
reduction in NET formation and NE-/- mice formed NET-rich thrombi similarly to 
WT mice (Appendix A-7). Therefore, NE-/- mice proved in our hands to not be 
suitable for studying NET defects in mouse thrombosis models.  These mice may 
be still be of interest for studying the in vivo impact of having NETs generated 
that are not containing NE on their surface, as this may have an effect on 
coagulation, antimicrobial function25, and vascular permeability. These results 
also indicate that a more efficient reduction of NET formation (such as by 
targeting PAD4) is needed to have a physiological impact in DVT.  
Lastly, we have studied Rac2-deficient animals because Rac2null 
neutrophils were shown to have a severe NET defect in response to stimuli that 
are ROS-dependent such as LPS or PMA26.  Furthermore, Rac2 is important for 
NADPH oxidase assembly27 and its expression is restricted to leukocytes28.  
Importantly, platelet function doesn’t appear to be compromised in these mice.  
In collaboration with Dr. David Williams at Boston Children’s Hospital, we 
confirmed that Rac2null neutrophils had reduced NET formation and his group is 
currently working on parsing out other components of the signaling cascade.  I 
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had hoped that studying these mice in the venous stenosis model would begin to 
clarify the driving force behind the initiation of NETosis during thrombosis.  
However, while we saw a trend toward reduction in the Rac2null mice in the 
percentage of the mice forming thrombi compared to WT mice, the thrombi that 
did form in Rac2null animals were quite large.  When analyzing these 
histologically, I saw that the thrombi from Rac2null animals were very neutrophil 
dense and contained H3Cit+ NETs.  The Rac2null animals have elevated 
neutrophil counts that reach 2.5-3 times the level of WT mice29.  Even if the 
Rac2null neutrophils have substantially impaired NETosis during thrombosis, the 
fact that there are more of them in circulation is likely negating any effect we 
would see as a result of this NETosis defect.  Therefore, further experiments are 
needed where similar numbers of neutrophils are present in circulation.  This 
could be done by infusing neutrophils from either WT or Rac2null animals into 
PAD4-deficient mice.  WT neutrophil supplementation was enough to initiate 
thrombosis in PAD4-/- mice, and I would hypothesize that Rac2null neutrophils 
would be less well able to rescue thrombosis.  This would allow for the study of 
the importance of the NADPH oxidase-driven NETosis pathway during 
thrombosis.   
 
What induces NETosis during thrombosis? 
The signaling pathways and other molecular mechanisms driving NET 
formation during thrombosis remains to be established.   It has been proposed 
that activated platelets can induce NET formation22,30, but the exact interaction 
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occurring between platelets and neutrophils leading to NETosis is unknown.  In 
pathological thrombosis, endothelial cell activation leads to release of the 
contents Weibel-Palade bodies, such as von Willebrand factor (VWF) and P-
selectin, which in turn help to recruit leukocytes and platelets to initialize a 
growing thrombus21,31. NETting neutrophils at this site of leukocyte/platelet 
accumulation may help to drive further platelet as well as red blood cell 
recruitment, as both were shown to bind to NETs when whole blood was 
perfused over pre-formed NETs in a flow chamber32.  In addition, VWF is closely 
associated with NETs in thrombi produced in animal models21,32 as well as in 
thrombi harvested from venous thromboembolism patients33.  VWF is critical to 
the recruitment of platelets to activated endothelium34, and VWF was also shown 
to be able to bind histones35 long before NETs were discovered.  The signaling 
pathways in the neutrophil as a result of contact with activated platelets remain to 
be identified; PSGL-1 is one likely candidate, as a ligand for P-selectin which 
drives the initial interaction between neutrophils and platelets/endothelial 
cells36,37. Also, VWF may be participating to induce NETosis either directly or 
indirectly via platelets.   
Our lab has identified the presence of NETs in thrombi from human 
patients with a confirmed venous thromboembolism diagnosis: either deep vein 
thrombosis, pulmonary embolism, or IVC filter clots (33, Appendix 4).  NETs were 
identified in certain stages of thrombus development; mainly during the 
organizing phase when large amounts of neutrophils and platelets are present38. 
Some NETs were also found in unorganized, fresh clots.  This, along with the 
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mouse data in Brill et al.39 and Chapter 2, indicates that NETs are forming early 
during thrombus initiation, and may be in part responsible for stabilizing the clot.  
Again, what drives the initial trigger for neutrophils to throw NETs during 
thrombosis remains to be established.  The role that NETs may have later in 
thrombus maturation is an exciting future direction for this study.  NETs could be 
involved in thrombus organization and may affect neovascularization that occurs 
as the thrombus develops into an organized, tissue-like structure.   
 
NET inhibition in sepsis 
 In sepsis, neutrophils were proposed to be induced by activated platelets 
to undergo NETosis30.  In vitro, the combination of activated platelets and 
neutrophils lead to increased bacterial trapping but also to increased endothelial 
damage30, highlighting that NET release has bystander effects in addition to 
trapping bacteria.  In live bacterial sepsis mouse models, indeed neutrophil 
depletion can be either detrimental or highly protective depending on the timing 
of the depletion: depletion at the beginning of the infection leads to increased 
bacterial burden and mortality while depletion after the first 12 hours prevents 
neutrophil-associated tissue damage40.  In fact, mice depleted 12 hours after 
CLP had drastically reduced bacterial loads, indicating that neutrophils may at 
some point be driving bacteremia.  There are now conflicting reports in the 
literature as to the effect of removing NETs by DNase infusion: one group 
reported that DNase accelerated mortality and led to transiently increased 
bacterial burden41, while another group recently published the opposite finding, 
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that DNase protected from lung injury and decreased bacterial loads 
systemically42.  Again, timing may be essential here and there is likely a dual 
effect of DNase digestion of NETs.  Locally, reducing NET concentration may be 
beneficial by preventing tissue injury such as in the lung.  However, DNase may 
be systemically disseminating NET fragments into the circulation which has 
damaging consequences to endothelial cells and thus could also lead to organ 
damage. 
Our approach with the PAD4-/- mice differs from DNase infusion in that 
NETs are never released so any potential effect of freeing up NET nucleosomes 
within the vasculature are not present.  Also, using the PAD4-/- mice differs from 
neutrophil depletion experiments in that PAD4-/- mice have otherwise functional 
neutrophils other than their inability to release NETs (8, 43, Chapter 3). They 
behave like WT mice in terms of recruitment to sites of inflammation, production 
of reactive oxygen species, phagocytosis, and degranulation. My results in 
Chapter 3 show that lacking NETs does not have any major impact on the 
outcome of cecal ligation puncture, so NETs are not likely playing a substantial 
role in bacterial killing in this model. The neutrophil has much more in arsenal 
than throwing NETs, and there may be specific settings in which NETs play a key 
role in preventing pathogen dissemination from a localized site, perhaps by 
promoting fibrin deposition.  To see if NETs have a negative impact on the host 
in CLP, I am planning to perform the model with the administration of antibiotics 6 
hours after CLP surgery to observe whether under these conditions the PAD4-/- 
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mice may fare better than WT mice since the bacterial growth would be 
contained. 
 The LPS-induced sepsis model allowed me to study the host response to 
a bacterial insult in the absence of a live bacterial infection.  Here, I 
demonstrated that a portion of the DNA/histones being released into the 
circulation came from NETs, and that the failure to release NETs in the PAD4-/- 
mice had a positive impact on the physiological responses of these mice, 
ultimately delaying mortality.  Current therapies for septic patients include 
antibiotic treatment and supportive care44.  Activated protein C, which degrades 
histones45, was a promising candidate for ameliorating the negative 
consequences of NET formation in patients, but this treatment came with serious 
bleeding risk46 and is no longer used clinically.  Antibodies neutralizing histone 
H4 were protective in a mouse model of CLP, but mice had to be given 
antibiotics in order to not succumb to the infection45.  Histone-targeted treatments 
also target histones being released from cells dying by other means than 
NETosis.  Histones themselves are also bactericidal47, and therefore anti-histone 
therapy may be too non-specific and could lead to increased susceptibility to 
infection. 
 
Future directions 
Based on the work presented in this dissertation, I propose that targeting 
PAD4 to prevent NET release from taking place altogether is an ideal solution, 
especially in a world where antibiotic use is prevalent and any potential reduced 
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bacterial clearance would be mitigated by their use. There is, however, still much 
to be learned regarding the role of NETs in inflammatory processes.  I have 
outlined in Chapter 1 many unanswered questions that remain. Understanding 
what drives NET formation during pathological thrombosis will be an important 
next step.  Also, investigating how NETs impact thrombus progression will 
provide valuable insight into possible therapeutic interventions that could be 
taken once thrombi have already formed, as a majority of patients present with 
an existing thrombus.   
Even with all of our knowledge about risk factors associated with VTE, 
thrombotic events remain a frequent complication in patients that have 
undergone surgery or been immobilized48. Therefore, new risk factors continue 
be explored. Genome-wide association studies have identified PAD4 as a 
susceptibility locus for rheumatoid arthritis in Japanese and Korean 
populations49-51. However, the exact variants have not been identified52. It would 
be of great interest to perform similar analyses in venous thromboembolism 
patients, as mutations in PAD4 could render the enzyme more active and make 
these affected persons more susceptible to aberrant NET formation. This could 
help to identify patients who would benefit from NET-targeted therapy as a 
prophylactic treatment.   
Currently, treatment of existing VTE is limited to months-long treatment 
with anticoagulants.  This comes with significant bleeding risk and once 
anticoagulation is stopped the risk of VTE recurrence is high53.  The best 
candidate for preventing recurrence available now is low-dose aspirin54,55, and to 
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remove thrombi that don’t naturally dissolve involves tPA infusion and 
mechanical disruption via a catheter56. Combining DNase to degrade the NET 
component of the thrombus scaffold in addition to tPA which targets the 
proteinaceous fibrin backbone may be more effective in reducing clot burden57,58.  
PAD4 inhibitors may then be useful in preventing new thrombus growth, 
stabilization, or recurrence.   
In conclusion, I have discussed that NETs are produced under both 
infectious and sterile inflammatory conditions, and contribute to the pathologies 
of both deep vein thrombosis, and sepsis.  The PAD4-/- mice have been an 
invaluable tool to study these disease processes in vivo.  I hope that the work 
presented in this dissertation will help to drive the development of anti-NET 
targeted therapeutics. I propose that PAD4 is an ideal target, both in pathological 
thrombosis as an anti-thrombotic that wouldn’t impact normal hemostasis, and 
perhaps even in sepsis where its use could be combined with antibiotics.   
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Figure S2.1. Characterization of thrombi formed 6 h after IVC stenosis.  A. 
Composite image of a thrombus collected from a WT mouse 6 h after IVC ligation 
and immunostained for H3Cit and DNA.  In contrast to 48 h where extracellular 
H3Cit is present in abundance, thrombi at 6 h contained mostly nuclear H3Cit 
staining.  H3Cit, green; DNA, blue.  Scale bar, 1 mm.  B.  In contrast to WT, 
H3Cit staining is completely absent in PAD4-/- thrombi collected 6 h after IVC 
ligation.  Representative of n=3, scale bar, 100 µm.  C.  Hematoxylin and eosin 
staining shows similar leukocyte densities at 6 h between WT and PAD4-/- 
thrombi.  n=3-4. Scale bar, 20 µm. 
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Figure S2.2. Characterization of bone marrow chimeras generated for IVC 
stenosis experiments. A. Bone marrow chimeras were generated by lethally 
irradiating WT mice and immediately transfusing at least 1 x 107 WT or PAD4-/- 
BM cells.  Both animals groups had similar recoveries as seen by body weight 
gain over time.  Black line, WT donor; red line, PAD4-/- donor.   B.  The success 
of the chimerism was tested by stimulating blood leukocytes with ionomycin for 2 
h and immunostaining for H3Cit.  The total leukocyte population was studied 
rather than isolated neutrophils in order to minimize the volume of blood being 
drawn from mice prior to DVT surgeries.  Leukocytes from PAD4-/- bone marrow 
chimeras failed to hypercitrullinate histone H3 as determined by quantification of 
immunostained leukocytes. C. Representative images of H3Cit immunostaining 
used to evaluate chimerism. Scale bar, 100 µm. D, E.   Recipients of WT bone 
marrow (D) produced thrombi containing H3Cit-positive extracellular staining, 
while the thrombus formed in a PAD4-/- bone marrow chimera (E) showed no 
H3Cit staining, similar to the PAD4- /- thrombus in Fig. 2.2H. Scale bar, 100 µm. 
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Figure S2.3. Platelet counts from 48 h venous stenosis experiments.  Red 
color indicates mice that formed thrombi and black represents mice with no 
thrombi. WT baseline control compared to WT+WT neutrophil infusion 48 h DVT 
with thrombi, p<0.02, PAD4 baseline control compared to PAD4-/-+WT neutrophil 
infusion 48 h DVT with thrombi, p<0.04). 
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Figure S2.4. Histological analyses of thrombi collected from WT or PAD4-/- 
mice after IVC stenosis. A. Thrombi collected from WT mice or the PAD4-/- 
mouse that formed a thrombus 48 h after IVC stenosis showed an abundance of 
neutrophils by Ly6G immunostaining (upper panels, red) and few monocytes by 
F4/80 staining (lower panels, red).  Scale bar, 100 µm. DNA is shown in blue.  B. 
Thrombi from WT or PAD4-/- mice 48 h after IVC stenosis contained very few 
F4/80+ monocytes/macrophages.  Scale bar, 20 µm. C. Isolated bone marrow 
neutrophils used for in vivo infusions were >95% pure as assessed by Wright-
Giemsa staining of cytospins.  Scale bar, 20 µm. D. Neutrophils were present in 
the thrombi of WT neutrophil-infused PAD4-/- mice at 48 h after ligation while few 
F4/80+ cells were detected, as is the case in thrombi produced in WT animals.  
Left panel, Ly6G (red); right panel, F4/80 (red).  Scale bar, 20 µm. 
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Figure S3.1.  Additional blood cell parameters measured in low-grade CLP 
model.  Leukocyte and neutrophil counts were similar between PAD4+/+ and 
PAD4-/- CLP-operated mice in blood (A, B) and peritoneal lavage fluid (D, E).  
Blood platelet counts were also similar (C). F. Low-grade CLP resulted in 
significant increases in circulating plasma DNA in PAD4+/+ compared to PAD4-/- 
mice. G. Plasma alanine aminotransferase (ALT), a marker of liver injury, was 
similarly increased in low-grade CLP mice in both PAD4+/+ and PAD4-/- mice.  
*p<0.05. 
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Figure S3.2. Characterization of endotoxemia induced by LPS from 
Salmonella spp typhimurium. Infusion of 10 mg/kg LPS i.v. in PAD4+/+ mice 
resulted in a drop in platelet and leukocyte numbers in circulation (A) and 
increasing plasma DNA and LDH levels (B).  By 6h after 10 mg/kg LPS infusion, 
fragmented histone H3 was detected in plasma of PAD4+/+ mice by Western blot 
(C).  At this same time point, H3Cit was not yet detected, but by 24h H3Cit was 
found in a majority of PAD4+/+ mice (D).  Vehicle-infused mice did not have 
significant levels of histone H3 or H3Cit in plasma.  n=3-7. E. H3Cit-positive 
staining in neutrophils was present in the lung 24h, but not 6h after LPS infusion 
in PAD4+/+ mice.  No H3Cit+ staining was identified in liver, spleen, or kidney at 
the same time points (data not shown). n=3-4. F,G. Survival curves indicating 
degree of mortality in PAD4+/+ (black line) vs PAD4-/- (red line) mice injected with 
10 mg/kg LPS (F) or  2.5 mg/kg LPS (G). More PAD4+/+ mice died with the 10 
mg/kg LPS dose (F), while a great majority of mice survived the 2.5 mg/kg LPS 
dose (G).  
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Summary. Background: Upon activation, neutrophils can
release nuclearmaterial known as neutrophil extracellular traps
(NETs), whichwere initially described as a part of antimicrobial
defense. Extracellular chromatin was recently reported to be
prothrombotic in vitro and to accumulate in plasma and
thrombi of baboons with experimental deep vein thrombosis
(DVT). Objective: To explore the source and role of extracel-
lular chromatin in DVT. Methods: We used an established
murine model of DVT induced by flow restriction (stenosis) in
the inferior vena cava (IVC). Results: We demonstrate that
the levels of extracellular DNA increase in plasma after 6 h
IVC stenosis, compared with sham-operated mice. Immuno-
histochemical staining revealed the presence of Gr-1-positive
neutrophils in both red (RBC-rich) and white (platelet-rich)
parts of thrombi. Citrullinated histone H3 (CitH3), an
element of NETs# structure, was present only in the red part
of thrombi and was frequently associated with the Gr-1
antigen. Immunofluorescent staining of thrombi showed
proximity of extracellular CitH3 and von Willebrand factor
(VWF), a platelet adhesion molecule crucial for thrombus
development in this model. Infusion of Deoxyribonuclease 1
(DNase 1) protected mice from DVT after 6 h and also 48 h
IVC stenosis. Infusion of an unfractionated mixture of calf
thymus histones increased plasma VWF and promoted DVT
early after stenosis application. Conclusions: Extracellular
chromatin, likely originating from neutrophils, is a structural
part of a venous thrombus and both the DNA scaﬀold
and histones appear to contribute to the pathogenesis of
DVT in mice. NETs may provide new targets for DVT drug
development.
Keywords: citrullination, deep vein thrombosis, histones,
neutrophil extracellular traps, von Willebrand factor.
Introduction
Neutrophils stimulated with microbes or proinflammatory
agents, reactive oxygen species (ROS) or activated platelets,
release their nuclear material, forming a web-like extracellular
network. These webs, formed by DNA, histones and neutro-
phil granule constituents [1], are designated as neutrophil
extracellular traps (NETs) and are implicated in antimicrobial
defense [2]. NETs are present in blood under septic conditions
and platelets play a role in NETs production in a process
involving binding of LPS to platelet toll-like receptor-4 (TLR4)
[3]. In in vitro studies, NETs were shown to be prothrombotic
and procoagulant [4,5]. Histones have also been reported to
stimulate platelet aggregation [4,6] and promote platelet-
dependent thrombin generation [7].
In addition to neutrophils, mast cells, monocytes and
eosinophils have also been reported to liberate such extracel-
lular DNA traps [8–10]. NETs can result not only from the
presence of microbes but also accompany sterile inflammation,
for example, in small-vessel vasculitis or pre-eclampsia [11,12].
Formation of NETs is a step-wise process characterized by
nuclear membrane dissolution, chromatin decondensation and
cytolysis [13]. Histone citrullination is a hallmark of chromatin
decondensation in neutrophils [14]. It is a post-translational
modification (conversion of arginine to a non-conventional
amino acid citrulline) mediated by peptidylarginine deiminase 4
(PAD4), an enzyme expressed highly in granulocytes [15,16].
Inactivation of PAD4 results in suppression ofNETs formation
[16]. PAD4)/)neutrophils have aprofounddefect in their ability
to kill bacteria and PAD4)/) mice are less protected against
bacterial infection than wild-type mice [16].
Deep vein thrombosis (DVT) is diagnosed in approxi-
mately 900 000 cases in the US annually [17]. We have
recently demonstrated that extracellular DNA accumulates
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in plasma in experimental DVT in baboons and the
presence of DNA and histones in venous thrombi [4]. The
ability of histones to upregulate thrombin generation in
plasma by suppressing protein C activation [18] may have
direct implications on DVT as deficiency in protein C or
resistance to activated protein C, due to factor V Leiden
mutation, are risk factors for DVT in humans [19–21]. In
this study, we explore the role of extracellular chromatin
and histones in a murine model of flow restriction-induced
DVT [22]. Venous thrombi developed in this model are
structurally similar to human thrombi with white (platelet-
rich) and red (RBC-rich) parts [22,23]. We show that venous
thrombi contain large amounts of extracellular citrullinated
histone H3 (CitH3), often in proximity to von Willebrand
factor (VWF), an important molecule in the initiation of
DVT [22]. We also demonstrate that intravenously admin-
istered histones exacerbate DVT, whereas Deoxyribonuclease
1 (DNase 1), which degrades NETs [4], protects mice from
venous thrombosis.
Material and methods
Mice
Wild-type C57BL/6J (WT) mice were from Jackson Labora-
tory (Bar Harbor, ME, USA). All mice were 7–9-week-old
males weighing 22–26 g. All experimental procedures involving
micewere approved by theAnimal Care andUseCommittee of
the Immune Disease Institute.
Flow restriction model
The murine model of DVT was performed as described [22]. In
brief, mice were anesthetized by isoflurane-oxygen, intestines
were exteriorized and the inferior vena cava (IVC) was
diligently separated from aorta. A suture was placed on the
IVC just below the renal veins over a spacer (diameter of
0.26 mm) and then the spacer was removed. This procedure
has been shown to decrease vascular lumen by about 90% and
avoid endothelial injury. All visible IVC side branches were
also sutured. Thereafter, peritoneum and skin were closed,
mice were sacrificed after 1–48 h and thrombi formed in the
IVC were harvested. Sham-operated mice were opened and
IVC sutured similarly to the experimental mice, but the suture
was removed immediately after ligation.
Histone infusion
A mixture of all histones isolated from calf thymus
(Worthington, Lakewood, NJ, USA) was dissolved in sterile
saline and infused intravenously in mice immediately before
IVC stenosis application. The dose used (10 mg kg)1) is
known to produce a 25% decrease in platelet count 10 min
after infusion [6]. The infused solution of histone mix was
essentially endotoxin-free (< 0.025 EU mL)1; measured
using the endotoxin detection kit [Lonza, Walkersville,
MD, USA] according to the manufacturer!s instructions).
Control mice received infusion of sterile saline. Mice were
sacrificed 1 h after surgery and thrombus formation was
examined.
DNase 1 infusion
DNase 1 (Pulmozyme!, Genentech, San Francisco, CA, USA)
wasdilutedinsterilesalineandinjectedimmediatelyaftersurgery
(50 lg intraperitoneally and 10 lg intravenously). In experi-
ments with 48 h IVC stenosis, injections were repeated three
more times after every 12 h.Controlmicewere injectedwith the
Pulmozyme vehicle buffer (8.77 mg mL)1 sodium chloride and
0.15 mg mL)1 calcium chloride) diluted in sterile saline.
Determination of extracellular DNA in plasma
Blood (100 lL) was drawn from the periorbital eye plexus and
stabilized with 5 lL of 0.5 M EDTA. Time points for blood
drawing were: 24 h before (all mice) and then either 6, 24 and
48 h after DVT (three mice) or sham surgery (four mice), or 6
and 48 h after DVT (three mice) or sham surgery (four mice).
Plasmawasobtainedbycentrifugationat2300 g, diluted50-fold
withPBS containing 0.1%BSA,mixedwith an equal volume of
1 lM of the fluorescent DNA dye SytoxGreen (Invitrogen,
Carlsbad, CA, USA) and fluorescence of dye bound to DNA
was immediatelydeterminedbyafluorescencemicroplate reader
(Fluoroskan, Thermo Scientific, Waltham, MA, USA) as
described [4]. Background fluorescence of PBS-plasma mixture
(without SytoxGreen) was subtracted from all samples.
Frozen sections
Thrombi with or without the surrounding IVC wall or sham
IVC (IVC fragment of 6–8 mm ligated at both ends with blood
remaining inside) were harvested, embedded in Optimal
Cutting Temperature (OCT) compound (Sakura Finetek,
Torrance, CA, USA) and then cryosectioned into 10-lm
sections.
Immunohistochemistry
Immunohistochemistry was performed as previously described
[24]. Briefly, anti-mouse Gr-1 antibody (dilution 1:500, clone
RB6-8C5; BD Pharmingen, Franklin Lakes, NJ, USA) and
rabbit polyclonal [CitH3] antibody to citrullinated histone H3
(dilution 1:300, citrulline 2 + 8 + 17; ab5103, Abcam,
Cambridge, MA, USA) were used as first antibodies. Histofine
Simple Stain Mouse MAX PO for rat (414311F) and rabbit
(414351F), respectively, purchased from Nichirei Corporation
(Tokyo, Japan), were used as secondary antibodies. Diam-
inobenzidine (DAB) substrate kit (Vector Laboratories,
Burlingame, CA, USA), containing DAB and DAB-Ni, was
used for visualization of staining. Finally, sections were count-
erstainedwithNuclearFastRed (Sigma-Aldrich, StLouis,MO,
USA). No first antibodies were applied in control sections.
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Immunofluorescent staining
Sections were incubated with zinc fixative for 15 min, washed
in PBS, and permeabilized with 0.1% Triton X-100, 0.1%
sodium citrate on ice. After washing and blocking with 3%
bovine serum albumin (BSA, Sigma-Aldrich), the sections
were incubated for 16 h at 4 !C in 0.3% BSA in PBS with
0.3 lg mL)1 rabbit polyclonal anti-CitH3 (citrulline
2 + 8 + 17; ab5103, Abcam), and sheep polyclonal anti-
VWF (1:50 dilution of IgG fraction; ab11713, Abcam). For
longitudinal sections of isolated thrombi, anti-CitH3 Ab was
applied overnight and anti-VWF Ab for 90 min. After
washing, sections were incubated with the following Alexa
Fluor-conjugated secondary antibodies (all from Invitrogen)
in 0.3% BSA in PBS: Alexa Fluor 488 donkey anti-rabbit
IgG and Alexa Fluor 568 donkey anti-sheep IgG (2 lg mL)1
for all Abs) for 2 h at room temperature. DNA was labeled
with 1 lg mL)1 Hoechst 33342 (Invitrogen). Fluorescent
images for cross-sections were acquired using an Axiovert
200 inverted widefield fluorescence microscope (Zeiss, Thorn-
wood, NY, USA) in conjunction with a Zeiss Axiocam MRm
monochromatic CCD camera. Mosaic reconstruction of entire
cross-sections was performed with MOSAICJ [25] for IMAGEJ
software (National Institutes of Health, Bethesda, MD, USA;
http://rsbrreb/nih/gov/iji) and consists of two to six fields of
view per image shown. Images for longitudinal sections were
obtained by a widefield fluorescence microscope using an
Axioplan microscope (Zeiss) with color HRc Zeiss camera.
Images were analyzed with AXIOVISION software (Zeiss).
Plasma VWF measurement
The assay was performed as described [22]. The level of VWF
in pooled plasma of 20 C57BL/6J WT mice was used as a
reference standard.
Statistics
Results obtained on the same animal at different time points
(difference in plasmaDNA levels between baseline and 6 h and
plasma VWF content) were compared using paired Student!s
t-test. PlasmaDNA levels in mice with IVC stenosis and sham-
operated animals were compared by Mann–Whitney test.
Difference in thrombi prevalence between different groups of
micewas comparedusingacontingency tableand the chi-square
test. Differences were considered significant at P < 0.05.
Results
Flow restriction in the IVC promotes plasma DNA
accumulation
We performed IVC stenosis in WT mice. Blood was drawn
24 h before and 6, 24 and 48 h after surgery and plasma DNA
levels were measured. Plasma of non-operated mice contained
284 ± 18.9 ng mL)1 DNA. Stenosis of the IVC led to an
increase in plasma DNA levels 6 h post surgery (Fig. 1) to
515 ± 34.7 ng mL)1 (P < 0.003 vs. baseline and P < 0.03
vs. sham-operated mice). This effect did not result from the
surgical procedure because sham-operated mice had plasma
DNA levels similar to non-operated animals (326 ±
47.4 ng mL)1,P = 0.9). The concentration ofDNA in plasma
48 h after surgery returned to baseline and was not different in
DVT- and sham-operated mice. Appearance of DNA in
plasma 6 h after stenosis application, when about half of the
mice form visible thrombi (as described in the text), indicates
that chromatin release occurs early in the thrombotic process.
Venous thrombi contain CitH3 located predominantly in the
red part of the thrombus
Besides neutrophils, other cell types can release chromatin [8–
10]. Histone citrullination by PAD4 occurs in activated
granulocytes and is necessary for the formation and release
of NETs [14–16,26]. To assess the presence of NETs in venous
thrombi, we stained thrombi developed in mice after 48 h IVC
stenosis, for CitH3. The white part of the thrombus (the
platelet-rich part remote from the suture) contained numerous
Gr-1-positive cells but was essentially devoid of CitH3 (Figures
2A,B and 3A). Gr-1 is an antigen present on polymorphonu-
clear leukocytes and also on plasmacytoid dendritic cells and a
small subset of monocytes (reviewed in [27]). The large red part
of the thrombus (the RBC-rich part proximal to the suture)
contained loci heavily stained for either Gr-1 only (Fig. 2C,
yellow arrowhead) or both Gr-1 and CitH3 with substantial
overlap of the two antigens (Fig. 2C, red arrowhead). Some
Gr-1-positive cells formed extracellular fiber-like structures that
strongly stained for CitH3, probably representing NETs
(Fig. 2D, red arrowheads; Fig. 3B).
We have previously reported an important role of VWF in
venous thrombosis initiation [22]. In baboon DVT thrombi,
extracellular DNA was shown to co-localize with VWF [4].
Immunofluorescent staining for VWF in murine venous
thrombi was often associated with extracellular CitH3
staining in the red part of thrombi (Fig. 3A,B,E,F). Multiple
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Fig. 1. Plasma DNA level is elevated 6 h after IVC stenosis application.
Blood was drawn from wild-type mice before and 6, 24 and/or 48 h after
IVC stenosis application (DVT)or sham surgery. Plasmawas prepared and
DNA levels determined by SytoxGreen dye; n = 3–8 per time point.
*P < 0.003vs. thesamemiceatbaseline (paired t-test).P < 0.03,6 hDVT
vs. sham-operated mice (Mann–Whitney test). Error bars represent SEM.
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CitH3-positive cells were also revealed by the immunofluo-
rescent staining in the core of the red part of thrombi
(Fig. 3A), confirming our immunohistochemical data
(Fig. 2C,D). No substantial CitH3 staining was observed in
the white part of thrombi (Fig. 3A asterisk), IVC wall
(Fig. 3E), sham-operated IVC (Fig. 3G) and in control
sections stained without first antibody (Fig. 3C,D,H). Thus,
histones present in murine IVC thrombi are likely to
originate from neutrophils releasing NETs predominantly in
the red part of thrombi. In mice, similar to baboon [4],
thrombi extracellular chromatin frequently co-distributes with
VWF.
Histones increase plasma VWF levels and promote DVT
Extracellular histones are cytotoxic to endothelial cells and
activate platelets in vitro; histone infusion at a high dose of
75 mg kg)1 is lethal to mice [4,28]. We therefore used a
lower dose (10 mg kg)1) of histone mix, a dose that
produces only mild thrombocytopenia [6], to test whether
it renders mice more prone to venous thrombosis. Only two
of 14 vehicle-treated mice (14%) produced thrombi after 1 h
IVC stenosis (Fig. 4), while five of nine mice that received
histones prior to the surgery (55%) developed a thrombus
(P < 0.04).
Histones have been shown to cause Ca2+ influx in different
cell types [6,29,30]. Increase in intracellular Ca2+ level triggers
VWF secretion from endothelial cells and platelets, with some
of the VWF remaining associated with the plasma membrane
of these cells [31]. Platelet recruitment mediated by VWF is a
key step in the initiation of venous thrombosis in this model of
DVT [22]. Therefore stimulation of VWF secretion could be
one of themechanisms responsible for the prothrombotic effect
of histones. Indeed, histone infusion increased plasma VWF
levels compared with baseline (Table 1). In contrast, VWF
plasma levels in vehicle-treated mice remained unchanged.
Thus, histone infusion increases plasma concentration of
VWF, which could contribute to the effect of histones on
DVT in the flow restriction setting.
DNase 1 infusion protects mice from DVT
Based on the presence of histones, DNA and NET-like
structures in deep vein thrombi in baboons [4] and mice (this
report) and on the ability of DNase 1 to disassemble NET-
induced thrombi in a flow chamber [4], we hypothesized that
White part Red part
Control red part
Control white part
Gr-1
CitH3
DNA
A
B C D E
Fig. 2. Neutrophils expressing citrullinated histone H3 are present in deep vein thrombi. Frozen sections of a thrombus formed in the mouse IVC after
48 h IVC stenosis were stained for Gr-1 (brown) and CitH3 (grey-black), and counterstained for DNA (pink). (A) Composite of photographs of a stained
longitudinal section of the entire thrombus with white (remote from the suture towards the tail) platelet-rich and red (adjacent to the suture) RBC-rich parts
designated (dotted green line approximately delineates the white part of the thrombus). (B) High magnification of the white thrombus part. Note abundant
Gr-1-positive neutrophil staining and absent CitH3 staining. (C, D) High magnification of the red part of the thrombus. (C) Orange arrowhead indicates
single Gr-1 staining; red arrowhead designates double Gr-1/CitH3 staining. (D) Red arrowheads indicate NETs-like CitH3-positive structures. Inset
represents high magnification of the circled area with NETs-like structures. (E) Negative control without first antibody from the red (upper panel) and
white (lower panel) parts of the thrombus. (A) bar 500 lm; (B–E) bar 50 lm.
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DNase 1 might prevent DVT in vivo. To test this possibility,
we infused DNase 1 in mice immediately after surgery and
examined thrombosis after 6 or 48 h of IVC stenosis (in 48-h
DVT experiments, infusions were repeated every 12 h). In the
6-h model, half (seven of 14) of the vehicle-treated mice
produced a thrombus (Fig. 5), whereas in mice that received
A B
C D
E F
G H
Fig. 3. Extracellular citrullinated histone H3 is partially associated with VWF in murine deep vein thrombi. (A–D) Widefield fluorescence microscopy
analysis of longitudinal sections of a thrombus developed in the IVC after 48 h stenosis. Sections were immunostained for VWF (red) and for CitH3
(green) (upper panels). Incubation with only secondary antibodies served as a negative control (lower panels). (A) The !white part" of the thrombus (*)
was positive for VWFbut negative for citrullinated histoneH3, whereas the !red part" of the thrombus was positive for both VWF andCitH3. The red part-
associated CitH3 could be observed as a punctiform (intracellular) or diﬀuse (extracellular) staining. (A, C) Scale bars, 500 lm. (B) Higher magnification
images show frequent co-distribution of extracellular CitH3 with VWF within the red part of thrombus as indicated by the arrowheads. (B, D) Scale bars,
50 lm. (E, F, H) Widefield fluorescence microscopy analysis of cross-sections of the red part of a thrombus developed in the IVC after 48 h stenosis and
including vessel wall. (E, F, G) Sections were immunostained for VWF (red) and CitH3 (green) and counterstained for DNA (Hoechst 33342, blue); (H)
control staining without first antibody. (E, F) Prominent CitH3 staining could be found within the thrombus and was often in proximity to VWF (F,
arrowheads). No extracellular CitH3 could be detected in a sham-operated vessel containing only blood (G). (E–H) Scale bars, 100 lm.
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DNase 1, only one mouse of 10 formed a thrombus
(P < 0.05). In the 48-h IVC stenosis model, mice treated
with control buffer developed a thrombus in 63% of cases
(five of eight), whereas thrombus prevalence in mice treated
with DNase 1 was 17% (two of 12, P < 0.04). These data
suggest that extracellular chromatin may play a role in flow
restriction-induced thrombosis and DNase 1 infusion is
protective against thrombosis in this model.
Discussion
Several cell types have been shown to release extracellular
chromatin upon activation. The role of the nuclear material
originating from neutrophils, NETs, in antimicrobial defense
has been convincingly demonstrated [2]. We recently published
evidence that extracellular chromatin could be implicated in
thrombosis because NETs can form a scaffold able to recruit
both platelets and RBCs in vitro [4]. Perfusion of blood over
NETs in a flow chamber results in the formation of a red
thrombus, which was entirely NET-dependent as DNase 1,
which destroys NETs, prevented recruitment of both cell types.
This suggested a mechanistic link between NETs and DVT
because (i) recruitment of platelets is one of the early events
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Fig. 4. Histone infusion promotes flow restriction-induced thrombosis in mice. Histone mix (10 mg kg)1) was infused into WT mice immediately
before DVT surgery. Mice were sacrificed after 1 h stenosis and thrombi developed in the IVC were examined and harvested. Values for weight (A) and
length (B) of the thrombi are shown with medians (horizontal bars). (C) Percentage of mice that developed a thrombus. Vehicle-treated mice, n = 14;
histone-treated mice, n = 9.
Table 1 Histone infusion elevates plasma VWF levels. Blood was drawn
24 h before and 1 h after infusion of saline or histone mix (10 mg kg)1). P
value was calculated by the paired t-test. Saline-injected mice, n = 8;
histone-injected mice, n = 6
Saline Histone mix
Baseline 1 h after infusion Baseline 1 h after infusion
83 ± 2.7% 78 ± 5.2% 78 ± 4.2% 94 ± 6.7%
– P = 0.43 – P < 0.003
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Fig. 5. DNase 1 infusion protects mice from flow restriction-induced thrombosis. Wild-type mice underwent IVC stenosis for 6 h (A–C) or 48 h
(D–F). Mice received infusion of either vehicle or DNase 1 (50 lg ip and 10 lg iv) before the surgery (A–F) and every 12 h thereafter (D–F). (A, D)
Thrombus weight and (B, E) thrombus length are presented; horizontal lines represent median. (C, F) Percentage of mice with a thrombus; 6 h vehicle,
n = 14; 6 h DNase 1, n = 10; 48 h vehicle, n = 8; 48 h DNase 1, n = 12.
NETs promote deep vein thrombosis 141
! 2011 International Society on Thrombosis and Haemostasis
141
pivotal for thrombus initiation in mice [22] and (ii) DVT
thrombi are rich in RBCs [23]. Thrombi developed in the
murine flow restriction model of DVT also consist of a large
RBC-rich red part and a smaller platelet-rich white part with
both parts containing fibrin [22]. Thus, thrombi formed in this
murine model share close morphological similarity to human
DVT thrombi, which also include white and red parts [23].
Thrombi obtained in an experimental DVT model in
baboons have been shown to contain extracellular DNA, H3
and DNA/H2A/H2B complex [4]. Here we demonstrate that
histone H3 was also abundantly present in murine DVT
thrombi.We show that histoneH3was citrullinated, suggesting
that it is likely to have originated from neutrophils forming
NETs. PAD4, the enzyme responsible for arginine conversion
to citrulline, is abundantly expressed in granulocytes [15,16].
Staining for Gr-1, a neutrophil marker, revealed neutrophil
presence in both red and white parts of the murine venous
thrombi. Neutrophil-specific staining in the red part of thrombi
was frequently associated with CitH3, with CitH3 being either
confined to nuclei or localized extracellularly. This suggests
that here neutrophils are at different stages of NETosis
(Figures 2 and 3). Interestingly, little CitH3-positive staining
was observed in the white part of thrombi despite abundant
presence of Gr-1-positive cells. As NETosis is an irreversible
process, one may speculate that neutrophils in the white part
have spent less time in the thrombus compared with the red
part neutrophils. This may suggest that the white part,
originally adjacent to the stenosis site where thrombus growth
begins, has a role in recruiting neutrophils from the surround-
ing blood. This is likely to be through binding to the activated
platelets. Later on, these neutrophils may also become
activated and form NETs, which in turn would contribute to
recruitment of RBCs and the formation of red thrombus.
This model corroborates the reported ability of stimulated
platelets to bind neutrophils and induce formation and release
of NETs [3,5]. In addition, flow restriction may create hypoxic
conditions in the vessel wall and cells buried inside a thrombus
are exposed to even more severe hypoxia due to isolation from
the blood stream. Hypoxia potentiates the release of ROS [32].
Besides neutrophils, platelets also can generate ROS, such as
superoxide [33]. It has been shown that ROS not only directly
contribute to thrombosis [34] but also can trigger formation of
NETs [13,35]. Therefore, the adherent neutrophils exposed to
twomajor triggers of NETs production, activated platelets and
ROS, release extracellular chromatin, which then contributes
to further thrombus development.
At the early stages of flow restriction, massive recruitment
of both platelets and leukocytes to the endothelium occurs
simultaneously [22]. It has recently been reported that
co-culture of neutrophils with activated endothelial cells can
also induce NET formation, which in turn promotes
endothelial damage [36]. As the activation state of the
endothelium is critical for DVT initiation [22], it is possible
that NETs-endothelial interactions could be involved in
thrombus initiation. This fits with our observation that NETs
biomarkers accumulate in plasma within hours after flow
restriction induction and that histones cause an increase in
plasma VWF levels, probably from the activated endothe-
lium.
As NETs are generated during the early stage of thrombus
initiation and are also abundantly present in mature thrombi, it
would be reasonable to hypothesize that NETs degradation
might affect thrombosis. DNase 1 has been shown to degrade
NETs in vitro [2]; a lesser ability of DNase 1 to dismantle NETs
in plasma of patients with systemic lupus erythematosus
correlates with severity of kidney dysfunction [37]. Here,
infusion of DNase 1 protected mice from flow restriction-
induced DVT regardless of the length of stenosis (6 or 48 h,
Fig. 5). As no visible thrombus was detected in most DNase 1-
treated mice, DNase 1 apparently cleaves NETs early,
disrupting the pathways of cellular activation and preventing
the cascade of events leading to thrombosis. The anti-throm-
botic effect of DNase 1 is likely to be mediated by removal of
NETs generated locally at the site of stenosis, similar to
cleavage of endothelium-boundVWFbyADAMTS13. Similar
to ADAMTS13, DNase 1 infusionmay not reduce the amount
of circulating DNA but rather affect its size and local
concentration.
It is known that blood coagulation contributes to DVT and
hypercoagulable states are considered risk factors for the
disease [19–21]. The murine DVT model used in our study
recapitulates this feature of human DVT because fibrin could
be detected throughout the thrombus [22]. Although antico-
agulants have not been tested in this model, a procoagulant
state, such as in mice with high plasma levels of soluble P-
selectin [38], is associated with increased DVT induced by
stasis in the IVC [39]. It remains unclear whether DNase 1
infusion attenuates, directly or indirectly, blood coagulation
and a potential off-target effect of DNase 1 on some
components of the coagulation cascade cannot be fully ruled
out.
We observed that strings of extracellular CitH3 frequently
co-localized with VWF in the thrombi produced by IVC
stenosis. This finding corroborates in vitro observations that
histone [40] and NETs bind VWF [4]. Secretion of VWF
from Weibel–Palade bodies (WPBs) to the surface of
endothelial cells appears required for the development of
DVT in mice [22].
Interestingly, VWF expression is downregulated in the
venous valvular sinus, which experiences stasis and hypoxia,
likely to maintain a thromboresistant phenotype at this
thrombosis-susceptible site [41]. In thrombi, VWF may orig-
inate not only from endothelium but also from platelets, in
which it is stored in alpha-granules. It is tempting to speculate
that VWF andNETs form amutually supportive network that
contributes to VWF A1 domain activation [31] and to growth
and stabilization of a venous thrombus.
Histones also are likely to participate in the process of
thrombus initiation. Infusion of histone mix facilitated throm-
bosis in mice (Fig. 4). This may result from the observed
deleterious effect of histones on endothelium in vitro [28], which
at a lower dose in vivo might activate endothelium and
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stimulate the release of VWF as we observed (Table 1).
Another prothrombotic effect of histones could result from
activation of platelets [4,6]. Activated platelets can stimulate
NETs production [3,5] and promote release of WPBs [42],
leading to further recruitment of platelets and leukocytes. In
either case, histones would contribute to the process of
thrombus initiation and propagation.
In conclusion, our study demonstrates an important func-
tional role of NETs in DVT induced by flow restriction and
provides possible new targets for drug development.
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Summary. Background: A growing health problem,
venous thromboembolism (VTE), including pulmonary
embolism (PE) and deep vein thrombosis (DVT),
requires refined diagnostic and therapeutic approaches.
Neutrophils contribute to thrombus initiation and devel-
opment in experimental DVT. Recent animal studies
recognized neutrophil extracellular traps (NETs) as an
important scaffold supporting thrombus stability. How-
ever, the hypothesis that human venous thrombi involve
NETs has not undergone rigorous testing. Objective: To
explore the cellular composition and the presence of
NETs within human venous thrombi at different stages
of development. Patients and Methods: We examined 16
thrombi obtained from 11 patients during surgery or at
autopsy using histomorphological, immunohistochemical
and immunofluorescence analyses. Results: We classified
thrombus regions as unorganized, organizing and orga-
nized according to their morphological characteristics.
We then evaluated them, focusing on neutrophil and
platelet deposition as well as micro-vascularization of
the thrombus body. We observed evidence of NET
accumulation, including the presence of citrullinated his-
tone H3 (H3Cit)-positive cells. NETs, defined as extra-
cellular diffuse H3Cit areas associated with
myeloperoxidase and DNA, localized predominantly
during the phase of organization in human venous
thrombi. Conclusions: NETs are present in organizing
thrombi in patients with VTE. They are associated with
thrombus maturation in humans. Dissolution of NETs
might thus facilitate thrombolysis. This finding provides
new insights into the clinical development and pathology
of thrombosis and provides new perspectives for thera-
peutic advances.
Keywords: blood platelets; clinical pathology; histones;
neutrophils; venous thromboembolism.
Introduction
Venous thromboembolism (VTE), which includes both
deep vein thrombosis (DVT) and pulmonary embolism
(PE), is the most common cardiovascular disease after
myocardial infarction (MI) and ischemic stroke [1]. In
animals, neutrophils contribute importantly to the path-
ogenesis of venous thrombosis [2–5]. Neutrophil-related
pro-coagulant mechanisms might contribute to large-ves-
sel thrombosis in various types of cardiovascular dis-
eases [6]. Our group has previously reported that
neutrophil extracellular traps (NETs) provide a scaffold
for experimental thrombus formation by binding ery-
throcytes and platelets [7]. NETs consist of released
nuclear DNA containing histones and neutrophil granule
proteins, such as elastase, myeloperoxidase (MPO) and
cathepsin G [8,9]. NETs localize in experimental DVT in
baboons [7] and extracellular chromatin comprises part
of the structure of venous thrombi in mice [10,11].
Treatment with deoxyribonuclease I (DNase I), an enzyme
that degrades DNA, protects mice from flow restriction-
induced DVT [10,11]. Our recent experimental study
indicates that neutrophil chromatin decondensation
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mediated by peptidylarginine deiminase 4 (PAD4), an
enzyme required for NET formation (NETosis) [12], par-
ticipates crucially in venous thrombosis in mice [13], thus
emphasizing the impact of NETs on DVT. Increased lev-
els of circulating nucleosomes and markers of neutrophil
activation are associated with a 3-fold higher risk of DVT
in humans [14]. An elevated plasma DNA concentration
correlates with biomarkers of DVT [15] and with a pro-
thrombotic state in patients with severe atherosclerosis
[16].
Thrombus evolution generally proceeds through three
distinct phases [17]. Initially, thrombi are unorganized. If
formed under conditions of continued blood flow,
roughly alternating layers of platelets and red cells gen-
erate laminae, denoted as lines of Zahn; if formed in a
static environment, the thrombus has a more uniform
appearance. After a few days, the thrombus begins to
organize, with inflammatory cells (initially neutrophils
and later lymphocytes and monocytes) infiltrating the
edges of the thrombus in association with fibroblasts,
collagen deposition and neovascularization. Over weeks
or more, an organized thrombus assumes a more
ordered fibrotic appearance with associated hemosiderin-
laden macrophages, but an otherwise sparse inflamma-
tory infiltrate. The times suggested are approximate min-
imums, and should not be taken as absolutes; the
progress of thrombus organization can vary significantly.
Numerous factors, including host immune status, degree
of residual blood flow at the thrombus site and medica-
tion use, can all affect the process to varying degrees.
Additionally, at any given time, a single thrombus will
often display multiple stages of development; typically,
the periphery adjacent to a vessel wall exhibits the great-
est organization, with the center of the thrombus show-
ing the least.
Few reports have sought NETs in thrombi from
humans. Extensive histone citrullination was observed in
the thrombus of a patient with microscopic polyangiitis
complicated by pneumonia and DVT [18]. Also, coronary
thrombi removed from patients with acute MI contain
NETs [19], as do intraluminal thrombi from abdominal
aortic aneurysm patients [20]. Histone proteins H2A/H2B
with DNA are found in human arterial thrombi removed
from acutely (age 1–3 days) thrombosed grafts and in
chronic (more than 1 year) aortic hematoma samples
[21].
NETs furnish an important new link between innate
immunity, inflammation, hemostasis and thrombosis
[2,3,22,23]. Their recognition provides an opportunity to
develop biomarker(s) based on NET components for
human VTE diagnosis and to design new therapeutic
approaches to improve the efficacy of thrombolysis. The
current study aimed to establish the presence of NETs
during the different stages of thrombus development in
humans with VTE.
Materials and methods
Sample acquisition
Specimens were identified through a search of the elec-
tronic records of the Department of Pathology and Lab-
oratory Medicine at Brigham and Women’s Hospital by
a cardiovascular pathologist who had full access to the
origin of the samples and selected the specimens based
on the prespecified inclusion criteria below. Search
parameters included any one of the text strings contain-
ing ‘deep vein thrombosis’, ‘deep vein thrombus’, ‘pul-
monary embolus’ or ‘pulmonary embolism’, being
identified as an embolectomy specimen during accession-
ing, or being identified as a leg amputation and contain-
ing the text ‘thrombus’ or ‘thrombosis’. Reports for
cases meeting these criteria were manually reviewed to
identify cases where deep vein thrombi, inferior vena
cava (IVC) filter clots and/or pulmonary emboli were
sampled and processed as formalin-fixed paraffin-embed-
ded (FFPE) specimens. Those specimens meeting such
criteria were then retrieved from the archives of the
Department, and de-identified sections were generated
for study. These procedures were reviewed and approved
by the Human Research Committee (HRC) of Partners
HealthCare, and conform to current national and inter-
national standards for ethical conduct of human subjects
research.
Histology
FFPE tissue sections cut at 4-lm thickness were stained
with either hematoxylin and eosin (H&E) or Masson’s
trichrome. A cardiovascular pathologist categorized the
specimens using histomorphological features as unorga-
nized (lack of collagen deposition, interspersed regions of
fibrin/platelets and red blood cells), organizing (poorly
organized collagen and/or neovasculature, and/or granu-
lation tissue-like appearance) or organized (well-orga-
nized collagen with intermixed hemosiderin-laden
macrophages, with or without a well-formed neovascula-
ture) [17].
Immunohistochemistry
Following deparaffinization, microwave antigen retrieval
used citrate buffer (pH 6.7) for 8 min, followed by the
incubation of slides in heated buffer for an additional
20 min. After endogenous peroxidase activity blocking
in methanol/H2O2 (100 : 1) for 30 min at room temper-
ature, single immunohistochemical staining used an
anti-H3Cit antibody (ab5103, 1 : 250 dilution, Abcam,
Cambridge, MA, USA). Histofine Simple Stain MAX
PO (MULTI) (414152F, ready to use, Nichirei Corpora-
tion, Tokyo, Japan) served as a secondary antibody.
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The Diaminobenzidine (DAB) substrate kit (415192F,
Nichirei) enabled visualization of staining by H3Cit
antibody. Finally, sections were counterstained with
hematoxylin. Isotype-matched IgG was used instead of
primary antibody as a negative control of the staining.
Because of differences observed in the amount of H3Cit
staining, we performed a blinded semi-quantitative
analysis using an H3Cit scoring system based on the
proportion of H3Cit-positive cells across an entire sam-
ple. The regions with a majority of H3Cit-positive stain-
ing among the entire population of cells (observed with
counterstaining) were defined as positive (+, or high
H3Cit score). Those cases where H3Cit-positive signals
were observed in less than half of the region’s cells were
classified as (!) and areas without or with very few
H3Cit-positive cells were scored as negative ("). All
specimens were characterized blindly by a co-investigator
who did not have knowledge of the nature of the speci-
mens at the time of scoring.
A rabbit monoclonal anti-CD11b (ab52478, 1 : 250
dilution, Abcam) served to identify leukocytes and mouse
monoclonal anti-CD42b (ab74449, ready to use, Abcam)
to visualize platelets. Also, the combination of anti-
CD11b and mouse monoclonal anti-MPO (ab24467,
1 : 250 dilution, Abcam) antibodies was used to specify
the origin of CD11b-positive cells. Histofine Simple Stain
MAX PO (MULTI) was used as a secondary antibody
for anti-CD11b, the first primary agent. Alkaline Phos-
phatase (AP)-goat anti-mouse IgG (H+L) (No. 626522,
1 : 500 dilution, Invitrogen, Carlsbad, CA, USA) was
applied as a secondary antibody for anti-MPO, the sec-
ond primary agent. The DAB substrate kit (SK-4100,
Vector Laboratories, Burlingame, CA, USA) was used
for visualization of double immunohistochemical staining.
Finally, sections were counterstained with Nuclear Fast
Red (Sigma-Aldrich, St Louis, MO, USA). Images were
captured using Axiovision software (Zeiss, Thornwood,
NY, USA) and a Zeiss Axioplan microscope coupled with
a Zeiss AxioCam HRc camera. Individual images were
manually aligned to generate composite images of entire
thrombus sections.
Immunofluorescence analysis
Antigen retrieval was performed after deparaffinization.
The slides were briefly boiled in sodium citrate buffer
(10 mM, pH 6.0) in a microwave and then incubated in
heated buffer for an additional 15 min. The slides were
washed twice in PBS and then permeabilized with 0.1%
Triton X-100 for 10 min on ice. After blocking with 3%
bovine serum albumin for 1 h at 37 °C or 10% normal
goat serum for 2 h at room temperature, slides were incu-
bated overnight in antibody dilution buffer (0.3% BSA,
0.05% Tween-20) containing one of the following: rabbit
polyclonal anti-citrullinated histone H3 (ab5103,
0.5 lg mL"1, Abcam), mouse monoclonal anti-myeloper-
oxidase (MPO) (ab25989, 0.67 lg mL"1, Abcam), mouse
monoclonal anti-peptidylarginine deiminase 4 (PAD4)
(ab128086, 4 lg mL"1, Abcam), sheep polyclonal anti-
von Willebrand factor (VWF) (ab11713, IgG fraction
1 : 250 dilution, Abcam), rabbit polyclonal anti-citrulline
(panCit) (ab6464, whole antiserum, 1 : 1500 dilution, Ab-
cam) or mouse monoclonal anti-CD31 (ab9498,
2 lg mL"1, Abcam). For each staining, an IgG used at
the same concentrations as the primary antibody served
as the negative control. After thorough washing with
PBS, slides were incubated in antibody dilution buffer
containing 1.5 lg mL"1 Alexa488-conjugated rabbit IgG,
1.5 lg mL"1 Alexa568-conjugated sheep IgG or
1.5 lg mL"1 Alexa555-conjugated mouse IgG (all from
Invitrogen) for 2 h at room temperature. After thorough
washing, DNA was counterstained using 1 lg mL"1 Hoe-
chst 33342 (Invitrogen) and cover-slipped using Fluorogel
mounting medium. Images were acquired using a Zeiss
Axiovert widefield fluorescence microscope in conjunction
with a Zeiss MRm monochromatic CCD camera and Ax-
iovision software.
Results
Clinical specimen characteristics
This analysis is based on 16 thrombi collected from 11
individuals (mean age 52.0 ! 17.9 years; three men and
eight women, Table 1.) Six thrombus samples were
derived from three autopsy cases (all within 24 h of
Table 1 Patient clinical data and thrombus samples included in the
study
No. of patient Age Gender Diagnosis Tissue
Surgical
Patient 1 36 F CTEPH PE
IVC clot
Patient 2 47 F CTEPH PE
Patient 3 72 F Metastatic
endometrial
adenocarcinoma
DVT
Patient 4 69 F s/p lung transplant
for UIP
PE
IVC clot
Patient 5 16 M CTEPH PE
Patient 6 60 M s/p hernia repair PE
Patient 7 44 F CTEPH PE
Patient 8 53 M Idiopathic recurrent
VTE
IVC clot
Autopsy
Patient 9 74 F s/p aortic valve
replacement
PE
DVT
Patient 10 38 F Obesity, recurrent VTE DVT
PE
Patient 11 63 F Lung adenocarcinoma PE
DVT
CTEPH, chronic thromboembolic pulmonary hypertension; s/p, sta-
tus post; UIP, usual interstitial pneumonia; VTE, venous thrombo-
embolism.
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death), and 10 from eight surgical cases. Clinical diagno-
ses included: chronic thromboembolic pulmonary hyper-
tension (n = 4), recurrent venous thromboembolism
(n = 2), cancer (one case of metastatic endometrial adeno-
carcinoma and one of lung adenocarcinoma) and one case
each of hernia, aortic valve replacement and status post-
lung transplant. Six thrombus specimens were obtained
from three patients with PE and DVT; PE and IVC clot
samples (n = 4) were collected from another two patients.
Four thrombi were derived from patients with PE as a
main diagnosis and two from patients with either DVT or
IVC clot.
According to the morphological criteria described
above, based on the results of hemotoxylin and eosin and
of trichrome staining, thrombus regions fell into three
major stages of thrombus development [17]: unorganized
(16 regions from 11 patients), organizing (13 regions from
11 patients) and organized (eight regions from seven
patients).
We then used immunohistochemical analysis to deter-
mine the distribution of platelets and leukocytes in the
human thrombi during each stage of maturation, as well
as the presence of H3Cit as a marker of NETosis. At
least two regions corresponding to different stages of
thrombus organization were identified in 15 out of 16
specimen samples.
Unorganized thrombi harbor rare H3Cit-positive cells, while
these cells and NETs abound in the organizing stage of
thrombus development
Figure 1 shows a representative thrombus from a PE
patient with both unorganized (square box 2) and orga-
nizing (square box 1) regions. We observed platelet- and
fibrin/erythrocyte-rich zones, defined by the presence of
lines of Zahn (white arrows, Fig. 1A). The organizing
part of a thrombus mainly contained leukocytes positive
for CD11b (brown, Fig. 1A). The majority of CD11b-
positive cells (brown) were identified as neutrophils by
double staining with MPO (blue), showing that most
CD11b-expressing cells are also MPO positive (dark
blue). Prominent H3Cit-positive staining (brown, Fig. 1A,
last panel) localized only within the organizing, but not
the unorganized, part of the thrombus. This observation
suggests that NETosis occurs in human thrombi during
the organizing stage of maturation.
To clarify the composition of the human thrombus
samples observed in this study, Fig. 1(B) presents larger
images of the organizing region at higher magnification
(areas indicated as oval 1 in Fig. 1A). We also performed
immunofluorescence staining (Fig. 1C). We observed both
intracellular (H3Cit-positive nuclei, green arrow in
Fig. 1C) and diffuse extracellular H3Cit-positive staining
patterns (green asterisk in Fig. 1C), suggesting ongoing
NETosis and the prominent presence of NETs in this
inflammatory stage of thrombus development.
We have previously shown that NETs bind VWF [7]
and that VWF co-distributes with NET biomarkers in
thrombi from baboons and mice [7,10]. Here we found
platelets stained strongly positive for VWF. In addition,
we observed regions with diffuse VWF staining (white
asterisk) associated with H3Cit extracellular staining
(Fig. 1C, lower left panel), indicating the interaction of
VWF with NETs. Single channels showing VWF (diffuse
VWF staining is indicated by white asterisk) and H3Cit
expression patterns are presented in Figure S1. We also
stained thrombus samples for PAD4, the enzyme required
for NETosis [12,24,25], and found PAD4-positive cells in
corresponding areas of neutrophil infiltration and NETo-
sis (Fig. 1C, lower middle panel). Also, panCit antibody,
which recognizes citrulline modifications on proteins,
visualized an intracellular and a diffuse extracellular
staining pattern (Fig. 1C, lower middle panel), again indi-
cating that protein citrullination occurs in human
thrombi. IgG-isotype control staining showed no positive
signal by either immunohistochemical (Fig. 1B, far right
panel) or immunofluorescence (Fig. 1C, second row, far
right panel) analyses.
We also observed the presence of lines of Zahn
(Fig. 2A) with platelet aggregates (Fig. 2B) and neutro-
phil infiltrates (Fig. 2B and 2C) in an organizing deep
vein thrombus. Of interest, H3Cit-positive cells (Fig. 2D
and 2E) originating from neutrophils (Fig. 2F) localized
predominantly in the immediate vicinity of VWF-positive
(Fig. 2H) platelet-rich zones (Fig. 2E and 2H), suggesting
a possible involvement of NETs in the process of platelet
recruitment during human thrombus organization. We
further found PAD4 and panCit staining in these areas
(Fig. 2G), whereas isotype-control staining displayed no
specific signal (Fig. 2I). Thus, the intensity of H3Cit
staining was varied throughout the different stages of
thrombus development.
Organized thrombi contain multiple microvessels while
NETs are rare at this stage
Organized thrombi contained microvessels, observed by
trichrome staining (Fig. 3A, blue square is magnified in
Fig. 3C) and confirmed by immunofluorescence analysis
using an anti-CD31 antibody (Fig. 3B). The negative con-
trol staining using isotype-matched IgG showed no spe-
cific signal. A few microvessels were observed in only one
case of an organizing thrombus surgically removed from
a PE patient (Figure S2).
We observed areas of collagen-rich connective tissue in
organized regions of thrombi (Fig. 4A, blue square box
indicates a representative region), which were leukocyte
deficient (Fig. 4B–C and Fig. 4F) with only a few neu-
trophils found in the thrombus body (Fig. 4C). Both
immunohistochemical (Fig. 4D and 4E) and immunofluo-
rescence (Fig. 4F and 4G) analyses showed the lack of
prominent H3Cit-positive staining, with many completely
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Fig. 2. Platelet-rich zones are often surrounded by MPO and H3Cit-positive staining in the organizing deep vein thrombus. Representative
images from a DVT sample collected during autopsy. (A–C) Thrombus was classified as organizing based on the presence of minimal collagen
deposition, early neovascularization and/or granulation-like tissue (A), CD42b-positive platelet aggregates (blue, B) and infiltrating CD11b-
positive neutrophils (brown, B), co-stained with MPO (dark blue, C). (D) H3Cit-positive cells were detected in neutrophil-rich zones. Images
A–D are composites of photographs of stained sections of the entire thrombus. The area indicated by the blue square is shown at a higher
magnification in E and F and the area indicated by the orange square in G, H and I. Platelet-rich zones stained for VWF (red) and were sur-
rounded by H3Cit-positive cells (H). PAD4 (red) and panCit (green) were seen primarily in neutrophil-rich areas surrounding platelet islands
(G). Negative control staining was performed using isotype-matched non-specific IgG (I). Scale bars, 500 lm (A–D), 50 lm (E and F), 20 lm
(G–I).
Fig. 1. Evidence of prominent NETosis observed in the organizing, but not unorganized, portions of a pulmonary embolism thrombus. Repre-
sentative composite images from analysis of a pulmonary embolism (PE) sample obtained from autopsy. Consecutive sections of the thrombus
were stained. (A) Trichrome stain revealed organizing (square 1) and unorganized (square 2) regions of the thrombus and the presence of lines
of Zahn (white arrows). Double immunohistochemical staining for CD11b (brown, leukocytes) and CD42b (blue, platelets) showed both plate-
lets and leukocytes within the organizing stage of the thrombus (oval 1), whereas the unorganized part contained mostly platelets (square 2).
H3Cit-positive cells (brown) were observed mostly in the CD11b/MPO-double positive (dark blue) region of the organizing area. Higher magni-
fication images from the organizing part of a thrombus (indicated as oval 1) are shown in B and C. (B) Punctiform (intracellular) and diffuse
(extracellular) H3Cit staining (brown) was observed together with MPO (dark blue) within platelet/neutrophil-rich zones. Negative control
staining was performed using isotype-matched IgG. Images in A and B are composites of photographs of stained sections of the entire throm-
bus (A) and its organizing portion (B). (C) Upper panel confirmed the close localization of the intra- (green arrow) and extracellular (green
asterisk) H3Cit with MPO (single channels and merge are shown). Platelet islands stained for VWF (red), and diffuse VWF (white asterisk)
were present in areas containing H3Cit. A positive staining pattern for PAD4 (red) was seen in regions with neutrophil infiltration. Citrullinat-
ed proteins were detected using anti-panCit antibody (green). IgG isotype control served as a negative control. Sections were counterstained for
DNA as indicated (Hoechst 33342, blue). Scale bars, 500 lm (A), 100 lm (B), 50 lm (C).
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negative sections, indicating that NETosis does not char-
acterize mature regions of organized thrombi. Control
staining with isotype-matched IgG showed no positive
signal (Fig. 4H).
Quantification confirms that excessive H3Cit staining was
observed only in the organizing stage of thrombus
development
Semi-quantitative analysis of H3Cit-positive cells was per-
formed in a blinded fashion. We developed an H3Cit
scoring system based on the frequency of positive staining
for H3Cit (Material and Methods). This scoring system
classified the specimens with predominant H3Cit-positive
cells as H3Cit score (+), the specimens with less than half
H3Cit-positive cells as H3Cit score (!), and specimens
with no or very minor positive staining for anti-H3Cit
antibody as negative H3Cit score (").
Only organizing thrombi received a high H3Cit (+)
score (Fig. 5A and 5B). Thrombus samples from PE and
DVT patients revealed a similar distribution of H3Cit
scores, whereas no IVC clot samples had a high H3Cit
score (Fig. 5A). Of interest, an H3Cit (+) score was seen
in 54% of all organizing thrombi and in the remaining
46% a score of (!) was seen (Fig. 5B). No H3Cit (")
cases were identified in regions of early organization,
whereas 56% of unorganized and 50% of organized
thrombi had a (") H3Cit score (Fig. 5B). These data
showed that NETosis occurs almost exclusively within the
organizing stage of thrombus development.
Discussion
This study evaluated the composition of venous thrombo-
emboli obtained either surgically or from autopsy speci-
mens. The results show accumulation of NETs during the
organizing stage of pathological venous thrombus devel-
opment and thus support the participation of NETs in
the organization of human thrombi.
Histomorphological and immunological assays using
cell marker-specific antibodies showed differences in
platelet and neutrophil deposition as well as micro-vascu-
larization within the unorganized, organizing and orga-
nized stages of thrombus development. These findings
suggest that immunohistological analysis could become a
useful adjunct for the pathological description of human
thrombi.
The process of leukocyte infiltration and monocyte
recruitment during thrombus formation and the impact of
NETs have received previous attention in experimental
DVT [10,11,13,26]. This study shows evidence of ongoing
NETosis in the organizing stage of human thrombus
development, including both intra- and extracellular H3Cit
closely associated with MPO, as well as extracellular DNA
Trichrome
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DNA DNA
CD31
100 µm
50 µm
500 µm
A
B
C
Fig. 3. Accumulation of microvessels within the organized region of a pulmonary embolism thrombus. (A,C) Trichrome stain indicated organ-
ized regions of a thrombus with micro-vascularization (area within blue square is magnified in C). (B) CD31-positive vascular endothelial cells
were found in the area with newly formed blood vessels. Negative staining with non-specific IgG showed no specific pattern and nuclei are
observed as distinct round shapes in this cell-rich region stained for DNA. Images A and C are composites of photographs of a stained section.
Scale bars, 500 lm (A), 100 lm (B), 50 lm (C).
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in H3Cit-rich areas. Thrombus composition did not differ
between patients with PE and DVT. Thus, NETs appear
to form as part of the inflammatory response and organi-
zation in human thrombus development.
NETs’ DNA and histones provide a scaffold for
thrombi by binding RBCs and promoting platelet aggre-
gation in vitro and in mice [6,7]. The results of this study
suggest that this concept could apply to human thrombo-
genesis as well. Murine venous thrombi contain H3Cit, a
marker of NETs, co-distributing with VWF predomi-
nantly in the red blood cell (RBC)-rich portion of the
thrombus [10], and VWF-platelet interaction contributes
substantially to VTE development in animals [27,28].
Plasma VWF secreted from activated vascular endothe-
lium is induced by histone infusion, which also promotes
DVT in mice [10]. This finding could result from
the enhancement of thrombin generation by extracellular
histones that occurs via a platelet-dependent mechanism
[29,30]. We observed that H3Cit-positive cells surrounded
VWF-positive platelet islands in human DVT samples
and that diffuse VWF-positive staining was associated
with diffuse H3Cit patterns in the organizing regions of
thrombi. This observation supports the notion that NETs
together with VWF could enhance thrombus formation/
stability in humans.
Of interest, we found that diffuse extracellular H3Cit-
positive areas in the organizing part of thrombi also con-
tained PAD4, an enzyme required for chromatin decon-
densation during NETosis. PAD4-deficient mice, which
cannot produce NETs [12], exhibit protection from DVT
[13] and MI [31]. Thus, these data show NETting neu-
trophils in human venous thrombosis and identify PAD4
as a potential target for future drug development.
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Fig. 4. H3Cit is rare in the organized regions of thrombi. Analyses of a surgically removed IVC clot. (A) Collagen-rich connective tissue (blue)
was present within the organized part of the thrombus and is indicated with a blue square. (B–C) Cell-specific immunohistochemical analyses
revealed few platelets and neutrophils within the entire thrombus body and their absence in the organized part of the thrombus. (D) Immuno-
histochemical staining for H3Cit antibody (brown) displayed a negative reactivity (area indicated as a blue square). Images A–D are composites
of photographs of stained sections of the entire thrombus. (E–H) High magnification images of the organized part from the area indicated with
a blue square in A–D. No staining was detected using anti-H3Cit (E–G), MPO (F) and VWF (G) antibodies in this thrombus. Negative control
using IgG isotype showed a non-specific staining pattern (H). Scale bars, 500 lm (A–D).
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Fig. 5. Summary of clinical, histomorphological and immunological analyses performed for all thrombus samples. (A) Table summarizes clin-
ical data from patients included in this study as well as results of histopathological validation. H3Cit score is presented for each of the cases.
H3Cit scoring system: + (highlighted in blue), strongly positive with the majority of H3Cit-positive cells throughout the entire thrombus
body; !, focally positive with a few H3Cit-positive cells in the population; ", negative with mostly H3Cit-negative cells. (B) Graph shows
the distribution of H3Cit score (percentage and number (n) of corresponding thrombus regions) between the different stages of thrombus
organization.
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Targeting NET components may also provide a foun-
dation for molecular imaging to identify patients with
thromboembolic disease that may respond optimally to
thrombolytic therapy. Molecular imaging techniques
using magnetic resonance and radionuclide scanning have
been shown to distinguish fresh from chronic thrombi but
have not yet reached widespread clinical use [32,33].
Fibrin clots containing DNA and histones have pro-
longed resistance to fibrinolysis that is reversed by
DNase [7,34]. Our observations support targeting NETs,
in addition to fibrin, as an approach to facilitate throm-
bolytic therapy in patients. DNase I has decreased the
incidence of thrombosis in experimental DVT in mice
[10,11]. Furthermore, we have recently reported that
DNase I also has an anti-inflammatory effect when
administered to mice with experimental myocardial
infarction [31]. The anticoagulant heparin can also disso-
ciate NETs [7] and prevent histone interactions with
platelets, thus protecting mice from histone-induced
thrombocytopenia [35]. Aspirin, a known anti-throm-
botic, can inhibit NETosis in vitro [36] as well as reduce
the incidence of recurrent VTE [37,38]. The combined
approach of heparin or aspirin with DNase I or PAD4
inhibitors might enhance venous thrombus prevention.
Co-administration of DNase I with a fibrinolytic might
facilitate thrombolysis, particularly during the organizing
stage of thrombus development.
In conclusion, this study demonstrates the presence of
NETs during the process of thrombus organization in
human VTE. NETs can provide a scaffold for human
thrombus stability during its maturation and could
become a diagnostic or therapeutic target to improve the
effectiveness of thrombolytic therapy in patients with
thromboembolic diseases.
Addendum
A. S. Savchenko performed experiments, analyzed data,
designed research and wrote the paper; K. Martinod, S.
L. Wong and J. I. Borissoff performed experiments and
analyzed data; M. A. Seidman collected thrombus sam-
ples and performed histological examination; G. Piazza,
P. Libby, S. Z. Goldhaber, R. N. Mitchell and D. D.
Wagner designed research, provided essential expertise on
cardiovascular and clinical pathology, analyzed data and
co-wrote the manuscript.
Acknowledgements
The authors thank L. Cowan for help with the prepara-
tion of the manuscript. This research was supported by
National Heart, Lung, and Blood Institute of the
National Institutes of Health grant R01HL102101
(DDW). JIB is a recipient of a Rubicon fellowship
(825.11.019) from the Netherlands Organization for Sci-
entific Research.
Disclosure of Conflict of Interests
The authors state that they have no conflict of interests.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Fig. S1. High magnification images from the organizing
region (indicated as oval 1 in Figure 1A) of a pulmonary
embolism thrombus document the expression pattern for
VWF and H3Cit. Left panel shows the bright VWF stain-
ing for platelet-rich zones and diffuse staining (white
asterisk) was observed in areas with H3Cit-positive cells
and H3Cit diffuse staining (single channel, middle panel).
Right panel displays the merged image. Scale bars,
50 lm.
Fig. S2. Evidence of blood vessel formation within an
organizing part of a pulmonary embolism thrombus.
CD31-positive microvessels were observed only within
one organizing region (region 1) and were not detected in
any other organizing portions of thrombi. Left image is a
composite of photographs of a stained section of the
entire thrombus. Anti-CD31 antibody also stained platelet
islands (region 2). Negative control staining was per-
formed using non-specific IgG isotype control. Scale bars,
500 lm (trichrome stain), 50 lm (immunofluorescence
analyses).
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Cancer-associated thrombosis often lacks a clear etiology. However,
it is linked to a poor prognosis and represents the second-leading
cause of death in cancer patients. Recent studies have shown that
chromatin released into blood, through the generation of neutro-
phil extracellular traps (NETs), is procoagulant and prothrombotic.
Using a murine model of chronic myelogenous leukemia, we show
that malignant and nonmalignant neutrophils are more prone to
NET formation. This increased sensitivity toward NET generation is
also observed in mammary and lung carcinoma models, suggesting
that cancers, through a systemic effect on the host, can induce an
increase in peripheral blood neutrophils, which are predisposed to
NET formation. In addition, in the late stagesof the breast carcinoma
model, NETosis occurs concomitant with the appearance of venous
thrombi in the lung. Moreover, simulation of a minor systemic in-
fection in tumor-bearing, but not control, mice results in the release
of large quantities of chromatin and a prothrombotic state. The
increase in neutrophil count and their priming is mediated by
granulocyte colony-stimulating factor (G-CSF), which accumulates
in the blood of tumor-bearing mice. The prothrombotic state in
cancer can be reproduced by treating mice with G-CSF combined
with low-dose LPS and leads to thrombocytopenia and micro-
thrombosis. Taken together, our results identify extracellular chro-
matin released through NET formation as a cause for cancer-
associated thrombosis and unveil a target in the effort to decrease
the incidence of thrombosis in cancer patients.
Thrombosis is the second most common cause of death incancer patients. Even in the absence of obvious thrombosis,
cancer patients commonly have a hypercoagulable condition with-
out a clear etiology (1). Cancer frequently induces a systemic
effect similar to infection and/or inﬂammatory disease, including
changes in cell numbers in peripheral blood and levels of in-
ﬂammatory cytokines (2). A feature of chronic myelogenous
leukemia (CML) is the excess of granulocytic myeloid cells of
varying maturation stages (3). In murine models of solid tumors
and a variety of human cancers, an increase in myeloid cells is
observed (4, 5). Granulocyte colony-stimulating factor (G-CSF) is
a cytokine produced by leukocytes and endothelium and is often
associated with leukocytosis and neutrophilia. G-CSF is also
produced by various tumors and cancer cells (6), including leu-
kemic cells of CML patients in chronic phase (7). Its concentra-
tion can be elevated in the blood of cancer patients and has been
associated with poor clinical outcome (8–10). G-CSF activates
neutrophils, stimulates oxidative metabolism (11), and increases
agonist-induced platelet aggregation ex vivo (12). Despite these
effects of G-CSF, only a few cases of thrombotic events have been
associated with G-CSF treatment in healthy donors (13).
The release of neutrophils extracellular traps (NETs) has been
identiﬁed as a mechanism of bacterial killing (14). Recently, NETs
were found to promote thrombosis (15, 16) and coagulation (17).
Upon contact with bacteria, neutrophils become activated, and
their primary response is the engulfment of pathogens into phag-
osomes. At later time points, in vitro experiments suggest that
NET-mediated entrapment and/or killing becomes predominant
(18). Furthermore, in vitro activation of human neutrophils with
a strong stimulus such as phorbol-12-myristate-13-acetate or hy-
drogen peroxide leads to NET generation (18). The same effect is
observed with a combination of weaker stimuli such as GM-CSF
and LPS or C5a (19). This suggests that priming of neutrophils
predisposes them to NET formation upon secondary stimulation.
Because an increase in neutrophils is a hallmark of CML, we
hypothesized that malignant neutrophils may be more prone to
NET formation. To our surprise, not only the transformed neu-
trophils but also normal neutrophils from mice with CML-like
myeloproliferative neoplasia (MPN) were primed to generate
extracellular DNA traps. In addition, using solid tumor models,
we show that cancers can induce an increase in peripheral blood
neutrophils that are sensitized toward NET formation and that
spontaneous thrombosis is associated with NET generation
in vivo. We also show that cancer-associated G-CSF predisposes
the host to an exacerbated innate immune response that results
in a prothrombotic state. Our ﬁndings may further explain the
association of cancer with thrombosis.
Results
Peripheral Blood Neutrophils from Mice with CML-Like MPN Are Prone
to Generate Extracellular DNA Traps. To determine whether malig-
nant transformation promotes NET formation, we ﬁrst assessed
the ability of neutrophils from mice with CML-like MPN to form
NETs. In this model, engraftment of bone marrow cells coex-
pressing breakpoint cluster region–Abelson (BCR-ABL1) and
green ﬂuorescent protein (GFP) occurs around 14 d after bone
marrow transplant (20) and produces an increase in BCR-ABL1+
peripheral blood neutrophils without a signiﬁcant increase in
platelet count compared with control mice (Fig. S1). Coexistence
of normal BCR-ABL1− (GFP−) and BCR-ABL1+ (GFP+) mye-
loid cells was observed at day 20 posttransplant when 29.49% ±
10.39% of cells were GFP+ (n = 8). Plasma analysis revealed a
greater level of plasma DNA in the CML-like mice compared with
controls, suggesting a possible generation of NETs in vivo (Fig.
1A). Isolation of peripheral blood neutrophils from control or
leukemic mice routinely yielded a purity of greater than 90% (Fig.
1B). Platelet-activating factor (PAF) stimulation of isolated neu-
trophils from mice with CML-like MPN induced a signiﬁcant in-
crease in NET formation in a dose-dependent manner compared
with neutrophils from control bone marrow recipients (Fig. 1C
and Fig. S2A). Interestingly, at a high dose of PAF, the majority of
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isolated neutrophils from CML-like mice generated NETs,
whereas only about 30% of them were BCR-ABL1+. This sug-
gested that it was not only the BCR-ABL1+ neutrophils that were
more sensitive to NET formation but rather the entire population.
To address this more rigorously, we used FACS sorting to separate
the GFP+ BCR-ABL1+ neutrophils from the GFP− neutrophils
and evaluated their NETosis potential. Again, the majority of both
GFP+ and GFP− neutrophils from CML-like mice generated ex-
tracellular DNA traps (Fig. 1D). Normal C57BL/6 neutrophils,
which had been sorted by ﬂow cytometry, acted as controls and
were shown to make NETs far less efﬁciently, indicating that the
isolation of neutrophils through FACS sorting did not stimulate
NET formation (Fig. S2B). In accordance with these results,
in vitro pretreatment with imatinib or dasatinib, two abl-speciﬁc
tyrosine kinase inhibitors (21), had no effect on NET formation
(Fig. S2C). Although the leukemic cells underwent apoptosis in
response to treatment, normal neutrophils were not affected.
Thus, NETs were still being made more efﬁciently by the non-
malignant neutrophils from CML-like animals than by neutrophils
from control mice. These results show that CML predisposes
BCR-ABL1+ and also BCR-ABL1− neutrophils to generate ex-
tracellular DNA traps, suggesting that a systemically acting factor
may be stimulating NET formation.
Solid Tumors Generate a Leukemoid Reaction and Predispose
Neutrophils to Extracellular DNA Trap Formation. Because all
neutrophils from mice with CML-like MPN are more prone to
generating NETs, we asked whether neutrophils from mice
bearing solid tumors would also be more sensitive to NET
formation. As described previously by DuPré et al. (22), in-
jection of the 4T1 mammary carcinoma cell line into BALB/c
mice induced a large increase in peripheral blood neutrophils
(Fig. 2A) that correlated with tumor growth (Fig. S3A).
Plasma analysis also revealed a signiﬁcant increase in plasma
DNA at the later stages of the disease, day 21 postinjection,
which drastically increased by day 28 (Fig. 2A). Regression
analysis performed with plasma DNA (μg/mL) as the de-
pendent variable suggests that the increase in plasma DNA
could be better determined by the number of circulating
neutrophils than by tumor size (Fig. S3B). This suggests that
NETs could be the source of the plasma DNA. Isolation of
peripheral blood Gr-1+ neutrophils from tumor-bearing mice
and control mice showed similar purity and morphology (Fig. 2B).
As in the leukemia model, PAF-mediated induction of NET for-
mation by neutrophils from tumor-bearing mice revealed a tumor-
age dependence in the susceptibility, reaching almost 100% NET
formation 14-d after tumor implantation (Fig. 2C and Fig. S3C).
Interestingly, a signiﬁcant increase in NET formation was ob-
served in isolated neutrophils from 28-d tumor-bearing mice
without any additional stimulus, again suggesting that NET for-
mation is occurring in these mice. An increase in peripheral blood
neutrophils and enhanced NET formation was also observed after
s.c. inoculation of Lewis lung carcinoma (LLC) cells in C57BL/6
mice (Fig. S4 A and B). The susceptibility of mice bearing different
types of tumors to produce NETs suggests that priming or acti-
vation of the neutrophils occurred in these animals. Immunoﬂu-
orescence staining for DNA and histone H3 of neutrophils treated
with PAF from tumor-free mice showed slight decondensation of
the chromatin, whereas neutrophils from 7- and 14-d tumor-
bearing mice showed complete destruction of the nuclear shape
and, ultimately, a spider web-like pattern, with only a few
distinguishable nuclei (Fig. 2D). Moreover, extracellular his-
tone H3 staining was observed along with DNA. Together,
these results suggest that in murine models of CML, breast,
and lung cancer, a systemic environment is created that sen-
sitizes neutrophils to generate extracellular DNA traps.
Spontaneous NET Formation in Cancer Is Associated with the Presence
of Lung Thrombosis. We demonstrated previously that NETs are
prothrombotic (15, 16). Our mammary carcinoma model showed
signs of a prothrombotic state with increasing levels of plasma
von Willebrand factor (VWF), soluble P-selectin, and ﬁbrinogen
(23–26) during tumor progression (Fig. S3D). Immunostaining of
the lungs of tumor-bearing mice showed VWF- and ﬁbrin-rich
thrombi in veins of four out of four lungs evaluated at 28-d post
implantation, whereas no indication of thrombi was observed
in control mice or at earlier stages of the disease (Fig. 2E).
Moreover, citrullinated histone H3 (H3Cit), a histone modiﬁ-
cation necessary for NET production (27, 28), was present in the
plasma at a late stage of the disease when plasma DNA is high,
consistent with a drop in the number of hypercitrullinated neu-
trophils in peripheral blood (Fig. 2F). Thus, our results suggest
that at 28-d after mammary tumor implantation, NETosis occurs
and is associated with thrombosis. Together, these results suggest
that NETs are implicated in cancer-associated thrombosis.
Exacerbated Effect of Low-Dose LPS in Mammary Tumor–Bearing
Mice on NET Formation and Induction of a Prothrombotic State.
NETosis has been deﬁned previously as part of the innate im-
mune defense against infection (14, 18). We, thus, evaluated the
effect of LPS in vitro on neutrophils isolated from tumor-free
and 14-d mammary tumor–bearing mice. As observed with PAF
stimulation, LPS-treated neutrophils from tumor-bearing mice
showed a signiﬁcant increase in NET formation (Fig. 3A), sug-
gesting that a minor infection in a tumor-bearing host would
generate a larger quantity of NETs than in tumor-free mice. To
test this, we injected tumor-free and tumor-bearing mice with
low doses of LPS and assessed whether the predisposition of the
neutrophils to form NETs would materialize in vivo and generate
a procoagulant state. Two hours after injection of LPS, the neu-
trophil count in the blood was reduced by more than 15,000
neutrophils/μL in tumor-bearing mice and by only about 1,000 in
tumor-free mice (Fig. 3B). This large decrease in neutrophil
count in tumor-bearing LPS-treated mice was associated with
a signiﬁcant reduction in platelet count that was not observed in
mice free of tumors (Fig. 3C). To determine if these effects could
be related to NET formation in vivo, we evaluated NET bio-
markers in blood. Plasma analysis revealed an increase in DNA
and in histone H3 only in the tumor-bearing LPS-treated mice
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Fig. 1. Neutrophils from mice with chronic myelogenous leukemia are more
prone to generate extracellular DNA traps. (A) Plasma analysis showed
a higher level of DNA in CML mice compared with control mice (n = 6; ***P <
0.001). (B) Wright–Giemsa staining showing the purity of the neutrophil
isolation from C57BL/6 mice. (Scale bar: 20 μm.) (C) Quantiﬁcation of NETs
after PAF stimulation of isolated neutrophils from CML mice (gray) shows
a signiﬁcant increase compared with control vector–transduced bone marrow
recipients (white) (n = 6; **P < 0.01). (D) Fluorescent images of NET formation
after PAF stimulation and Hoechst staining of ﬂuorescence-activated cell–
sorted GFP+ leukemic cells or control GFP− cells showed no difference in the
numbers of NETs (n = 4). (Scale bar: 20 μm.) Graph presents means ± SEM.
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(Fig. 3 D and E). No increase was observed in the tumor-bearing
mice treated with vehicle or in the tumor-free mice treated with
LPS, suggesting a stronger effect of LPS on chromatin release in
the tumor-bearing mice. To assess whether DNA originated
from NETs, we evaluated the presence of cathelicidin-related
antimicrobial peptide (CRAMP), the murine homolog of human
cathelicidin, a protein highly expressed in neutrophils and shown
to be associated with NETs (29), and H3Cit in the plasma.
Whereas a small increase in CRAMP was observed in the plasma
of LPS-treated tumor-free mice, a higher level was observed in
the plasma of LPS-treated tumor-bearing mice (Fig. 3E), likely
indicating greater formation of NETs. H3Cit was detected only
in the plasma of tumor-bearing mice treated with LPS. These
results suggest that although low-dose LPS injection activates
neutrophils and probably generates small quantities of NETs in
the vasculature of tumor-free mice, as observed by the presence
of CRAMP in plasma, NET formation was strongly enhanced
only in the presence of cancer. Moreover, low-dose LPS treat-
ment reduced the bleeding time of tumor-bearing mice without
affecting that of tumor-free mice, a sign of a powerful effect of
LPS on hemostasis in tumor-bearing mice (Fig. 3F). Adminis-
tration of DNase1, which digests NETs, to tumor-bearing mice
prevented the reduction of bleeding time associated with LPS
injection. This suggests that the presence of undigested circu-
lating extracellular DNA may promote platelet plug formation.
DNase1 pretreatment did not affect neutrophil counts or prevent
the reduction in the number of platelets (Fig. S5). These results
show that mice with cancer develop a systemic environment that
increases the ability of neutrophils to generate NETs, which
contribute to the prothrombotic state of the host.
G-CSF Potentiates Neutrophils to Generate NETs. G-CSF increases
neutrophil numbers in the circulation and activates them. The 4T1
tumor cells produce G-CSF, and its presence in the serum of tu-
mor-bearingmice is associated with a leukemoid-like reaction (22).
Elevated G-CSF levels were observed in the plasma of the CML-
like mice and both the mammary and lung carcinoma models
compared with control mice (Fig. 4A). To assess whether G-CSF
could be responsible for the increased predisposition of peripheral
blood neutrophils to form NETs, we treated healthy mice with
recombinant human (rh)G-CSF. A 4-d treatment led to an increase
in neutrophil count and a decrease in platelet count (Fig. S6A).
PAF stimulation resulted in a dose-dependent increase in NET
formation in isolated neutrophils similar to what we observed with
the three cancer models (Fig. 4B). Moreover, treatment of 4T1
tumor–bearing mice with a G-CSF–neutralizing antibody pre-
vented accumulation of neutrophils in the blood (6) and reduced
their sensitization towardNET generation in vitro (Fig. 4C andD).
Similar to the mammary carcinoma model, immunostaining of
isolated neutrophils revealed hypercitrullination of histone H3,
corroborating their predisposition to form NETs (Fig. 4E).
Combination of G-CSF and Low-Dose LPS Induces NETs, and This Leads
to Thrombocytopenia and Microthrombosis. As with the tumor-
bearing mice, injection of low-dose LPS in the rhG-CSF–treated
mice decreased neutrophil and platelet counts and increased
plasma DNA (Fig. 5A). Similarly, reduction in tail-bleeding time
was observed in the rhG-CSF–treated mice that received low-
dose LPS for 1 h (Fig. 5A). Interestingly, 24 h after LPS chal-
lenge, DNA was still present in the plasma of rhG-CSF–treated
mice, but an increase in tail-bleeding time was observed. This
correlated with marked thrombocytopenia, suggesting platelet
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Fig. 2. Neutrophils from mammary tumor–bearing mice are more prone
to NET formation and signs of spontaneous NETosis are associated with
thrombosis at late stages of the disease. Tumor cells were injected in the
mammary fat pad of BALB/c mice. (A) Neutrophil counts and plasma DNA
were evaluated every 7 d (n = 6–10; *P < 0.05; ***P < 0.001). (B) Wright–
Giemsa staining (scale bar: 20 μm) and Gr-1 (red) immunostaining with
Hoechst (blue) counterstaining (scale bar: 10 μm) showing the purity of the
neutrophil isolation of tumor-free and 14-d 4T1 tumor–bearing BALB/c
mice. (C ) Quantiﬁcation of NETs after PAF stimulation of isolated neu-
trophils from tumor-bearing mice at different times after tumor cell
injections shows a signiﬁcant increase in NET production compared with
tumor-free mice (n = 6–7; **P < 0.01; ***P < 0.001). (D) Histone H3 (green)
combined with Hoechst staining (blue) of neutrophils stimulated with 50
μM PAF for 1 h at low (Upper) and high (Lower) magniﬁcation. [Scale bars:
20 μm (Upper); 5 μm (Lower).] (E ) VWF (green) and ﬁbrinogen/ﬁbrin (red)
immunostaining with Hoechst staining (blue) of lungs of tumor-bearing
mice and tumor-free mice. VWF- and ﬁbrin-rich thrombi (asterisk) were
detected only 28 d after tumor injection (n = 4). (Scale bar: 50 μm.) (F)
Percentage of hypercitrullinated neutrophils obtained following H3Cit
immunostaining of isolated neutrophils from tumor-bearing-mice. At day 21
after tumor injection, most of the neutrophils are hypercitrullinated. At
day 28, only some hypercitrullinated neutrophils remain. A minimum of
10 ﬁelds (at least 300 cells) were evaluated for hypercitrullination of
histone H3 in the nucleus. Similar observations were made in four dif-
ferent animals. Western blot analysis of H3Cit in the plasma of tumor-
bearing mice revealed the presence of H3Cit at day 28. A distinct band
was observed in four out of seven plasma from 28-d tumor-bearing mice.
Data shown in A, C, and F are means ± SEM.
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consumption possibly by microthrombosis. In control mice, the
24 h LPS challenge did not affect tail-bleeding time; however, it
increased plasma DNA and decreased platelet numbers to
a lesser extent than in rhG-CSF–treated mice. This suggests that
NET formation occurs in control mice but is strongly enhanced
by rhG-CSF treatment. After 24 h, in both groups, the number of
blood neutrophils rebounded, likely because of the up-regulation
of G-CSF after LPS injection (30). To determine whether the
rhG-CSF–treated mice challenged with LPS for 24 h showed
signs of thrombosis, we measured the level of thrombin–anti-
thrombin (TAT) complexes, a marker of thrombin generation, in
the plasma and analyzed the lungs for signs of ﬁbrosis. As has
been reported in healthy donors receiving rhG-CSF (31), a
higher level of TAT was observed in mice treated with rhG-CSF
compared with control mice at baseline (Fig. 5B). Whereas no
signiﬁcant change was observed in control mice 24 h after LPS
challenge, TAT levels were signiﬁcantly reduced in rhG-CSF–
treated mice, suggesting a consumption of coagulation factors.
Histology and immunoﬂuorescence analysis revealed signs of
ﬁbrosis and ﬁbrinogen-/ﬁbrin-rich microthrombi in the lungs of
both rhG-CSF–treated and untreated mice after LPS challenge.
However, the effect was greatly enhanced in rhG-CSF–treated
mice (Fig. 5C). No signs of ﬁbrosis were observed in mice that
had not received LPS. A greater accumulation of ﬁbrinogen/ﬁ-
brin deposits was also found in the renal glomeruli of the rhG-
CSF–treated group after LPS challenge (Fig. 5C). These results
suggest that in rhG-CSF–treated mice, NETs are formed early
after LPS injection and induce a prothrombotic state. Such
a state could lead, in the extreme, to the consumption of plate-
lets and coagulation factors and microthrombosis. Taken to-
gether, our results indicate that increased levels of G-CSF, which
are generated in different types of cancers, can produce a sys-
temic environment that primes peripheral blood neutrophils to
generate NETs more readily. This effect may contribute, at least
in part, to the prothrombotic state observed in cancer.
Discussion
Cancers are known to elevate the risk of thrombosis. Leukocy-
tosis, thrombocytosis, microparticles, cytokines, tissue factor,
soluble P-selectin, and elevation in coagulation factors could all
be partially responsible for the prothrombotic state (32). Here,
we report that cancer induces a systemic environment that primes
neutrophils to release NETs, thereby further promoting a pro-
thrombotic state. Our results show that (i) peripheral blood
neutrophils from leukemic mice and solid tumor–bearing mice
are more prone to NET formation ex vivo; (ii) NETosis is as-
sociated with lung thrombosis in the breast carcinoma model;
(iii) injection of a low dose of LPS in tumor-bearing mice
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Fig. 3. Low-dose LPS induces extracellular DNA trap formation in mammary
tumor–bearing mice. (A) Quantiﬁcation of NET formation by isolated neu-
trophils from tumor-free (white) or 14-d 4T1 tumor–bearing (gray) mice after
stimulation with low doses (as indicated) of LPS (n = 6; **P < 0.01). (B–F) Four-
teen-day tumor-bearing mice (gray) or tumor-free mice (white) were injected
with low doses of LPS. Signiﬁcant decreases in peripheral blood neutrophil
counts (B) and platelet counts (C) were observed in tumor-bearingmice. Plasma
analysis of DNA (D) andWestern blot analysis for histone H3, histone H3Cit and
CRAMP (E) showed much higher levels of these NET biomarkers in tumor-
bearing mice than in tumor-free mice when treated with LPS (1 mg/kg). (F)
Tail-bleeding time 1 h after LPS injections was signiﬁcantly reduced in tumor-
bearing mice, indicating increased prothrombotic activity. Pretreatment with
DNase1 before LPS injections prevent the reduction in tail bleeding (n = 9–17;
*P < 0.05; **P < 0.01; ***P < 0.001). Data shown are means ± SEM.
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Fig. 4. Tumors produce G-CSF, which elevates blood neutrophil count and
predisposes neutrophils to generate NETs. (A) Increased quantities of G-CSF
were observed in the plasma of CML (Left), mammary carcinoma (Center), and
lung carcinoma (Right) tumor–bearing mice compared with tumor-free mice
(white) (n = 5–9; *P < 0.05). (B) BALB/c mice were treated in vivo with 2.5 μg
(gray) or 10 μg (black) rhG-CSF, neutrophils were isolated, and PAF-mediated
induction of NETs was evaluated and compared with neutrophils from control
mice (white). rhG-CSF signiﬁcantly increased the percentage of cells forming
NETs (n = 4–5; *P < 0.05; **P< 0.01). (C) Mice bearing 4T1 tumors were treated
daily with neutralizing anti–G-CSF antibody starting 2 d after tumor cell in-
jection. The anti–G-CSF treatment reduced the number of peripheral blood
neutrophils in 4T1 tumor–bearing mice (hashed) (n = 5). (D) The anti–G-CSF
treatment signiﬁcantly diminished the ability of neutrophils to form NETs ex
vivo upon PAF stimulation compared with control isotype–treated 4T1 tumor–
bearing mice (gray) (n = 5). **P < 0.05. (E) Citrullinated histone H3 (green)
immunostaining with Hoechst (blue) counterstain revealed an increase in cit-
rullination in isolated neutrophils from rhG-CSF–treated mice (Left). (Center
and Right) H3Cit alone (Center) and higher magniﬁcation (Right). (Scale bar:
10μm). Data shown in A–D represent means ± SEM.
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increases plasma NET biomarkers and induces a prothrombotic
state; and (iv) the increased predisposition of neutrophils to
NET formation could be attributable to elevated G-CSF in the
plasma of mice with cancer. Thus, by generating G-CSF, cancers
prime neutrophils to undergo NETosis.
NETs were originally described as a defense mechanism
against infection (14). Recently, our group showed that NETs
activate platelets and trigger thrombosis (15) and are implicated
in the pathogenesis of deep vein thrombosis (DVT) in mice (16).
An increased risk of thrombosis is associated with many cancers,
and such cancers may even be diagnosed only following a
thrombotic event such as DVT. Therefore, one may hypothesize
that the predisposition to generate extracellular DNA traps in
cancer patients could increase the risk of thrombosis. DNA,
histones, and neutrophil granular proteins have been shown to
promote coagulation and to be injurious to tissues (17, 33–35).
NETs’ products and histones also induce platelet activation and
aggregation, red blood cell accumulation, and VWF release,
hallmarks of venous thrombus formation (15–17, 36).
Although CML is not associated with a high risk of thrombosis
(37), our results show that the neutrophils from mice with CML-
like MPN are primed to NET formation, and plasma DNA is
observed. It is conceivable that neutrophil activation and NET
generation are important players in cancer-associated thrombo-
sis but are not sufﬁcient. Production of tissue factor by various
tumors (38), for example, could further potentiate the pro-
thrombotic state. In addition, our results indicate that a further
activation of the innate immune system in a cancer patient could
precipitate a thrombotic event and organ damage through NET-/
histone-induced injury. Given the close interaction of platelets
and neutrophils during infection and the implication of platelet
activation in the generation of NETs (39, 40), their potential
contribution in the cancer models should be addressed.
NET induction by LPS in the solid tumor model rapidly gen-
erates a large quantity of injurious products in the bloodstream
with the onset of a prothrombotic state, leading to pulmonary
microthrombosis. This latter effect has also been observed in
mice after an injection of large quantities of histones, leading to
sepsis-like disease (34). Moreover, our laboratory showed that
injection of a sublethal dose of histones in healthy mice results in
thrombocytopenia (36). In mice with late-stage cancer, we ob-
served thrombi in the lung, even in the absence of additional
stimulation. This correlated with the presence of a high quantity
of plasma DNA. Interestingly, our laboratory in collaboration
with that of Bernhard Lämmle recently reported increased levels
of DNA and neutrophil markers in plasma from cancer patients
with acute thrombotic microangiopathies (41).
Similar to the solid cancer mouse models, in humans, elevated
serum G-CSF levels (8–10, 42) and extreme leukocytosis
(>40,000/μL) related to a paraneoplastic leukemoid reaction
have been reported for a variety of solid tumor types (43). Al-
though initially clinically stable, the vast majority of patients with
a neutrophilic predominance have poor clinical outcomes, with
76% dying within 12 wk of development of extreme leukocytosis
(43). It is, thus, possible that NETs are generated in late-stage
cancer patients and play a role in the critical outcome. De-
termination of DNA levels in the plasma of these patients in
relation to leukocytosis would assess this further.
G-CSF is broadly used to treat neutropenia or for hematopoi-
etic stem cell mobilization in patients and healthy donors. Studies
have reported endothelial cell dysfunction, clotting activation, an
increase in blood oxidative status, platelet aggregation, and neu-
trophil activation in healthy donors during treatment with G-CSF
(31, 44). Despite this, most of the G-CSF–treated healthy subjects
do not experience thrombotic events (13, 44, 45), and G-CSF is
considered a safe mobilizing agent. The prothrombotic effects
that have been associated with G-CSF have been linked to its use
in the treatment of inﬂammatory or already-prothrombotic states,
such as acute myocardial infarction, through mobilization of au-
tologous stem cells (45, 46). This is in accordance with our results
suggesting that, in the presence of G-CSF, neutrophils may be
more sensitive to NET formation, in particular, upon encoun-
tering a “second hit,” such as low-grade infection.
In conclusion, we have uncovered an important role for ex-
tracellular chromatin that is generated in animals with cancer,
predisposing them to thrombosis. Release of large quantities of
DNA in the blood occurs at late stages of the disease or upon
a “second hit,” such as a minor infection, and could be detri-
mental to the host. It will be important to determine whether
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Fig. 5. Low-dose LPS injection induces a prothrombotic state
in rhG-CSF–treatedmice. Micewere treated with vehicle (control;
white) or rhG-CSF (black) and challenged with low-dose LPS
(1mg/kg) for 1 or 24 h. (A) One hour after LPS injection, the blood
counts showed a signiﬁcant reduction in neutrophils and plate-
lets, which corresponded to an increase in plasma DNA and a re-
duction in tail-bleeding time only in rhG-CSF–treated mice. Only
the neutrophil count was reduced in control mice. Twenty-four
hours after LPS treatment, decreased platelet counts and in-
creased DNA levels were also observed in control mice without
modulation of tail-bleeding time. In contrast, 24 h after LPS in-
jection the tail-bleeding time was prolonged in rhG-CSF–treated
mice (n = 5–9; *P < 0.05; **P < 0.01; ***P < 0.001 compared with
no LPS treatment). (B) Twenty-four hours after LPS challenge,
a decrease in TAT complexes was observed in rhG-CSF–treated
compared with control mice (n = 5–9; *P < 0.05; **P < 0.01). (C)
Hematoxylin and eosin staining (top images) of the lungs of mice
24 h after LPS challenge showed some signs of ﬁbrosis in mice
treated with LPS, but ﬁbrosis was strongly enhanced in rhG-CSF–
treated mice. (Scale bar: 50 μm.) Anti-ﬁbrinogen staining (red)
revealed an enhanced presence of ﬁbrinogen-/ﬁbrin-rich micro-
thrombi (arrows) in the lungs (middle images) and the glomeruli
of the kidneys (bottom images) of rhG-CSF–treated mice chal-
lenged with LPS for 24 h. [Scale bar: 20 μm (Middle) and 10 μm
(Lower)]. Hoechst, blue. Data in A and B represent means ± SEM.
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agents neutralizing G-CSF and/or NETs can decrease the in-
cidence of thrombosis in cancer patients.
Materials and Methods
For a full description of all methods, see SI Materials and Methods.
Animals. Experimental procedures were approved by the Institutional Animal
Care and Use Committee of the Immune Disease Institute and Massachusetts
General Hospital. Experiments are described in SI Materials and Methods.
Stainings and Plasma Analysis. Neutrophils/NETs were stained with anti–Gr-1
and anti–histone H3 antibodies. Lung sections were stained with hematox-
ylin and eosin or anti-ﬁbrinogen antibody and anti-VWF. Hoechst-33342 was
used as a counterstain. ELISAs are described in SI Materials and Methods.
DNA was quantiﬁed with a Quant-iT Picogreen assay (Invitrogen). For
Western blot analysis, equal amounts of plasma were analyzed using anti-
CRAMP, anti–histone H3 or anti–histone H3 (citrulline 2, 8, 17) antibodies.
Peripheral Blood Neutrophil Isolation and NET Induction. Peripheral blood
neutrophils were isolated on a Percoll gradient, followed by hypotonic lysis
and stimulated with PAF or LPS. DNA was stained with Hoechst-33342, and
cells were ﬁxed before visualization. NETs were counted from six different
ﬁelds in triplicate wells and expressed as percentage of NET-forming cells per
total number of cells in the ﬁeld.
Statistical Analysis. Data are represented as means ± SEM and were analyzed
by a two-sided Mann–Whitney test performed between groups. All P values
were considered signiﬁcant at or below 0.05.
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SI Materials and Methods
Cell Lines and Reagents.The 4T1 and LLC cell lines were purchased
from ATCC and maintained in high-glucose Dulbecco’s modiﬁed
Eagle medium (DMEM) plus L-GlutaMAX-1 [supplemented with
10% (vol/vol) FCS, 10 mM Hepes buffer, 10 mM sodium car-
bonate (4T1 cells)]. The 4T1 cell line was originally isolated from
a spontaneously arising mammary tumor in a BALB/c mouse (1),
whereas LLC cells originated from C57BL/6 mice. The 4T1 and
LLC cells were injected in mice after less than 4 and 10 serial
passages in vitro, respectively. All cell culture products were
purchased from Life Technologies/Invitrogen.
Animals.All animal procedures were performed using 6- to 8-wk-
old BALB/c female or C57BL/6 female mice (Jackson Labora-
tory). All experimental procedures involving mice were approved
by the Animal Care and Use Committee of the Immune Disease
Institute. All transplantation experiments were approved by the
Institutional Animal Use and Care Committee of Massachusetts
General Hospital.
Bone Marrow Transduction and Transplantation. Transduction/trans-
plantation experiments were performed as described (2, 3). Brieﬂy,
ecotropic replication-defective retrovirus was generated by co-
transfection of MSCV-IRES-GFP-p210-BCR-ABL or MSCV-
IRES-GFP (vector control) and the kat packaging plasmids into
293 cells. The retrovirus was harvested and used to infect the bone
marrow of 5-ﬂuorouracil–pretreated C57BL/6 mice twice. Con-
sequently, the bone marrow was transplanted into lethally irradi-
ated (900 cGy) C57BL/6 mice in a dose of 3–5 × 105 cells/mouse
by tail vein injection. Disease induction was monitored by weekly
full blood count analyses by using a Vetscan 5 HM (Abaxis) and
by ﬂow cytometry of peripheral blood after red blood cell lysis
(ACK lysing buffer; Lonza) and staining of leukocytes with
a phycoerythrin (PE)-conjugated antibody to CD11b (clone M1/
70; BioLegend). Disease burden was measured by percentage of
GFP+ CD11b+ cells in peripheral blood. Necropsies were per-
formed on euthanized mice, and spleen weights were recorded to
conﬁrm establishment of CML at the time the NET experiments
were performed.
Induction of Solid Tumors.The 4T1 cells (4× 105) were inoculated in
themammary fat pad of 6- to 8-wk-old BALB/c mice. For the LLC
model, 5× 105 cells were inoculated in the right ﬂank of 6- to 8-wk-
oldC57BL/6mice. Animals weremonitored twice a week, at which
time tumors were carefully measured using calipers. The tumor
volume was calculated using the formula V = lw2 × 0.4, where l is
the length and w the width (4). Mice were killed at the indicated
time or when tumor volume reached 2,500 mm3 or animals were
moribund. For peripheral blood cell count, blood was collected
using EDTA-coated capillaries and analyzed with a Hemavet he-
matology analyzer (Drew Scientiﬁc). At sacriﬁce, bloodwas collected
through the retroorbital sinus into Tyrode’s buffer containing
10 mMEDTA, centrifuged at 3,300 × g for plasma collection, and
centrifuged again at 13,400 × g to remove any contaminating cells.
Injection of Low-Dose LPS. Fourteen-day tumor-bearing mice or
rhG-CSF–treated mice were injected intraperitoneally with LPS
(Sigma-Aldrich) at the indicated concentration. The mice were
killed at different time points (as indicated) and bled into 3.2%
(wt/vol) sodium citrate for plasma collection. A drop of blood was
also collected in EDTA-coated capillaries for blood cell count.
DNase1 Treatment. Fourteen-day tumor-bearing or tumor-free mice
were injected intraperitoneally with 50 μg of DNase1 (Pulmozyme;
Genentech) or saline (APP Pharmaceuticals) 3 h before LPS
injections for 1 h before tail-bleeding experiments.
Tail-Bleeding Time. Mice were anesthetized with 2.5% tri-
bromoethanol, and tail-bleeding time was determined by re-
moving 2 mm of the distal mouse tail and immediately immersing
the tail in PBS at 37 °C. A complete cessation of bleeding for
more than 120 s was deﬁned as the bleeding time.
rhG-CSF Treatment. Mice received s.c. injections between the
scapulae with 2.5 or 10 μg of rhG-CSF (Neupogen; Amgen) once
daily for 4 d to stimulate durable granulopoiesis (5). Control mice
received vehicle [5% (wt/vol) dextrose] following the same in-
jection schedule. On day 5, plasma was collected, and peripheral
blood neutrophils were isolated.
Anti–G-CSF Treatment. Mice were injected with 4 × 105 4T1 cells
in the mammary fat pad. After 2 d, mice were injected in-
traperitoneally with 10 μg of mouse neutralizing monoclonal
antibody to G-CSF (R&D Systems) or with a matching isotype
control IgG (R&D Systems) daily for 12 d. On day 14, plasma
was collected, and peripheral blood neutrophils were isolated.
Peripheral Blood Neutrophil Isolation.Mice were exsanguinated into
PBS containing 1% (wt/vol) BSA and 15 mM EDTA. After cen-
trifugation, blood cellswere resuspended and layered onto a Percoll
gradient of 78%, 69%, and 52% in PBS (vol/vol), centrifuged and
cells at the 69%/78% interface were collected. Red blood cell
contamination was eliminated by hypotonic lysis, and ﬁnal cell
concentration was determined by hemacytometer. Neutrophil pu-
rity was established to be routinely >90%, as assessed by Wright–
Giemsa staining on cytospin.
Cell Sorting by Flow Cytometry. Flow cytometry–based cell sorting
of GFP+ or control GFP− cells was performed after drawing of
a leukocyte-speciﬁc and, consequently, a myeloid cell–speciﬁc
gate by an SORP 7-laser LSR-II (BD Biosciences).
Induction of Extracellular DNA Traps in Vitro. Isolated peripheral
blood neutrophils (1.5 × 104) were seeded into 96 wells and
allowed to adhere at 37 °C and 5% CO2 for 15 min before
stimulation with PAF or LPS at the indicated concentrations for 1
or 2-1/2 h, respectively. DNA was stained with Hoechst-33342
(Invitrogen), and cells were ﬁxed with 2% (vol/vol) parafor-
maldehyde before visualization using an epiﬂuorescent Axiovert
microscope (Zeiss). For quantiﬁcation, NETs were counted from
six different ﬁelds in triplicate wells for each condition and ex-
pressed as percentage of NET-forming cells per total number of
cells in the ﬁeld.
Quantiﬁcation of Plasma VWF, Soluble P-Selectin, Fibrinogen, G-CSF,
and DNA. The VWF ELISA was performed as described (6) using
the level of VWF in pooled plasma of 20 C57BL/6J WT mice
as a reference standard [normal mouse plasma (nmp)]. Plasma-
soluble P-selectin, ﬁbrinogen, G-CSF, TAT, and DNA levels
were determined using the mouse sP-Selectin/CD62P Quanti-
kine ELISA (R&D Systems), the mouse ﬁbrinogen ELISA
(Genway Biotech), the Quantikine mouse or human G-CSF
ELISA (R&D Systems), human TAT ELISA (Afﬁnity Bio-
logicals), and Quant-iT Picogreen assay (Invitrogen) according
to the instructions of the manufacturers.
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Immunostaining of Neutrophils and NETs. Isolated neutrophils were
plated on a cell culture slide and stimulated as described above.
After stimulation, cells were ﬁxed in 2% paraformaldehyde and
permeabilized, and neutrophils were stained with a rat anti–Gr-1
antibody (BD Bioscience) and NETs with a rabbit anti–histone
H3 antibody (Abcam). Alexa 555–conjugated goat anti-rat IgG
or Alexa 488–conjugated goat anti-rabbit IgG were used as
secondary antibodies (Invitrogen). For H3Cit staining, isolated
neutrophil cytospins were stained with a rabbit anti–histone H3
(citrulline 2, 8, 17) antibody (Abcam) and Alexa 488–conjugated
goat anti-rabbit IgG (Invitrogen) used as secondary antibody. All
immunostainings were counterstained with Hoechst-33342 to
visualize DNA, and slides were mounted with Fluoro-gel
(Electron Microscopy Sciences) and observed under an epi-
ﬂuorescent Axiovert microscope (Zeiss).
Western Blot Analysis. Equal amounts of plasma were analyzed on
a 4–20% SDS/PAGE gel and transferred onto Immobilon PVDF
membranes using a Mini-Trans Blot Electrophoretic Transfer
Cell System (Bio-Rad Laboratories). The membranes were
blocked with 5% milk in TBS/0.05% Tween-20 overnight and
blotted for 2 h with primary antibodies. Membranes were probed
with a rabbit polyclonal anti-cathelicidin (CRAMP) or anti–
histone H3 and anti–histone H3 (citrulline 2, 8, 17) antibodies
(Abcam). Secondary antibodies consisted of horseradish perox-
idase–conjugated anti-rabbit IgG (Bio-Rad Laboratories). De-
tection was carried out with a Pierce ECL Western Blotting
Substrate (Thermo Scientiﬁc). After detection, membranes were
stained with Coomassie blue to ensure equal loading of all wells.
Lung Histology and Immunostaining. Lungs were harvested from
killed animals and ﬁxed in zinc ﬁxative (100 mM Tris-HCl con-
taining 37 mM zinc chloride, 23 mM zinc acetate, and 3.2 mM
calcium acetate). Parafﬁn-embedded sections were deparafﬁ-
nized in xylenes and rehydrated through a graded alcohol series.
Sections were stained with hematoxylin and eosin, mounted in
DPX mountant (Fluka BioChemika), and observed by light mi-
croscopy. For ﬁbrinogen/ﬁbrin and VWF staining, the sections
were stained with a sheep anti-ﬁbrinogen antibody (ABD Bio-
logicals) and rabbit anti–human VWF antibody (Dako) and in-
cubated with anti-sheep Alexa-555 and anti-rabbit Alexa-488
(Invitrogen) as secondary antibodies. Sections were counter-
stained with Hoechst-33342 to visualize all nuclei, mounted with
Fluoro-gel (Electron Microscopy Sciences), and observed under
an epiﬂuorescent Axiovert microscope (Zeiss).
Statistical Analysis. Data are represented as means ± SEM and
were analyzed by a two sided Mann–Whitney test performed
between groups. Regression analysis was performed with plasma
DNA (μg/mL) as the dependent variable using IBM SPSS Sta-
tistics (IBM), version 19.0. For this model, the adjusted R2 and
the standardized regression coefﬁcients (β) of the independent
variables were calculated. All P values were considered signiﬁ-
cant at or below 0.05.
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Fig. S1. Induction of CML-like disease increases neutrophils without affecting platelets. Bone marrow transduced with a retrovirus encoding BCR/ABL and GFP
was transplanted into lethally irradiated C57BL/6 mice to induce CML. Control mice were transplanted with bone marrow transduced with a vector encoding
only GFP (Ctrl). At days 18–20 posttransplantation, peripheral blood was collected, and numbers of neutrophils and platelets were evaluated in the blood of
CML-like (gray) and control (white) mice (n = 6; **P < 0.01). Representative ﬂow cytometry dot plot showing the percentage of leukemic (BCR-ABL+) cells in the
peripheral blood assessed by the expression of CD11b and GFP. Data shown are means ± SEM.
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Fig. S2. Malignant and nonmalignant neutrophils from CML-like mice generate extracellular DNA traps. Representative ﬂuorescent images of Hoechst
staining after PAF stimulation (A) Nuclear decondensation of isolated neutrophils from CML-like mice shows a signiﬁcant increase compared with control
vector–transduced bone marrow recipients (Ctrl). Arrow, NET-forming cells. (Scale bar: 20 μm.) (B) NET formation of ﬂuorescence-activated cell–sorted WT
neutrophils (control for Fig. 1D). Arrow, NET-forming cells. (Scale bar: 20 μm.) (C) Neutrophils were isolated from CML-like or control mice and pretreated in
vitro with dasatinib or imatinib, abl-speciﬁc tyrosine kinase inhibitors, at 10 μM for 4 h before PAF stimulation. This treatment induces apoptosis of leukemic
cells but does not affect normal neutrophils. PAF stimulation showed that even after destruction of the malignant neutrophils, normal neutrophils from CML-
like mice form NETs. (Scale bar: 20 μm.)
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Fig. S3. The increase in plasma DNA in the 4T1 mammary carcinoma model is associated with NET formation and thrombosis markers. Tumor cells were
injected in the mammary fat pad of BALB/c mice. (A) Tumor growth was measured every 7 d. (B) Plasma DNA was assessed as the dependent variable in
a regression analysis. For this, the adjusted r2 and the standardized regression coefﬁcients (β) of the independent variables were calculated. The β indicates the
change of the dependent variable, expressed in SD, when the independent variable increases 1 SD and all other variables in the model remain unchanged. The
increase in plasma DNA is determined more by the number of neutrophils than by tumor size. (C) Representative ﬂuorescent images showing chromatin
decondensation after PAF stimulation and Hoechst staining of isolated neutrophils from tumor-bearing mice at different times after tumor cell injections show
increased sensitivity to NET formation. (D) Plasma VWF, soluble P-selectin, and ﬁbrinogen levels were determined by ELISA. Graphs represent means ± SEM
(n = 6–10; *P < 0.05; **P < 0.01; ***P < 0.001).
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Fig. S4. Increased peripheral blood neutrophils in LLC tumor–bearing mice are more prone to NET formation. LLC tumor cells were injected in the right ﬂank
of C57BL/6 mice. (A) When tumor volume reached ∼500 mm3, peripheral blood neutrophil and platelet counts were determined (n = 4; *P < 0.05). (B)
Quantiﬁcation of NETs after PAF stimulation of isolated neutrophils from tumor-bearing mice showed a signiﬁcant increase of NETosis compared with tumor-
free mice. Data shown are means ± SEM.
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Fig. S5. DNase1 treatment of tumor-bearing mice does not prevent the reduction in neutrophil and platelet counts after LPS challenge. Fourteen-day tumor-
bearing mice or tumor-free mice were injected with 50 μg of DNase1 or saline for 3 h before injection of LPS (1 mg/mL). The pretreatment with DNase1 did not
prevent the reduction in the number of neutrophils and platelets observed 1 h after LPS injection (n = 5–9; ***P < 0.001). Data shown are means ± SEM.
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Fig. S6. rhG-CSF injection in WT mice results in an increase in peripheral neutrophils. rhG-CSF was injected s.c. daily at the indicated concentrations for 4 d.
A dose-dependent increase in neutrophil counts and a reduction in platelet counts was observed (n = 4–5; *P < 0.05).
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 Diabetes impairs wound healing which results in significant health problems. Neutrophils 
are the main leukocytes involved in the early phase of healing. As part of their anti-
microbial defense, neutrophils form extracellular traps (NETs) by releasing nuclear 
chromatin lined with cytotoxic proteins. NETs, with their histones and enzymes such as 
neutrophil elastase and myeloperoxidase, can also induce tissue damage. Here we show 
that neutrophils isolated from diabetic mice and neutrophils from healthy subjects 
exposed to high glucose in vitro are primed to form NETs. When subjected to excisional 
skin wounds, wild-type (WT) mice produced large quantities of NETs at the wound site, 
but this did not happen in mice lacking peptidylarginine deiminase 4 (PAD4-/-) which 
cannot decondense chromatin to form NETs. Impressively, PAD4-/- mice healed faster 
than WT mice, and their wound healing was not affected by diabetes. Furthermore, 
treatment with DNase 1, which disrupts NETs, significantly accelerated wound healing in 
both normoglycemic and diabetic mice. We conclude that NETs impair wound healing, 
especially in diabetes where neutrophils are more susceptible to NET production. 
Inhibiting NET formation or facilitating their clearance may be a new therapeutic strategy 
to improve wound healing and reduce the NET-driven chronic inflammation in diabetes. 
 
NETs were originally recognized as a host defense mechanism in which neutrophils release 
their nuclear and granular contents to contain and kill pathogens1. Bacterial endotoxins, such as 
lipopolysaccharides (LPS), stimulate the release of NETs1 that form extensive webs of DNA 
coated with cytotoxic histones and microbicidal proteases1,2. A prerequisite for NET formation 
(NETosis) is modification of arginine residues of histones to citrulline by PAD4, which changes 
the charge of the histones, leading to massive chromatin decondensation3,4. Recently it became 
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evident that NETs also form during sterile inflammation5. NETs are a key scaffold in pathologic 
thrombi and fuel cardiovascular, inflammatory and thrombotic diseases in mice and humans5,6.  
 
Under diabetic conditions, neutrophils produce more superoxide7,8 and cytokines9. Tumor 
necrosis factor-Į, which primes neutrophils for NETosis10,11, is increased in diabetic patients12. 
To test whether diabetes predisposes neutrophils to NETosis, we first investigated whether 
diabetic neutrophils are primed towards this process. In agreement with previous observations 
in humans7,8, we found that circulating neutrophils from mice made diabetic with streptozotocin 
(STZ) (Supplementary Fig. 1a-c) produced more reactive oxygen species (ROS) upon 
stimulation with phorbol 12-myristate 13-acetate (PMA) compared to controls (Fig. 1a). 
Immunostaining of fresh blood cells showed that diabetic mice had ~4 fold more neutrophils 
positive for citrullinated histone H3 (H3Cit), a biomarker of NETosis, than normoglycemic mice 
(Fig. 1b). About 4.5 fold more isolated neutrophils from diabetic mice were H3Cithigh (Fig. 1c) 
and ~2% produced NETs after incubation in vitro without stimulation, while <0.2% of NETs were 
seen in the normoglycemic controls (Fig. 1d). LPS further stimulated more neutrophils from 
diabetic mice to hypercitrullinate histones (Fig 1c,e) and form NETs (Fig. 1d,e) compared to 
vehicle-treated normoglycemic mice. Thus, diabetes has inflammatory or metabolic components 
that predispose neutrophils to NETosis. Neutrophil priming in diabetes is due to the increased 
PAD4 activity as indicated by the elevated H3Cit levels4 (Fig. 1b). This occurred without an 
increase in PAD4 mRNA levels (Supplementary Fig. 2). Increased neutrophil ROS production 
(Fig. 1a), which is known to induce NETosis13 via a PAD4-dependent pathway14, may contribute 
to the increased susceptibility to NETosis in diabetes. Plasma DNA levels of STZ-treated mice 
were not different from vehicle-treated controls (data not shown), indicating that the primed 
neutrophils in diabetes are not spontaneously producing NETs in vivo. 
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To examine whether high glucose levels in diabetic mice (Supplementary Fig. 1b) prime 
neutrophils, we isolated neutrophils from normoglycemic mice and pre-incubated them in media 
with normal or high glucose concentrations prior to LPS stimulation. LPS stimulated more of the 
high glucose-exposed neutrophils to hypercitrullinate histone H3 (Fig. 1f) and produce NETs 
(Fig. 1g). Thus, the increased susceptibility of diabetic neutrophils to NETosis is at least partly 
due to elevated blood glucose. Importantly, similar observations were obtained in neutrophils 
isolated from healthy subjects and exposed to high glucose in vitro (Fig. 1h). Pre-incubation of 
human neutrophils with high glucose medium also increased NETosis following stimulation by 
ionomycin (Fig. 1h, Supplementary Fig. 3a) or PMA (Fig. 1h, Supplementary Fig. 3b) 
compared to pre-incubation with normal glucose or equal concentrations of the non-
metabolizable sugar alcohol, mannitol. Our observations differ from earlier reports15,16 which 
showed that high glucose or diabetes does not affect or may impair NETosis. This is likely due 
to the pre-activation of human neutrophils during isolation with dextran sedimentation, a method 
that can induce ROS production and NET formation13,17 prior to culture, which could result in the 
loss of the primed neutrophil population during the preparatory process in the previous studies. 
Using minimally activating Histopaque/Percoll gradients for human neutrophil isolation18, we 
found a clear priming effect of high glucose to NETosis. 
 
Depletion of neutrophils in mice was previously shown to accelerate re-epithelialization of 
uninfected diabetic wounds19. Because NETs can be injurious to tissues20, we asked whether 
NETs form in wounds and impact healing. We examined excisional wounds21 from 
normoglycemic WT mice. H&E staining confirmed that neutrophil recruitment overlaps with the 
keratinocyte proliferation stage that leads to re-epithelialization (Supplementary Fig. 4). 
Therefore, neutrophils or NETs could interfere with healing. Analysis of wound proteins by 
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Western blotting showed a progressively increasing level of H3Cit that peaked from 3 to 7 days 
after wounding (Fig. 2a). Immunofluorescence images of 3-day wounds showed that 
hypercitrullinated neutrophils were present in the wound bed immediately beneath the scab 
(Fig. 2b; Supplementary Fig. 5). Confocal microscopy substantiated the presence of NETs in 
skin wounds. Externalized DNA colocalized with H3Cit in areas associated with intense staining 
of the neutrophil membrane marker, Ly6G (Fig. 2c). Of note, H3Cit and neutrophils were absent 
in the surface layers of unwounded skin (Supplementary Fig. 5). Skin expresses PAD isoforms 
1-322 which could citrullinate extracellular proteins in the scab. To verify the cellular source of 
H3Cit, we subjected &' ȕ integrin)-deficient (CD18-/-) mice, which are defective in 
leukocyte recruitment, to wounding. In these mice, both H3Cit and Ly6G were undetectable by 
Western blotting in 3-day wounds (Fig. 2d, left panels), a time when H3Cit was maximal in the 
WT wounds (Fig. 2a), indicating that H3Cit is of leukocyte origin. H&E staining and 
immunofluorescence microscopy showed that the few CD18-/- neutrophils present in these 
wounds had H3Cit and produced NETs (Supplementary Fig. 6a,b). Indeed, isolated CD18-/- 
neutrophils produced NETs as efficiently as WT (Supplementary Fig. 6c), showing WKDW ȕ
integrins are not required for NETosis. Wounds from WT mice with depleted neutrophils showed 
markedly reduced H3Cit (Fig. 2d, right panels). Thus, our data indicate that neutrophils are the 
source of the H3Cit and extracellular chromatin present in the wounds. 
 
To establish the role of NETs in wound healing, we compared wounds of WT to PAD4-/- mice. 
Unlike neutrophil recruitment-defective P-/E-selectin double mutants that have opportunistic 
infections23 and impaired wound healing21, wounds of the PAD4-/- mice did not show overt signs 
of infection (Fig. 3a) and healed faster than WT (Fig. 3a,b). This is likely because other 
neutrophil functions such as phagocytosis14, degranulation and ROS production (our 
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unpublished observations) are intact in PAD4-/- neutrophils. About 80% of PAD4-/- mice had all 
wounds healed on day 14 compared to only 25% of WT controls (Fig. 3c). The beneficial effect 
of PAD4 deficiency on wound healing was observed very early after injury (Fig. 3b), indicating 
that NETs might impair the onset of initial healing processes such as keratinocyte 
proliferation/migration. In line with this hypothesis, re-epithelialization progressed 3-fold faster in 
PAD4-/- mice compared to WT (Fig. 3d). In contrast to the robust H3Cit signals in WT wounds, 
no H3Cit was detected in wounds from PAD4-/- mice despite normal neutrophil recruitment (Fig. 
3e; Supplementary Fig. 7). Prominent extracellular DNA structures observed by H&E were 
absent in PAD4-/- scabs (Fig. 3f, upper panels), as were the H3Cit and extracellular chromatin 
patterns seen in WT mice by confocal microscopy (Fig. 3f, lower panels). Although WT and 
PAD4-/- neutrophils also express PAD2 and PAD314, our data demonstrate that PAD4, the only 
nuclear PAD, is essential for histone H3 citrullination and NETosis in skin wounds. Coudane et 
al.24 reported that PAD4 is the main PAD isoform detected in scabs of wounds from WT mice, 
and that PAD2 is unnecessary for citrullination of scab proteins as observed in PAD2-deficient 
mice, further strengthening the unique deimination role of PAD4 in the wounds. 
 
We next examined whether NETs interfere with diabetic wound healing. Diabetes was induced 
in WT and PAD4-/- mice and 8 weeks later these mice were subjected to wounding. Changes in 
body weight, fed blood glucose and induction rate were similar between the two genotypes 
(Supplementary Fig. 1d-f). As expected, diabetic WT mice healed more slowly than 
normoglycemic controls (Fig. 4a). All normoglycemic WT mice healed by day 16, while ~20% of 
diabetic mice still had open wounds on day 19 (Fig. 4d). Diabetic PAD4-/- mice healed >35% 
faster than diabetic WT mice on day 7 (Fig. 4b) and had all wounds closed by day 15 (Fig. 4e). 
Notably, diabetes did not impair wound healing in PAD4-/- mice (Fig. 4c,f), which underscores 
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NETs as the major determinant delaying healing in the diabetic mice. Antibiotics, provided to 
mimic the medical regimen of diabetic patients with chronic wounds, did not abolish the 
beneficial effect of PAD4 deficiency (Supplementary Fig. 8). 
 
Enhanced wound healing in PAD4-/- mice suggests that NETs may be a redundant host defense 
mechanism that compromises wound repair. NETs and histones can directly induce epithelial 
and endothelial cell death in vitro20. Histones disrupt cell membranes and induce calcium influx, 
resulting in cytotoxicity in vitro and in vivo25. High neutrophil elastase concentration, a 
component of NETs1,2, can cause degradation of the wound matrix and delay healing26. Such a 
cytotoxic environment produced by NETs may explain the slower keratinocyte repopulation in 
the wound beds of WT. Because PAD4 is not expressed in the skin22, its negative effect on 
wound healing is most likely due to infiltrating neutrophils. In fact, using NETs to defend against 
microbes may not be very effective during wound healing. Staphylococcus species are very 
abundant in diabetic wounds27, and Staphylococcus aureus expresses nucleases to degrade 
NETs and thus escape trapping28. Staphylococcal nuclease and adenosine synthase A can 
degrade and convert NETs into 2’-deoxyadenosine which promotes macrophage apoptosis29. 
Macrophages are the source of vascular endothelial growth factor and transforming growth 
factor-ȕimportant cytokines for wound healing30. Thus, the non-selective cytotoxicity of NETs 
and/or their degradation products by bacteria can profoundly delay wound healing.  
 
Farrera and Fadeel reported that pre-digestion of NETs with DNase 1 accelerated their 
clearance by macrophages in vitro 31. Facilitated clearance of NETs in wounds may reduce their 
toxicity and diminish wound matrix degradation that is essential for the directional migration of 
keratinocytes32. We thus tested whether DNase 1 could accelerate wound healing. Three days 
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post wounding, wound areas in normoglycemic mice treated with DNase 1 were smaller than in 
those treated with vehicle (Fig. 4g, left). Re-epithelialization was also enhanced by ~54% in the 
DNase 1-treated group (Fig. 4g, right), while neutrophil recruitment was not affected (data not 
shown). Similar beneficial effects of DNase 1 were observed in diabetic WT mice maintained on 
antibiotics. DNase 1 promoted wound area reduction by >20% (Fig. 4h, left) and enhanced re-
epithelialization by >75% (Fig. 4h, right), an extent similar to that of DNase 1-treated 
normoglycemic mice (Fig. 4h). These results demonstrate the beneficial effect of extracellular 
chromatin cleavage in wound repair and tissue regeneration. Our current findings also 
corroborate positive results from pilot clinical trials with activated protein C (APC), which cleaves 
and reduces the cytotoxicity of histones33 and facilitates healing of chronic wounds34 and 
diabetic ulcers35. Topical treatment with an ointment containing fibrinolysin and DNase (Elase) is 
used clinically for wound debridement. In addition to removing necrotic tissue, our findings 
suggest the DNase component may also cleave NETs to enhance wound recovery. 
 
In summary, our data demonstrate that diabetes activates neutrophils to overproduce NETs and 
identify NETs as a key factor delaying wound healing. PAD4 inhibition and facilitated clearance 
of NETs by DNase could be novel therapeutic approaches to wound resolution, not only to 
diabetic wounds, but also wounds resulting from aseptic procedures such as surgeries of 
normoglycemic patients. Because PAD4 and NET formation contribute to inflammatory and 
thrombotic diseases6 that are prominent in diabetics36,37, such therapy could have additional 
benefits. The increased NETosis in diabetes suggests that NETs may fuel these disorders and 
inhibiting NETosis or cleavage of NETs may lessen them. 
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METHODS 
Methods and associated references are available in the online version of the paper. 
Note: Supplementary information is available in the online version of the paper. 
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 Figure legends 
Figure 1. Diabetes or high glucose concentration in vitro primes neutrophils to undergo 
NETosis. (a) Whole blood from vehicle-treated or STZ-induced diabetic mice was either 
incubated with 100 nM PMA or left unstimulated for 20 min. Flow cytometry using the ROS-
sensitive dye dihydrorhodamine 123 revealed a larger increase in respiratory burst in 
neutrophils from diabetic mice. Ly6G+ neutrophils were gated during analysis. ***P<0.001, 
##P<0.01; n = 10 for Vehicle, n = 8 for STZ. (b) Blood cytospin was performed and cells were 
stained for H3Cit and Ly6G. More circulating neutrophils with elevated basal H3Cit level were 
detected in STZ-treated mice. ***P<0.001. (c-e) Neutrophils were isolated and stimulated with 
LPS from Klebsiella pneumoniae at indicated concentrations for 2.5 h. More neutrophils from 
STZ-induced diabetic mice were H3Cithigh (c) and formed NETs (d). US, unstimulated. *P<0.05, 
**P<0.01, ***P<0.001; n = 12 for Vehicle, n = 10 for STZ. (e) Representative images of isolated 
neutrophils from in vitro NETosis experiments. Neutrophils were exposed to LPS (25 µg/mL) for 
2.5 h. Green, H3Cit; Blue, DNA stained with Hoechst 33342. Yellow arrows indicate NETs. 
Scale, 50 µm. (f,g) Neutrophils were isolated from normoglycemic mice and pre-incubated for 1 
h in media with normal (5.5 mM) or high (22 mM) glucose concentration. Twenty-two mM 
corresponds to 396 mg/dL, which is similar to the fed blood glucose level in STZ-induced mice 8 
weeks post-induction (376.3 ± 26.9 mg/dL). Mannitol (16.5 mM added into medium with 5.5 mM 
glucose) was employed as an osmotic control. LPS (10 µg/mL, in respective medium) was 
added and neutrophils were further incubated for 2.5 h. More neutrophils in high glucose 
medium were H3Cithigh (f) and produced NETs (g). *P<0.05, **P<0.01; n = 10 per medium 
condition. (h) High glucose experiments, similar to those in (g), were performed on isolated 
neutrophils from healthy subjects using ionomycin (4 µM) or PMA (100 nM) as stimuli. 
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Consistent for every subject, more high glucose (HG)-treated neutrophils produced NETs 
compared to those in normal glucose (NG) or mannitol (M). Each color and symbol represents 
one individual. *P<0.05, **P<0.01.  
 
Figure 2. Neutrophil H3Cit and extracellular chromatin are observed in the wounds of WT mice, 
indicating the formation of NETs. (a) Western blots showing the time course of H3Cit 
appearance after skin injury. Wounds were generated with biopsy punches at the dorsal skin of 
the mice. Scab and the surrounding 0.5 mm skin were collected at the time indicated. H3Cit was 
detectable starting day 1 post wounding and peaked from day 3 to 7. H3Cit was absent in the 
control unwounded skin (Ctrl). **P<0.01 versus Ctrl, n = 3-5. (b) Immunofluorescence images of 
a 3-day wound bed immediately beneath scab. Cells were mostly positive for Ly6G and H3Cit. 
(c) Representative images of a 3-day wound using confocal microscopy. Area enclosed by the 
yellow box is magnified and shown on the right. H3Cit (green) co-localized with extracellular 
DNA (blue) in the Ly6G (red)-positive area in the scab. (d) Western blots of 3-day wounds 
collected from mice with defective leukocyte recruitment (CD18-/-, left) and mice depleted of 
neutrophils using an anti-Ly6G antibody (right, representative of n = 7). H3Cit was markedly 
reduced in these wounds.  
 
Figure 3. PAD4 deficiency facilitates wound repair in normoglycemic mice. (a) Photographs of 
wounds of WT and PAD4-/- mice. Wounds of PAD4-/- healed faster and both healed without 
apparent signs of infection. Scale, 5 mm. (b) Changes in wound area compared to day 0. 
Wound area reduced faster in PAD4-/- mice starting day 1 post wounding. *P<0.05, **P<0.01, 
***P<0.001 versus WT; n = 9-16. (c) Significantly more PAD4-/- mice had wounds completely 
closed by day 14. **P<0.01. (d) Hematoxylin and eosin (H&E) staining of 3-day wounds from 
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WT and PAD4-/- mice. Re-epithelialization was determined by the distance that keratinocytes 
migrated into the wound area from the shoulder of the wounds (indicated by blue dotted lines 
and arrows). Re-epithelialization occurred faster in PAD4-/- mice. ***P<0.001, n = 6-9. (e) 
Representative Western blots of wounds from WT (+/+) and PAD4-/- (-/-) mice. H3Cit was 
absent in the wounds from PAD4-/- mice. Ly6G levels in wounds were similar in both genotypes. 
(f) Images of H&E staining and confocal microscopy of 3-day wounds from WT and PAD4-/- 
mice. H&E (upper panels) revealed the presence of extracellular DNA (blue streaks, indicated 
by yellow arrows) in the scab of WT mice, while neutrophils appeared intact (ring-shaped, 
indicated by yellow arrowheads) in PAD4-/- scabs. Confocal immunofluorescence images (lower 
panels) showed intact neutrophil morphology and an absence of H3Cit in the scabs of PAD4-/- 
mice compared to the NETs in the scabs of WT mice.  
 
Figure 4. PAD4 deficiency or DNase 1 treatment enhances wound healing in diabetic mice. WT 
and PAD4-/- mice were treated with vehicle or STZ. Wounding was performed 8 weeks after 
diabetic induction. (a-f, h) All mice were provided with antibiotics (2.5% Sulfatrim) in the drinking 
water immediately after wounding. (a-f) Data from all groups were obtained simultaneously in 
multiple experiments but split into three graphs (a-c and d-f) to facilitate comparison. n = 6-9; 
*P<0.05, **P<0.01, ***P<0.001 between groups on respective post-wounding day (a-c) or 
between curves (d-f).  (a) Wound healing was impaired in STZ-induced diabetic WT mice 
compared to normoglycemic mice (vehicle). (b) PAD4-/- mice had much faster wound repair than 
WT under diabetic conditions. (c) Diabetes did not impair wound repair in PAD4-/- mice. (d) STZ-
induced diabetic WT mice had delayed wound closure compared to normoglycemic mice 
(vehicle). (e) STZ-treated PAD4-/- mice reached total wound closure earlier than STZ-treated 
WT mice. (f) Wound closure was not significantly different (NS) between normoglycemic 
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(vehicle) and diabetic (STZ) PAD4-/- mice. (g) Normoglycemic or (h) diabetic WT mice were 
treated with DNase 1 (dornase alfa) immediately before wounding and subsequently until wound 
harvest 3 days post wounding. DNase 1 treatment facilitated wound area reduction (left) and re-
epithelialization (right) in both (g) normoglycemic and (h) diabetic WT mice. *P<0.05 
***P<0.001; n = 6-10.  
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Appendix A-7 
Neutrophil elastase-deficient mice form neutrophil 
extracellular traps in experimental models of deep vein 
thrombosis and wound healing 
 
 
 
 
 
 
This chapter contains one manuscript in preparation: 
Martinod K, Wong SL, Gallant M, Wagner DD.  Neutrophil elastase-deficient mice 
form neutrophil extracellular traps in experimental models of deep vein 
thrombosis and wound healing.  In preparation for submission to the Journal of 
Leukocyte Biology. 
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Appendix A-7: Overview and Attributions 
Overview 
Our results in Chapter 2 and Appendix A-31 revealed that NETs comprise a 
crucial part of the thrombus scaffold.  We were interested in seeing if neutrophil 
elastase (NE) was also contributing to NET formation in thrombosis.  NE has 
been shown to degrade histones and thus aid in chromatin decondensation 
during NETosis in human neutrophils2.  However, mouse studies quantitatively 
evaluating NET formation remained to be performed and we were frequently 
asked to perform our in vivo NET models in NE-/- mice in parallel to PAD4-/- mice 
to have two mouse models where NETs are lacking.  However, we found that 
NE-deficiency only slightly inhibited NET production in mouse neutrophils.  This 
study is important as it shows that while a complete lack of NETs in the PAD4-/- 
mice resulted in fewer thrombi (Chapter 2) and improved wound healing 
(Appendix A-6), a slight reduction in NET formation in the NE-deficient mice had 
no effect on thrombus generation or rate of wound closure which is affected by 
NETs.  This highlights that NET-targeted therapies would need to be highly 
effective in order to have a substantial impact in vivo.  
 
Attributions 
 
For this manuscript, I performed all in vitro NET assays and deep vein 
thrombosis surgeries and analyses.  Siu Ling Wong performed all wound healing 
studies and analyses. We share first authorship and I wrote a majority of the 
paper. Maureen Gallant prepared cryosections of thrombi for immunostaining.  
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Denisa Wagner supervised the study, designed experiments, and revised the 
paper. 
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Abstract  
Neutrophil elastase was proposed to be involved in chromatin decondensation 
via its ability to translocate into the nucleus and degrade histones.  It has been 
hypothesized that neutrophil elastase-deficient (NE-/-) mice are unable to 
decondense chromatin or release NETs in response to a microbial stimulus.  We 
wished to establish if neutrophils from NE-/- mice would not produce NETs during 
sterile inflammation and to examine whether this would impact venous 
thrombosis and/or wound healing, two models in which we see abundant NET 
release in the absence of infection, with serious pathological consequences.  
What we found, however, is that NE-deficiency only resulted in a slight reduction 
in NET formation in vitro and that this had no effect on NET formation in vivo or 
outcome in models of thrombosis and wound repair.  Therefore, NE-/- mice do not 
phenocopy PAD4-/- mice, which remain the best model of studying lack of NET 
release in vivo.  Experiments using NE inhibitors with the goal of inhibiting NET 
formation in vivo are therefore not recommended.  
 
Introduction 
The serine protease function neutrophil elastase (NE) plays a crucial role 
in host defense3 and is present on neutrophil extracellular traps that are released 
from activated neutrophils4,5. In addition to being present on NETs, NE has also 
been implicated in chromatin decondensation in the process of forming NETs by 
cleaving histones. Indeed, NE translocates from azurophilic granules to the 
nucleus2, which occurs before translocation of other granule contents such as 
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myeloperoxidase (MPO). This occurs by a recently described mechanism 
independent of granule membrane fusion2 but dependent on reactive oxygen 
species (ROS) and MPO6.  In the Papayannopoulos et al. study, an elegant 
series of in vitro experiments was performed using isolated primary human 
neutrophils to show that NE, and not other serine proteases in the neutrophil 
such Cathepsin G or proteinase 3, aids in chromatin decondensation during 
NETosis2.  NE inhibitors greatly diminished NE entry into the nucleus, chromatin 
decondensation and NET formation in response to PMA.  The effect of NE was 
also tested in mice, where intranasal instillation of Klebsiella pneumoniae in WT 
mice led to extensive fiber formation in the alveolar space, whereas NE-/- mouse 
lungs remained free of such NET-like fibers.  While nuclear decondensation was 
shown to be decreased in the knockout using a cell-free assay in which the 
nuclei from thioglycollate-elicited peritoneal neutrophils are extruded, a 
quantitative in vitro NET assay remains to be performed using peripheral blood 
neutrophils which have not been activated in an inflammatory model.  In addition, 
the role of NE in non-infectious disease models strongly affected by NET 
production was not studied. 
 
Results/Discussion 
Neutrophils from NE-/- mice present only a small reduction in NET production 
We examined neutrophil elastase-deficient neutrophils for their ability to form 
NETs in response to several non-microbial stimuli (Figure 1). We isolated WT 
and NE/- neutrophils from mouse peripheral blood and stimulated them in parallel  
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Figure 1. Neutrophil elastase-deficient neutrophils form fewer NETs in 
response to calcium ionophore but citrullination is unaffected.  A. 
Neutrophils isolated from WT and NE-/- mice became hypercitrullinated at 
histone H3 to a similar degree in response to stimulation with PMA or 
ionomycin for 3.5 h. n=5-10. B. NET formation was similar between WT and 
NE-/- neutrophils in response to PMA, but was reduced by about 40% in NE-/- 
neutrophils in response to ionomycin. n=5-10. C. Representative micrographs 
of ionomycin-stimulated cells showing H3Cit-positive NETs forming both in WT 
and NE-/- neutrophils. White arrows indicate NETs.  H3Cit, green; DNA, blue.  
Representative of n=10, scale bar, 20 µm.  *p<0.05. 
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Figure 1: Neutrophil elastase-deficient mice form fewer NETs in 
response to calcium ionophore but citrullination is unaffected 
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with PMA or ionomycin for 3.5 hours.  The percentage of cells becoming 
hypercitrullinated at histone H3 was similar (Figure 1A), indicating the PAD4 is 
functional in these cells and that NE is not required for its nuclear transloation or 
activity.  NET release is thought to be impaired in the NE-/- mice as shown by 
electron microscopy of Klebsiella pneumonia infected lungs.  Although we also 
did find that NE-/- neutrophils formed less NETs at the same time point as WT 
mice, this reduction was only slight and a substantial portion of NE-/- neutrophils 
still released NETs (Figure 1B).  This can be seen in the representative images in 
Figure 1C which show staining for H3Cit+ NETs in response to ionomycin as 
indicated by white arrows.   
 
NE-/- mice form NET-rich thrombi in the IVC stenosis model 
Venous thrombosis in the IVC stenosis model is highly NET dependent7-9. DVT is 
therefore an interesting setting in which to study the role of NE in NETosis and 
thrombosis.  NET formation should be slightly reduced in the NE-/- animals and 
any NETs being released would be devoid of neutrophil elastase.  NE can cleave 
tissue factor pathway inhibitor10 and therefore NETs were proposed to enhance 
coagulation11. We hypothesized that thrombus size would be reduced in NE-/- 
mice since they form less NETs and release no NE.  Thrombus initiation was 
unaffected in NE-/- compared to WT mice 6 h after partial IVC ligation (Figure 2A, 
2B), but circulating plasma cell-free DNA levels were reduced by about 20%  
 
 
! 198 
 
 
 
 
 
 
 
Thrombus length
6h
WT
NE
-/- 
0
5
10
Th
ro
m
bu
s 
le
ng
th
 (m
m
)
Plasma DNA
WT NE-/- 
0
50
100
150
200
250
ng
 D
N
A
 / 
m
l p
la
sm
a
*
Figure 2: Neutrophil elastase-deficient mice form thrombi in the 
venous stenosis model  
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Figure 2. NE-/- mice form NET-containing thrombi in the venous stenosis 
model of DVT. A,B. NE-/- mice formed thrombi to a similar extent to WT mice 
after 6 h of IVC stenosis. C. Plasma DNA is slightly decreased after 6 h in NE-
/- mice compared to WT mice. D,E. At 48 h, NE-/- mice also presented with 
thrombi to a similar extent to WT mice. F. Both thrombi collected from WT or 
NE-/- mice 48 h after IVC stenosis showed an abundance of NETs as seen by 
H3Cit immunostaining (green) and extensive diffuse extracellular DNA staining 
(blue). Scale bar, 25 µm.  *p<0.05. 
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(Figure 2C), indicating that fewer NETs are being released in the NE-/- mice.  By 
48 h, thrombus frequency was again similar between WT and NE-/- mice (Figure 
2D, 2E), and NE-/- mice were capable of forming thrombi that were quite large in 
size (Figure 2D), indicating that they don’t have a major thrombotic defect and 
that the thrombi were stable. Thrombi from both the WT and NE-/- mice had a 
characteristic NET meshwork1,9 within thrombi at 48 h, as seen by extracellular 
H3Cit staining (Figure 2F).  These results greatly differ from the phenotype seen 
in PAD4-/- mice9 or from mice treated with DNase1,8 in the same model.  In IVC 
stenosis, PAD4-/- are highly protected from thrombus initiation and the few 
thrombi that do form are absent of NETs9.  Also, DNase 1, which cleaves NETs4 
significantly reduces the incidence of thrombosis1,8.   
 
NE-/- mouse wounds contain NETs and don’t have accelerated wound healing 
We have observed that a lack of NETosis in PAD4-/- mice facilitates wound 
healing and similar results were observed in mice treated with DNase 1 (Wong 
and Wagner, unpublished observation in Appendix 6). We next investigated the 
ability of NE-/- mice to produce NETs outside of the vasculature.  Full thickness 
skin wounds were performed on mice using a skin biopsy tool and were allowed 
to heal over the course of 2 weeks.  Similar quantities of H3Cit were detected in 
wound beds by Western blot in WT and NE-/- mice (Figure 3A), and this was not 
due to any differences in neutrophil infiltration as seen by analysis of Ly6G, a  
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Figure 3: NETs are present in wounds of NE-/- mice and NE 
deficiency does not benefit wound repair  
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Figure 3. NETs are present in wounds of NE-/- mice and NE-deficiency 
does not offer long-term wound healing benefits. Western blots show that 
levels of (A) H3Cit and (B) Ly6G were similar between wild-type (WT, +/+) and 
NE-/- mice (-/-) throughout days 1-7 after wounding. Mann-Whitney test; n=3-6. 
(C) Representative confocal microscopy image showing extracellular DNA 
(blue) positive for H3Cit (green) in Ly6G-rich areas (red) in the scab of a 3-day 
wound from the NE-/- mice. (D) Wound area reduction was faster in NE-/- mice 
only on day 1 after wounding. Their wound healing, however, became similar 
to that of the WT mice after 3 days. Mann-Whitney test. n= 3-25. 
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specific membrane marker of neutrophils, by Western blot (Figure 3B).  By 
confocal microscopy we were able to identify NETting neutrophils with H3Cit-
positive staining colocalizing with DNA within the wound scab (Figure 3C), 
similarly to what we see in WT mice (Appendix A-6).  Lastly, we analyzed the 
rate of wound closure in these mice and found that while at day 1 post-wounding 
the NE-/- mice have slightly decreased wound area, perhaps due to a small 
reduction in NETosis. However, this difference did not persist as the rate of 
wound closure was later similar between the WT and NE-/- mice (Figure 3D). By 
contrast, PAD4-/- mice, which never generate NETs in the wound bed, show 
significantly accelerated wound healing rates with significantly smaller wound 
areas throughout the entire time course of wound closure (Appendix A-6).   
Taken together, these results show that slightly reduced NET formation 
has little beneficial impact in vivo in non-infectious mouse models where NETs 
have been shown to have pathological consequences. This is in agreement with 
our observation that mice heterozygous for PAD4 showed no significant 
protection in DVT (unpublished result, Martinod and Wagner 2012). We had 
hypothesized that NE-/- mice would phenocopy PAD4-/- mice, which are 
completely unable to form NETs due to a lack of a histone-modifying enzyme 
required for chromatin decondensation9,12.  While we did see less NET release in 
the NE-/- mice, this reduction was minor and not observed under stimulation with 
PMA.  From our results, it would appear that NE inhibitors have additional 
activities besides inhibiting NE, as we could not reproduce their effect in the 
mouse genetically lacking NE.  There may also be differences in the molecular 
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mechanisms driving NETosis in mouse vs. human neutrophils, and mouse 
neutrophils are may be more dependent on PAD4 than NE.   
Our results have important implications for designing therapeutics 
targeting prevention of NET formation.  We have proposed that PAD4 would be 
an attractive candidate for this goal, but to date highly specific and effective 
PAD4 inhibitors remain to be generated.  Targeting NE could be beneficial in 
more aspects than just reducing NET formation, as protective effects have been 
seen using specific NE inhibitors in mouse models13. NE inhibition is unlikely to 
have major NET inhibition effects in vivo, and even partial NET release may be 
sufficient to drive venous thrombus formation, as neutrophils can adhere to the 
vessel wall, throw NETs, bind platelets and in turn initiate thrombus 
development8,14.  Furthermore, when more neutrophils are recruited to inflamed 
and NETs accumulate, the effect of partial NET inhibition is likely to be 
insignificant over time. NE-/- mice should not be used as a method to study 
mouse models addressing the role of NETs.  However, studying the effect of the 
lack of NE on NETs themselves in various disease settings remains an 
interesting approach and should be explored.   
 
 
Materials and Methods 
Mice  
Experimental procedures in this study were reviewed and approved by the 
Institutional Animal Care and Use Committee of the Immune Disease Institute 
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and Boston Children’s Hospital (Protocol No. 11-03-1919, 11-04-1848, 14-02-
2609R, 14-03-2631R).  C57Bl/6J (WT) and Elanetm1Sds/J (NE-/-) mice were 
purchased from The Jackson Laboratory.  
 
In vitro NET assays 
Peripheral blood was collected via the retroorbital venous plexus and neutrophils 
were isolated from 6-18 week-old male or female WT or NE-/- mice as previously 
described 15.  Cells were routinely assessed to be >90% pure by Wright-Giemsa 
stain.  Neutrophils in RPMI/HEPES were incubated at 37°C in 5% CO2 in glass-
bottom plates for 20 min prior to stimulation with 100 nM phorbol 12-myristate 13-
acetate (PMA, Sigma) or 4 µM ionomycin (iono, Invitrogen).  After 3.5 h, cells 
were fixed in 2% PFA and analyzed as previously described9.   
 
Venous stenosis model 
Venous stenosis experiments were performed as previously described under 
aseptic conditions7,9, with 90% ligation of the inferior vena cava and complete 
ligation of side branches to minimize variation between mice. Blood was 
collected 6 h or 48 h after stenosis via the retroorbital sinus plexus, and thrombi 
harvested, measured and embedded in OCT for cryosectioning and histological 
analysis.  All mice were given buprenorphine (0.1 mg/kg, s.c.) as an analgesic 
immediately before beginning surgery and every 8-12 h subsequently.   
 
Blood cell and plasma analysis 
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Whole blood was collected via the retroorbital sinus into EDTA-coated capillary 
tubes.  Twenty-five µl of whole blood collected via the retroorbital sinus plexus 
into EDTA-coated capillary tubes was analyzed by a Hemavet 950FS (Drew 
Scientific) for complete blood counts.  At the time of sacrifice in DVT experiments, 
at least 250 µl of citrated whole blood was centrifuged to prepare platelet-poor 
plasma as previously described9.  Plasma DNA concentrations were measured 
according to manufacturer’s instructions using the Quant-iTTM PicoGreen® 
dsDNA Assay kit (Invitrogen). 
 
Immunostaining and fluorescence microscopy 
Fixed cells or tissue sections were immunostained as described9.  Fluorescent 
images were acquired using an Axiovert 200 widefield fluorescence microscope 
(Zeiss). All channels were acquired in greyscale with an Axiocam MRm 
monochromatic CCD camera (Zeiss), pseudocolored using Zeiss Axiovision 
software, and analyzed using ImageJ software (National Institutes of Health, 
Bethesda, MD, USA).   
 
Wounding and wound area assessment 
Full-thickness excisional wounding was performed on 9-10 week-old wild-type 
and NE-/- mice aseptically as described16. Mice were anesthetized by 
intraperitoneal injection of ketamine and xylazine (100 mg/kg and 10 mg/kg, 
respectively). Hair of the dorsal skin was removed and cleaned with 70% ethanol 
and betadine. Using two 4-mm disposable sterile biopsy punches (Miltex), 4 
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wounds were made by punching twice through the dorsal skin folded at midline. 
Mice were then housed individually. Area of wounds were determined using 
ImageJ from digital photographs taken with a Sony Camcorder on days 1, 3 and 
7 post wounding, and expressed as percentages with respective to the area on 
day 0. 
 
 
Western blot 
H3Cit and Ly6G levels in the wounds were quantified with Western blotting. 
Wounds were snap frozen, homogenized on ice in protease inhibitor cocktail-
supplemented (Sigma) RIPA buffer, and centrifuged at 20000 g for 20 min at 4oC. 
Supernatant was collected and protein content was determined by bicinchoninic 
acid assay. Samples were resolved on gradient gels (4-20%, Lonza) and 
electroblotted on PVDF membranes, which were then incubated with primary 
antibodies (rabbit polyclonal anti-H3Cit, 1:1000, abcam; rabbit polyclonal anti-H3, 
1:6000, abcam; rat monoclonal anti-mouse Ly6G, 1:500, BD Pharmingen) at 4oC 
overnight. After several washes, the blots were incubated with the appropriate 
HRP-conjugated secondary antibodies for 2 hours at room temperature. The 
blots were developed with enhanced chemiluminescence substrate on film, and 
quantified with ImageJ. GAPDH (1:40000, Ambion) was probed to confirm equal 
loading. 
 
Confocal immunofluorescence microscopy 
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Presence of NETs was examined by confocal microscopy. Wounds were cut into 
halves and immediately embedded in OCT following tissue collection. They were 
then cryosectioned into 20 µm sections, post-fixed in zinc fixative (100 mM Tris-
HCl, 37 mM zinc chloride, 23 mM zinc acetate, 3.2 mM calcium acetate), 
permeabilized and incubated with primary antibodies against H3Cit (1:1000) and 
Ly6G (1:500) at 4oC overnight. After several washes, the sections were 
incubated with Alexa Fluor-conjugated secondary antibodies (1:1500, Invitrogen) 
for 2 hours at room temperature. DNA was stained with Hoechst 33342. Images 
were captured with Olympus Fluoview software using an Olympus IX 81 confocal 
microscope. 
 
Statistics 
Data are presented as means ± SEM unless otherwise noted and were analyzed 
using a two-sided Student’s t-test or Mann-Whitney U test. Thrombus 
frequencies were analyzed using chi-squared tests of contingency tables.  All 
analyses were performed using GraphPad Prism software (Version 5.0).  Results 
were considered significant at p<0.05.   * p<0.05, ** p<0.01, ***p<0.001. 
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Figure S1. WT and NE-deficient mice have similar changes in platelet and 
neutrophil counts after IVC stenosis.  A. Platelet counts dropped compared to 
control mice in both WT and NE-/- groups at 6 h.  At 48 h, NE-/- mice remain 
thrombocytopenic.  B. Neutrophil counts become similarly elevated 6 h after 
stenosis in both genotypes, and return to near normal levels by 48 h. 
 
 
 
 
 
 
Supplemental figure 1: WT and NE-deficient mice have similar 
changes in platelet and neutrophil counts after IVC stenosis 
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